US20060211044A1 - Translucent solid matrix assay device dor microarray analysis - Google Patents
Translucent solid matrix assay device dor microarray analysis Download PDFInfo
- Publication number
- US20060211044A1 US20060211044A1 US10/550,629 US55062905A US2006211044A1 US 20060211044 A1 US20060211044 A1 US 20060211044A1 US 55062905 A US55062905 A US 55062905A US 2006211044 A1 US2006211044 A1 US 2006211044A1
- Authority
- US
- United States
- Prior art keywords
- pixel
- signal values
- corrected
- array
- signal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000003556 assay Methods 0.000 title claims abstract description 30
- 239000011159 matrix material Substances 0.000 title abstract description 82
- 239000007787 solid Substances 0.000 title description 36
- 238000010208 microarray analysis Methods 0.000 title description 7
- 238000000034 method Methods 0.000 claims abstract description 155
- 229920001220 nitrocellulos Polymers 0.000 claims abstract description 76
- 239000000020 Nitrocellulose Substances 0.000 claims abstract description 75
- 230000003287 optical effect Effects 0.000 claims abstract description 46
- 238000007405 data analysis Methods 0.000 claims abstract description 13
- 229920000297 Rayon Polymers 0.000 claims abstract description 12
- 239000002964 rayon Substances 0.000 claims abstract description 12
- 229920000298 Cellophane Polymers 0.000 claims abstract description 11
- 239000000523 sample Substances 0.000 claims description 158
- 238000012360 testing method Methods 0.000 claims description 69
- 238000009739 binding Methods 0.000 claims description 57
- 230000027455 binding Effects 0.000 claims description 56
- 238000003384 imaging method Methods 0.000 claims description 52
- 239000012528 membrane Substances 0.000 claims description 13
- 238000001816 cooling Methods 0.000 claims description 5
- 238000001514 detection method Methods 0.000 abstract description 72
- 238000003491 array Methods 0.000 abstract description 37
- 108091023037 Aptamer Proteins 0.000 abstract description 31
- 239000000203 mixture Substances 0.000 abstract description 27
- 239000012491 analyte Substances 0.000 abstract description 21
- 239000000758 substrate Substances 0.000 abstract description 20
- 239000000243 solution Substances 0.000 description 53
- 230000008569 process Effects 0.000 description 43
- 108090000623 proteins and genes Proteins 0.000 description 42
- 102000004169 proteins and genes Human genes 0.000 description 40
- 239000003153 chemical reaction reagent Substances 0.000 description 35
- 239000011521 glass Substances 0.000 description 35
- 230000004907 flux Effects 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 32
- 239000000463 material Substances 0.000 description 32
- 238000002493 microarray Methods 0.000 description 30
- 238000004519 manufacturing process Methods 0.000 description 29
- 238000011534 incubation Methods 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 20
- 229940098773 bovine serum albumin Drugs 0.000 description 20
- 230000006870 function Effects 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 16
- 239000000427 antigen Substances 0.000 description 16
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 16
- 230000035945 sensitivity Effects 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 230000000903 blocking effect Effects 0.000 description 15
- 238000012937 correction Methods 0.000 description 15
- 239000013024 dilution buffer Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 13
- 238000010606 normalization Methods 0.000 description 13
- 239000004677 Nylon Substances 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000000670 limiting effect Effects 0.000 description 11
- 229920001778 nylon Polymers 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 150000002978 peroxides Chemical class 0.000 description 10
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 description 8
- 229940072049 amyl acetate Drugs 0.000 description 8
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 8
- 229960002685 biotin Drugs 0.000 description 8
- 235000020958 biotin Nutrition 0.000 description 8
- 239000011616 biotin Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000004891 communication Methods 0.000 description 8
- 230000002964 excitative effect Effects 0.000 description 8
- 238000011049 filling Methods 0.000 description 8
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 201000000050 myeloid neoplasm Diseases 0.000 description 8
- 238000005457 optimization Methods 0.000 description 8
- 229920003023 plastic Polymers 0.000 description 8
- 239000004033 plastic Substances 0.000 description 8
- 238000013500 data storage Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000010408 film Substances 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 230000009149 molecular binding Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000002699 waste material Substances 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 229910003460 diamond Inorganic materials 0.000 description 6
- 239000010432 diamond Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000011888 foil Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000010200 validation analysis Methods 0.000 description 6
- 108010090804 Streptavidin Proteins 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 241000714474 Rous sarcoma virus Species 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 108090001008 Avidin Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000186781 Listeria Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 210000000628 antibody-producing cell Anatomy 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- -1 cofactor Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000013021 overheating Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- HBROZNQEVUILML-UHFFFAOYSA-N salicylhydroxamic acid Chemical compound ONC(=O)C1=CC=CC=C1O HBROZNQEVUILML-UHFFFAOYSA-N 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 238000011896 sensitive detection Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 2
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 229950011321 azaserine Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003966 growth inhibitor Substances 0.000 description 2
- 239000000383 hazardous chemical Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 238000007500 overflow downdraw method Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000011410 subtraction method Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 241000199914 Dinophyceae Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- ZMUANTVDGHVAHS-UHFFFAOYSA-N OBOB(O)C1=CC=CC=C1 Chemical compound OBOB(O)C1=CC=CC=C1 ZMUANTVDGHVAHS-UHFFFAOYSA-N 0.000 description 1
- AWZJFZMWSUBJAJ-UHFFFAOYSA-N OG-514 dye Chemical compound OC(=O)CSC1=C(F)C(F)=C(C(O)=O)C(C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)=C1F AWZJFZMWSUBJAJ-UHFFFAOYSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000006117 anti-reflective coating Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000003110 dot immunobinding assay Methods 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000005183 environmental health Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000010429 evolutionary process Effects 0.000 description 1
- 238000002284 excitation--emission spectrum Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000004145 nucleotide salvage Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920000307 polymer substrate Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- BPSIOYPQMFLKFR-UHFFFAOYSA-N trimethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CO[Si](OC)(OC)CCCOCC1CO1 BPSIOYPQMFLKFR-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/548—Carbohydrates, e.g. dextran
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T3/00—Geometric image transformation in the plane of the image
- G06T3/40—Scaling the whole image or part thereof
- G06T3/4007—Interpolation-based scaling, e.g. bilinear interpolation
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T5/00—Image enhancement or restoration
- G06T5/40—Image enhancement or restoration by the use of histogram techniques
-
- G06T5/92—
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/80—Analysis of captured images to determine intrinsic or extrinsic camera parameters, i.e. camera calibration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00279—Features relating to reactor vessels
- B01J2219/00306—Reactor vessels in a multiple arrangement
- B01J2219/00313—Reactor vessels in a multiple arrangement the reactor vessels being formed by arrays of wells in blocks
- B01J2219/00315—Microtiter plates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00527—Sheets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00527—Sheets
- B01J2219/00533—Sheets essentially rectangular
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00527—Sheets
- B01J2219/00536—Sheets in the shape of disks
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00612—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports the surface being inorganic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00632—Introduction of reactive groups to the surface
- B01J2219/00637—Introduction of reactive groups to the surface by coating it with another layer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00659—Two-dimensional arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00722—Nucleotides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00725—Peptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/0074—Biological products
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B60/00—Apparatus specially adapted for use in combinatorial chemistry or with libraries
- C40B60/14—Apparatus specially adapted for use in combinatorial chemistry or with libraries for creating libraries
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/30—Subject of image; Context of image processing
- G06T2207/30004—Biomedical image processing
- G06T2207/30072—Microarray; Biochip, DNA array; Well plate
Definitions
- the present invention relates to the field of microarray analysis. More particularly, the present invention concerns methods, compositions and apparatus relating to translucent, solid, matrix assay devices for microarray analysis.
- the microarray may be a reconfigurable microarray.
- the methods concern methods of data analysis for optical detection of analytes. Still other embodiments concern apparatus, compositions and methods of use of a total optical assay device (TOADTM), which in preferred embodiments may be used with translucent coated slides or microtiter well plates.
- TOADTM total optical assay device
- Bioanalytes in particular pose numerous problems in analyte detection. Many bioanalytes, such as protein variants, may be structurally similar to other related compounds, resulting in cross-reactivity and false positive detection. Other bioanalytes may be relatively unreactive to detection reagents, causing low detection sensitivity and false negative detection.
- Microarray analysis involves the attachment of capture molecules, such as antibodies or oligonucleotides, to a solid matrix.
- the array is designed so that capture molecules specific for particular target analytes are attached to identifiable locations on the matrix.
- the matrix is analyzed to determine if substances in the sample bind to the capture molecules at one or more locations on the array.
- Two-dimensional microarrays have proven useful for a wide range of applications, such as genomic research.
- Arrays of oligonucleotide probes may be used to determine the match or mismatch for a given sample of DNA or RNA, as in the detection of disease-associated single nucleotide polymorphisms (SNPs).
- SNPs disease-associated single nucleotide polymorphisms
- Gene expression-profiling with microarrays containing probes against target gene mRNAs has been used to identify genes that are up- or down-regulated in response to disease, drug treatment, developmental stage and other conditions.
- Microarrays have also been of use for applications in protein research. However, proteins are more difficult to attach to a solid matrix and far more complex than oligonucleotides. Thus, techniques for use with protein (antibody) microarrays often require modifications compared to the more simple nucleic acid microarrays. (See, e.g., Constans, The Principle, 16:28, 2002.
- microarray platforms incorporating an appropriate solid matrix. These often contain capture molecules that have been printed or otherwise permanently affixed to the matrix.
- capture molecules that have been printed or otherwise permanently affixed to the matrix.
- One of the problems with such fixed arrays is that they are static. Once an array has been printed, it cannot be changed or adapted to conduct any tests other than the ones that it was originally designed for.
- a reconfigurable microarray would be very advantageous in allowing flexibility of use.
- microarrays face additional problems.
- the type of solid matrix used may affect the results obtained, depending on the method of analysis and the materials used.
- Most microarrays are produced using covalent, electrostatic or hydrophobic binding to attach capture probes to the surface of a solid matrix. The capture probes remain attached to the surface during sample analysis.
- Bound target molecules may be detected in a variety of ways. Most commonly, one or more fluorophore tags are attached to the target molecules or cells that are to be bound by a capture molecule. Once binding is complete the tags may be spectrophotometrically detected. Scanners, CCD cameras or similar detectors may be used to determine the location and signal intensity of fluorescent tags bound to matrix arrays.
- the amount of probe material that can be affixed on a matrix surface depends on the composition of the solid matrix. If insufficient amounts of probe are affixed to the matrix, the resulting fluorescent signal will be so weak that it cannot be detected even if the probe captures a tagged target molecule. It is also not sufficient to bind high concentrations of probe molecules to the surface of a solid matrix, if the matrix does not provide sufficient conformational or steric freedom to allow probes to bind to target molecules.
- the solid matrix must also preserve the functional activity of the probe. Proteins, such as antibodies, attached to a solid matrix may undergo denaturation over time, rendering antibodies inactive or enzymes dysfunctional. In such cases, the signal strength (and the amount of target protein identified in a sample) may vary by the length of time following matrix array manufacture. Although such time-dependent processes may be compensated for in part by the use of external standard proteins, the denaturation rates for different antibodies or enzymes affixed to the same matrix may not be identical.
- the opacity of the solid matrix may render it useless for certain kinds of analysis.
- Opaque materials only allow sample analysis to occur on the same side of the solid matrix as the probe array. This prevents the use of see-through optics that detect light from the opposite side of the matrix.
- a matrix array may be opposed to a fluidic cube or other fluidic device, with probe molecules attached to the array within a cavity formed by the fluidics cube. Detection of real-time binding of target molecules to the probes would be greatly facilitated if emitted light could be detected from the opposite surface of the array. This is not feasible if the array is opaque to the emitted light.
- Microarrays may be used in combination with optical image sensors for detection of analytes.
- image sensors for detection of analytes.
- analytic uses for image sensors is the evaluation and characterization of light interactions between one or more substances on a surface or in a reaction vessel. Light emitted by the object of interest or absorbed by the object when a beam of light passes through it may be detected and quantified.
- Most modern light detectors are designed to capture a spectral signal by presenting a two-dimensional array of sensitive photodiodes towards a target.
- the photodiodes are designed to produce current when exposed to light, and the resulting current may be analyzed in various ways.
- Modern sensors convert the analog photodiode signal to a digital signal format that may then be stored and processed for later analysis.
- Image sensors are often sensitive and responsive, acting to minimize background noise and interference. Image sensors are capable of accurately recording data regarding light striking the photodiode array of the sensor.
- High-resolution digital pictures may be produced pixel by pixel with an appropriate source of light, an optical system, an image sensor, and a computer. Using such a system, photographic pictures may be obtained in either monochromatic or color formats.
- a photodiode will produce an analog output signal that correlates with the energy striking the photodiode array only in special circumstances, such as when the target is illuminated by monochromatic light at a particular wavelength. Even though the output signal of a photodiode is essentially linear with respect to the illumination applied to the photodiode, the signal value for a pixel does not generally correlate accurately with the photon flux. This is because the quantum efficiency (QE) for converting the photon flux to a photodiode electrical energy varies with certain factors. In addition, in most cases more than a single wavelength of light will strike a photodiode.
- QE quantum efficiency
- Every photodiode has a certain QE factor that will vary with factors such as wavelength and temperature.
- Photon flux represents the electromagnetic energy striking the surface of a two-dimensional array, and the QE represents the capability of the photodiode to convert that energy into electrical energy.
- QE is usually expressed as a percentage of the energy flux, equaling some percentage less than 100 percent. Because QE varies greatly with the wavelength of light illuminating a photodiode, comparisons of a signal at one wavelength to that at another are difficult to interpret unless the QE factors are known for all wavelengths that apply.
- image sensors are designed by manufacturers to produce images that approximate the equivalent of what would be seen on a film or by the human eye. Manufacturers are interested in reproducing “life-like” pictures and colors. Manufacturers may provide access to the raw digital information for every pixel, but image sensors generally process that information before it is available for analysis to better render the “life-like” colors and intensities that represent human visual expectations.
- the data produced by an image sensor generally does not directly relate to the photon flux that impinges upon the photodiode array of the sensor. This factor limits the usefulness of image sensors for analytic purposes.
- the present invention resolves a long-standing need in the art by providing compositions for and methods of production and use of translucent solid 2D matrix arrays.
- the matrix arrays are microarrays, with binding molecule spots of between 1 ⁇ m and 999 ⁇ m in size.
- the spots may be between 100 and 500 ⁇ m in size. More particularly, the spots may be about 300 ⁇ m in size.
- the microarrays may be reconfigurable. Exemplary microarrays of potential use in the claimed methods are disclosed, for example in U.S. patent application Ser. No. 10/035,367, filed Dec. 28, 2001, the entire contents of which are incorporated herein by reference.
- the solid matrix arrays may exhibit one or more of the following characteristics: [1] inexpensive to produce; [2] long term stability (retain characteristic features over time); [3] ease of manufacture; [4] reproducible target molecule detection and/or quantification between lots; [5] bind high levels of probes; [6] do not interfere with probe functionality (e.g., binding affinity for target molecules); [7] translucent; and [8] do not interfere with probe-target molecule interaction.
- Such characteristics of the disclosed solid matrix arrays are advantageous compared to previously known solid matrix arrays.
- Certain embodiments of the invention concern efficient methods for producing a translucent (optically clear) nitrocellulose matrix supported on a solid substrate.
- Such translucent matrices are ideally suited for 2D microarray analysis.
- the translucent nitrocellulose matrix preserves protein (antibody) functionality and exhibits many of the characteristics listed above, such as high binding capacity.
- the translucent nitrocellulose solid matrix is suitable for genomic and proteomic work and can be used in a variety of diagnostic formats. Because it is translucent, it is suitable for use with see-through optics that detect light from the opposite side of the matrix from the capture molecules.
- a non-limiting example of a fluidics cube type biosensor of use with the claimed methods and compositions is disclosed in U.S. patent application Ser. No. 09/974,089, filed Oct. 1, 2001, the entire contents of which are incorporated herein by reference.
- inventions concern methods for producing a translucent, optically clear signal using small linker molecules bound to the surface of a solid matrix substrate.
- Aptamers, affibodies (e.g. U.S. Pat. No. 5,831,012), or other linkers that exhibit a high affinity for the Fc portion of certain antibodies may be used to attach antibodies or antibody fragments to a solid matrix.
- the use of such linkers overcomes the tendency for the solid matrix to display a lower binding capacity for larger molecules (e.g., antibodies).
- the methods may be used in combination with optically clear nitrocellulose matrix substrates to create reconfigurable microarrays. Alternatively, the methods may be used with traditional translucent substrates such as glass microscope slides.
- Still other embodiments concern methods of data processing and analysis for optical detection systems, for example to use with detection and/or quantification of analyte binding to 2-D matrix arrays.
- Certain embodiments of the invention concern methods, compositions and apparatus for a total optical assay device (TOADTM).
- TOADTM may be used with nylon slides coated with a layer of translucent nitrocellulose, rayon or cellophane (GRABBERTM slides) or with coated microtiter well plates (FOOTPADSTM).
- FIG. 1 shows an exemplary 96 Well Microplate Reagent and FootpadTM Format
- FIG. 2 illustrates an exemplary FootpadTM, showing an array with index spot and positioning in a reservoir with an inverted eppendorf pipet tip.
- FIG. 3 illustrates an exemplary method of use of a TOADTM apparatus with a translucent nitrocellulose-coated slide (GRABBERTM).
- FIG. 4 illustrates an illustrative example of a Total Optical Assay Device (TOADTM).
- TOADTM Total Optical Assay Device
- FIG. 5 shows an exemplary kit for use with a TOADTM.
- GRABBERTM slides are included for analyte detection.
- Alternative embodiments of kits may comprise 96 well microtiter plates
- FIG. 6 illustrates an exemplary set of GRABBERTM slides, along with an incubation sleeve with four reaction chambers.
- FIG. 7 shows a schematic diagram, illustrating the components of an exemplary TOADTM apparatus.
- FIG. 8 shows a schematic of the upper surface of a TOADTM apparatus with the casing 810 removed to show the stage 820 .
- FIG. 9 shows a non-limiting exemplary embodiment of an array of FootpadsTM 910 contained in a FootpadTM holder 920 .
- FIG. 10 shows a side view of an array of FootpadsTM 910 in a holder 920 .
- FIG. 11 shows a bottom view of an array of FootpadsTM 910 in a holder 920 .
- FIG. 12 illustrates an embodiment of an imaging operation.
- FIG. 13 is a flowchart illustrating an embodiment of an imaging process.
- FIG. 14 is a flowchart illustrating an embodiment of a leveling process.
- FIG. 15 illustrates an embodiment of a computer environment.
- FIG. 16 is an illustration of a CMOS image sensor
- FIG. 17 is an illustration of a Bayer color filter mosaic array
- FIG. 18 is an illustration of possible filter arrangements for an image sensor
- FIG. 19 is an illustration of microlens operation in an image sensor
- FIG. 20 is a graph of quantum efficiency of an exemplary image sensor
- FIG. 21 is a flow chart illustrating an embodiment of correction of QE factors
- FIG. 22 is a flow chart illustrating an embodiment of calibration for image sensor optimization
- FIG. 23 is a flow chart illustrating an embodiment of image sensor optimization
- FIG. 24 is a block diagram illustrating an exemplary computer that may be utilized in connection with an embodiment of the invention.
- FIG. 25 is an illustration of light scattering detection.
- analyte means any compound, molecule or aggregate of interest for detection.
- analytes include a protein, peptide, carbohydrate, polysaccharide, glycoprotein, lipid, hormone, growth factor, cytokine, receptor, antigen, allergen, antibody, substrate, metabolite, cofactor, inhibitor, drug, pharmaceutical, nutrient, toxin, poison, biowarfare agent, biohazardous agent, infectious agent, prion, vitamin, waste product, or any other molecule or atom, without limitation as to size.
- “Analytes” are not limited to single molecules or atoms, but may also comprise complex aggregates, such as a virus, bacterium, Salmonella, Streptococcus, Legionella, E. coli, Giardia, Cryptosporidium, Rickettsia, spore, mold, yeast, algae, amoebae, dinoflagellate, unicellular organism, pathogen or cell.
- cells exhibiting a particular characteristic or disease state such as a cancer cell, may be target analytes. Virtually any chemical or biological compound, molecule or aggregate could be a target analyte.
- Bioanalytes are “analytes” that are associated with, part of, contained within, incorporated into, metabolites of and/or products of biological systems (e.g., organisms, cells, bacteria, viruses, etc.)
- probe refers to a molecule or aggregate that has binding affinity for one or more targets. Within the scope of the present invention virtually any molecule or aggregate that has a binding affinity for some target of interest may be a “probe.” “Probes” include, but are not limited to, polyclonal antibodies, monoclonal antibodies, antibody fragments, FAb fragments, humanized antibodies, single-chain antibodies, chimeric antibodies, affibodies, oligonucleotides, polynucleotides, nucleic acids, aptamers, nucleic acid ligands and any other known ligand that can bind to at least one target molecule.
- the capture molecule is specific for binding to a single target, although in other embodiments the capture molecule may bind to multiple targets that exhibit similar structures or binding domains.
- the capture molecule is an antibody.
- Primary antibodies for detection of one or more targets of interest may be provided on a pre-spotted slide or may be selected by the user to load onto a slide or other array.
- detection and “detecting” are used herein to refer to an assay or procedure that is indicative of the presence of one or more specific analytes in a sample, or that predicts a disease state or a medical or environmental condition associated with the presence of one or more specific analytes in a sample. It will be appreciated by those of skill in the art that all assays exhibit a certain level of false positives and false negatives. Even where a positive result in an assay is not invariably associated with the presence of a target analyte, the result is of use as it indicates the need for more careful monitoring of an individual, a population, or an environmental site. An assay is diagnostic of a disease state or a medical or environmental condition when the assay results show a statistically significant association or correlation with the ultimate manifestation of the disease or condition
- GRABBERTM slides refer to nylon slides coated with a layer of translucent nitrocellulose, as discussed in more detail below.
- the nitrocellulose may be applied to a surface with an icon relief. Spotting may be done using a spotting template with the icon in a corner (e.g., the upper left or lower right corner) of the template and the nitrocellulose surface exposed.
- the invention is not limited to the illustrated preferred embodiments and the skilled artisan will realize that other types of slides, including but not limited to glass or other types of plastic slides, may be used in the practice of the claimed methods and apparatus.
- a “spotting template” refers to a tool that may hold slides (e.g., up to 6 slides at a time) when applying probes to the surface of a slide.
- the template may be used to accurately place spots in the proper field that will be obtained in imaging.
- slides may be provided with diamond marker points. Spotting of probes in the region between the diamond points provides for accurate imaging.
- a “focus template slide” is a glass slide with a semi-translucent template grid pattern identical to the spotting template.
- the slide may be used on the stage of the TOADTM to confirm that the test slide has been properly positioned for imaging. It is also useful in helping the user identify the position of a particular spot in the image.
- index marking solution refers to a ready formulated index protein with biotin affixed that when spotted on the surface of a slide, serves as a convenient position marker and positive control.
- the solution may be used without dilution by spotting onto the surface of the slide a column or row of spots in the same manner as is used in affixing primary probe antibodies.
- an “incubation sleeve” may refer to a sleeve with a sticky surface that is applied to a nitrocellulose surface, forming an incubation chamber.
- there are two openings on a diagonal in the window that may be used to fill and or empty the chamber during incubation.
- the sleeve may be affixed to a slide after the 2D array is formed, but before blocking, and may remain in place throughout the test, even during the imaging procedure.
- the thin surface outer window sheet may be peeled away to present a totally clear window during imaging.
- TOADTM bioilluminator refers to an imaging apparatus, equipped with a stage to accommodate a prepared slide, set of microtiter wells or other device to be optically imaged.
- the slide or other device may be placed on the stage so that a sleeve incubator (face up) is positioned accurately in the field for imaging. This may be confirmed in advance using a focus template slide and imager. Generally when an array is spotted between the diamond points on a template, the sleeve will be centered directly above the lens in the slotted stage.
- the apparatus is not limited to the disclosed preferred embodiments, and other types of devices besides slides or microtiter wells may be utilized for analyte detection with a TOADTM bioilluminator.
- Probe molecules have been attached to glass or plastic surfaces using cross-linking compounds.
- cross-linking compounds See, e.g., Schena, Microarray Analysis. J. Wiley & Sons, New York, N.Y., 648 pp., 2002.
- Probes may be printed as 2D arrays of spots, each of about 100 to 500 ⁇ m in diameter.
- the cross-linking compounds and any coating used to attach probes to the glass surface form a solid matrix, on top of the glass substrate.
- cross-linkers are known, depending on the type of reactive moieties (e.g., sulfhydryl, amino, carboxyl, phenyl, hydroxyl, aldehyde, etc.) available on the probe molecules that can be cross-linked to the surface without affecting probe functionality (e.g., target molecule binding).
- reactive moieties e.g., sulfhydryl, amino, carboxyl, phenyl, hydroxyl, aldehyde, etc.
- a problem with previous methods for probe attachment is that the capacity for attachment is limited. As probe size is increased, the number of possible binding sites for prospective target molecules is generally decreased. If the binding sites for the probe are saturated at a level below the threshold for detection, a signal will not be observed even if binding has occurred between probe and target molecule.
- Protein or peptide target molecules are often detected using antibodies as capture molecules.
- Two-dimensional arrays used in clinical diagnostics or proteomics frequently utilize antibodies as probes for protein or peptide target molecules.
- antibodies tend to be highly specific for their target antigens, they are not easily attached to glass surfaces with cross-linking agents and standard methods. This is because of the limited amount of material that can be affixed to the matrix with known chemistries, resulting in weak signals generated upon target binding.
- Another problem is that antibody specific binding cannot be maintained without adequate hydration and support in the matrix.
- long term stability of antibody-coupled solid matrix arrays tends to be limited, with inconsistent results obtained depending on the age of the array.
- PDBA phenyldiboronic acid
- SHA salicylhydroxamic acid
- This method is limited by the amount of antibody that can be bound to the surface. More importantly, the target antigen must be sufficiently small to diffuse through the brush border in order to react with antibodies affixed to the matrix. Such methods are not suitable for identifying and/or quantifying larger targets, such as whole cells or bacteria.
- Opaque matrix-coating materials used to produce microarrays include nylon, PVDF (polyvinylidene fluoride) and nitrocellulose. Nitrocellulose, a traditional polymer substrate in use for more than 50 years, is a substrate with very attractive properties for microarray applications. (E.g., Tonkinson and Stillman, Frontiers in Bioscience 7:c1-12, 2002.)
- nitrocellulose has been extensively used to immobilize proteins and nucleic acids for biomolecular analysis. Nitrocellulose immobilizes molecules of interest in near quantitative fashion and allows for short and long term storage. Nitrocellulose also allows for solution phase target species to efficiently bind to immobilized capture molecules. Diagnostic devices using ELISA methods have employed nitrocellulose membranes with a lateral flow process to bind capture reagents to the membrane (Jones, IVD Technology, 5(2):32, 1999).
- Nitrocellulose is normally produced in a microporous form that may be applied to the surface of glass slides to form an opaque surface. Probes may then be attached to the opaque nitrocellulose membranes in microarrays, using standard nitrocellulose binding methods. Such slides have been used with radioactive, fluorescent and chemiluminescent detection systems (e.g., Brush, The Engineer 14[9]:21, 2000).
- nitrocellulose membranes are also very brittle in the absence of a supporting structure or foundation, leading to frequent cracking or fragmentation. For this reason, opaque nitrocellulose has been used in a microporous form bound to plastic sheets. Such sheets are always opaque, due to the microporous form, and require a supporting structure (e.g. acetate or cellulose) to avoid damage during handling.
- a supporting structure e.g. acetate or cellulose
- opaque nitrocellulose membranes exhibit high binding capacity, stability and reasonably low interference with target-capture molecule interactions, they are not suitable for use with optical detection systems designed to work from the opposite side of a matrix array.
- compositions disclosed herein may be used to produce translucent surface coatings of colloidal nitrocellulose that retain advantageous binding characteristics of opaque nitrocellulose membranes.
- the interaction between probe and target molecules can be observed directly on a translucent nitrocellulose solid matrix.
- translucent nitrocellulose matrix arrays may be used in combination with a flow cell, fluidics cube or capillary system (e.g., U.S. patent application Ser. No. 09/974,089).
- the translucent nitrocellulose matrix may be attached to one side of a glass or plastic slide.
- Probes may be attached to the nitrocellulose and the interaction between probe and target molecules observed through the glass with a sensor or camera.
- the nitrocellulose material is totally translucent if formed according to the disclosed methods. Light signals may thus be observed without scatter or interference from opaque materials. This allows a greater signal-to-noise ratio and ease of detection of target molecules, compared to opaque microporous nitrocellulose matrix arrays. Such opaque matrix arrays can obscure portions of the light or reaction indicator species (e.g., dye) produced upon binding of target molecules.
- reaction indicator species e.g., dye
- Nitrocellulose in the form of a colloid in an amyl acetate solvent has been used by electron microscopists to make castings for specimens.
- Colloidal nitrocellulose is formed by casting as an ultra-thin film on a water surface. The film may then be picked up on a transmission electron microscopy (TEM) grid and used as a support film for TEM specimens. Because the film must be very clean and uniform, great care is exercised in its production.
- Colloidal nitrocellulose is readily soluble in amyl acetate. The amyl acetate is water soluble and evaporates evenly to form uniform films. It is supplied as a 1% solution of very pure nitrocellulose.
- High purity nitrocellulose in EM grade amyl acetate may be purchased from commercial sources.
- the amyl acetate is purified by refluxing over calcium oxide to remove all moisture. Soluble and suspended material is removed by slow distillation. The removal of all traces of moisture from the solvent permits the formation of very strong colloidal nitrocellulose films with virtually no holes.
- Collodion was obtained in bulk from Ernest P Fullam, Inc. (Latham, N.Y.) and used to manufacture high quality translucent nitrocellulose matrix arrays. An aliquot of 200 ⁇ L of 1% Collodion solution was pipetted onto the surface of freshly cleaned standard 25 ⁇ 75 mm glass slides. The Collodion was evenly spread to the edges of the glass slide surface in a dust free area. After drying for 2 hours at room temperature, the slides were heated for an additional hour or more at approximately 60° C. Dried slides were labeled and stored for production of microarrays.
- each slide When using a glass array surface, the edges of each slide were sealed with lacquer (e.g. nail polish) or other adhesive to prevent the ultra-thin nitrocellulose substrate from separating from the glass upon exposure to aqueous solutions.
- lacquer e.g. nail polish
- Slides may be composed of almost any translucent material as long as the amyl acetate does not react with the surface to discolor it or alter its properties. Certain types of plastics become opaque when exposed to amyl acetate and are not suitable for use with that solvent system.
- the colloidal nitrocellulose may be suspended in other volatile organic solvents besides amyl acetate before application to a glass or other translucent slide.
- the colloidal nitrocellulose slides may be spotted with probes using any known methods for microarray production. Methods for spotting proteins, peptides, oligonucleotides and nucleic acids onto nitrocellulose surfaces are well known in the art. Antibodies and biotinylated bovine serum albumin were used to determine the colloidal nitrocellulose binding capacity. The estimated protein binding capacity for the initial glass matrix arrays was in the range of 100 to 200 ⁇ g/cm 2 .
- CMOS imaging system that detected light emissions through the translucent nitrocellulose matrix arrays was used with a Cy5-streptavidin indicator dye.
- a Cy5-streptavidin indicator dye See, e.g., U.S. patent application Ser. No. 09/974,089, filed Oct. 1, 2001.
- biotinylated BSA was reproducibly detected at least down to 10 to 20 picograms of protein.
- Optimal CMOS images were obtained using a protein concentration range of about 20 to 100 ⁇ g/mL biotinylated BSA.
- the CMOS imaging data was confirmed using a 24 hour colloidal gold stain (BioRad, Hercules, Calif.) of the spot arrayed translucent nitrocellulose slides.
- the ability of the colloidal nitrocellulose matrix to maintain antibody binding activity was confirmed by spotting a variety of antibodies on the translucent surface. A concentration range of 20 to 200 ⁇ g/mL was used. Nonspecific protein binding sites on the nitrocellulose membrane were blocked with 0.1% BSA in buffer solution. The antibodies were then exposed to solutions containing the appropriate target antigen. Binding was detected using biotinylated second antibodies and Cy5-streptavidin indicator.
- a 2D array spotted with 5 nanoliters per spot of primary goat anti-mouse antibody solution and was developed using a secondary mouse Listeria monoclonal antibody and a secondary biotinylated goat anti-mouse antibody.
- the primary and secondary goat anti-mouse antibodies bound to different epitopes of the secondary mouse antibody.
- the two secondary antibodies were thus used to detect primary antibody bound to the array.
- the primary antibody could be detected down to a level of 100 picograms or less of antibody.
- the CMOS data was confirmed on the same slides using colloidal gold staining.
- the translucent nitrocellulose surface is that the progress of the probe binding reaction can be examined by looking through the translucent lower surface of the slide. This allows more effective probe binding to occur.
- the slide may also be adapted for use with a fluidic cube to mix and deliver samples to the surface. The progress of the probe-target binding reaction may also be monitored in real time through the underside of the slide.
- reconfigurable microarrays may be produced by using small linker molecules, such as aptamers or affibodies, bound to the surface of a solid matrix.
- Aptamers are oligonucleotides derived by an in vitro evolutionary process called SELEX (e.g., Brody and Gold, Molecular Biotechnology 74:5-13, 2000).
- Aptamers may be produced by known methods (e.g., U.S. Pat. Nos. 5,270,163; 5,567,588; 5,670,637; 5,696,249; 5,843,653) or obtained from commercial sources (e.g, Somalogic, Boulder, Colo.).
- Aptamers are relatively small molecules on the order of 7 to 50 kDa. Because they are small, stable and not as easily damaged as proteins, they may be bound in higher numbers to the surface of a solid matrix. This effectively amplifies the number of probe reactive sites on the surface of an array.
- Affibody® ligands (U.S. Pat. No. 5,831,012) are highly specific affinity proteins that may be designed and used like aptamers.
- Affibodies may be produced or purchased from commercial sources (Affibody AB, Bromma, Sweden). Aptamers and affibodies may be used in combination with antibodies to increase the functional avidity of translucent or non-translucent solid matrices for probe molecule binding. Increased binding in turn results in an increased signal strength, greater signal-to-noise ratio, more reproducible target molecule detection and greater sensitivity of detection.
- Reconfigurable microarrays may be used in combination with two antibodies and a capture probe.
- the capture probe may be an affibody, aptamer or any other probe capable of binding one of the antibodies. Both antibodies should selectively bind to a target cell, molecule or antigen.
- the effectiveness of binding is increased if the capture probe binds to a portion of an antibody characteristic of the IgG class.
- Such probes would only require a small part of the antibody structure to be present in order to react and bind to an antibody-target complex.
- Larger targets, such as microbes or cells are covered with numerous antigens that may form very large complexes with antibodies.
- truncated IgG antibody fragments could interact with such large targets and still bind to an aptamer or affibody probe on the slide surface.
- Antibodies are most stable in solution and optimal antigen-target molecule binding occurs with antibodies in solution, not attached to a solid matrix.
- the two antibodies may be allowed to bind to the target in solution.
- the complex Once target-antibody complexes are formed, the complex may be exposed to aptamer or affibody probe molecules on the reconfigurable matrix array.
- the probes may bind to a first antibody, while the second antibody may be conjugated to a fluorescent tag or other marker.
- the tagged complex may then be detected on the surface of the matrix array, using optical detection or any other known detection method.
- an aptamer may be tailored to specifically bind to the Fc portion of mouse IgG with high affinity.
- Samples containing target molecules of interest may be allowed to interact in solution with a mouse antibody specific for an antigen of interest.
- the sample may be mixed with a different biotinylated or otherwise tagged second (non-mouse) antibody that binds to a different epitope on the same antigen.
- the target antigen bound to the first and second antibodies may be exposed to the aptamer microarray.
- the anti-mouse aptamer affixes the complex to the solid matrix. After extensive washing to remove unbound tagged antibodies, the complex containing tagged antibody that is attached to the matrix array surface may be detected.
- multiple analytes may be simultaneously detected on a reconfigurable microarray.
- Such multiplex assays require that each second antibody specific for a different target antigen be labeled with a distinguishable label.
- three different second antibodies may be tagged with red, green or blue fluorophores.
- mouse antibodies specific for three different targets may be added to a sample and mixed with the target molecules and second antibodies. After exposure to the aptamer array, the presence of each target may be determined by the presence of red, green or blue fluorophores attached to the matrix.
- the invention is not limited to optically distinguishable fluorophore tags and that any known identifiable tag moieties, such as radioactive, fluorescent, luminescent, enzymatic, etc. may be used.
- the number of target analytes that may be simultaneously detected is limited only by the number of distinguishable tags that may be attached to the second antibody.
- a first antibody may be used in conjunction with multiple tagged second antibodies, each of which binds to a different epitope of the target molecule. This may occur, for example, where the available second antibodies are polyclonal antibodies. Alternatively, use of more than one second antibody with affinity for the same antigen may improve the sensitivity of detection. In another alternative, one second antibody may bind to a class of targets (for example, all E. coli bacteria) while a second antibody binds to a specific subclass (e.g., E. coli strain O157:H7).
- targets for example, all E. coli bacteria
- a second antibody binds to a specific subclass (e.g., E. coli strain O157:H7).
- the aptamer detection method may be used to detect microbes in a food sample.
- An aptamer that exhibits high affinity and specific binding for mouse IgG may be obtained.
- Such aptamers may be rapidly and readily obtained using SELEX.
- the anti-mouse IgG aptamer may be attached to a slide using standard methods, preferably with a translucent solid matrix. Non-specific binding sites on the matrix may be blocked and the slide washed before testing.
- an IgG mouse anti- Listeria m. antibody may be incubated with a food sample of interest at an appropriate concentration (typically 1 to 50 ⁇ g/mL).
- the sample with both antibodies may then be applied to the array containing anti-mouse IgG aptamers. After a short interval (approximately 15 minutes) the array may be washed so that only mouse IgG and rabbit biotinylated antibody complexed with Listeria m. is retained on the array.
- a solution of Cy5-strepavidin or other indicator applied to the surface may then reveal the presents or absence of an anti- Listeria m. antibody complex affixed to the surface.
- a single aptamer with high selectivity for IgG mouse antibodies may be used as a universal extender to capture and detect a variety of microbes. The only requirement would be that the mouse antibody to the microbe or antigen reacts only with the target and the aptamer, while the biotinylated second antibody reacts only with the target and not with the aptamer.
- Such an aptamer array is reconfigurable and is dependent only upon the nature of the solutions delivered to its surface.
- an aptamer array that binds to mouse IgG antibodies may in principal be used to detect any target for which a mouse IgG is available. It is far more cost effective to construct such a reconfigurable array, compared to constructing a series of fixed pattern arrays, each of which may only detect a limited number of targets.
- the present invention provides significant cost advantages for use in proteomic and genomic work.
- a fluidic cube, total optical assay device (TOADTM) or the equivalent may be attached to the reactive surface to deliver fluids to various parts of the array, allowing the user to determine which test results will be obtained for a given sample.
- Aptamers are more stable than antibodies and large proteins. They are also smaller and bind in higher concentrations to reactive surfaces. Thus, aptamer-based systems extend the avidity of an array for target molecules beyond what could be achieved using larger proteins for array binding.
- aptamers the skilled artisan will realize that affibodies or other small ligands could be used in the practice of the claimed methods.
- TOADTM Total Optical Assay Device
- FIG. 4 illustrates a non-limiting exemplary embodiment of a Total Optical Assay Device (TOADTM).
- the TOADTM comprises a light-tight casing 410 with a hinged lid 420 .
- the lid 420 is closed, the casing 410 blocks external light from the interior of the TOADTM, allowing highly sensitive detection of bioluminescence or other emitted light from samples to be analyzed.
- the lid 420 is opened to show a stage 430 .
- Devices to be imaged including but not limited to GRABBERTM slides or FOOTPADTM microtiter well devices, may be positioned on top of the stage 430 .
- the stage is a single focusing lens (not shown) that sits on top of a CCD (charge coupled device) chip or other light sensor (not shown).
- the slide or microtiter wells may be positioned on the stage 430 by aligning them with corresponding shaped depressions (see FIG. 8 ) on the top of the stage 430 .
- the casing 410 may comprise depressions, handles or other features to facilitate moving the TOADTM.
- FIG. 7 illustrates a schematic view of an exemplary embodiment of a TOADTM, with the body of the casing 710 displaced to show the internal components.
- the lid 720 overlies a stage 730 , which is used to position slides, microtiter wells or other devices over a CCD chip located at the top of an imaging device 750 .
- the imaging device 750 is a QICAM 10-bit mono cooled CCD camera (QimagingTM, Burnaby, B.C., Canada, catalog #QIC-M-10-C).
- the TOADTM is not limited to the exemplary embodiment and it is contemplated that other known types of imaging devices 750 may be utilized.
- a single focusing lens (not shown) is interposed between the CCD chip and the stage 730 and may be attached to the top of the imaging device 750 , for example using a C-mount adaptor.
- the imaging device 750 contains, in addition to a CCD chip, a Peltier heat exchange element surrounding the CCD chip.
- the rest of the imaging device 750 contains electronic components for processing the signals detected by the CCD chip, along with connections for a power supply, software interface and external data port, such as a 6-pin firewire connector.
- the Peltier heat exchanger removes heat from the CCD camera 750 and releases it inside the casing 710 .
- a separate fan driven cooling device 740 is positioned adjacent to the top of the imaging device 750 .
- the cooling device 740 drives hot air out of the casing through a light-tight vent at the back of the casing 710 (not shown) and circulates cool air through the casing 710 interior.
- the cooling device 740 operates efficiently enough that the CCD camera 750 may be operated continuously without overheating. Overheating of the CCD camera 750 results in substantial increase in background noise, producing random bursts of apparent light detection throughout the optical field of the CCD chip.
- the imaging device 750 rests on top of a base 760 that holds the imaging device 750 in position relative to the stage 730 .
- the bottom of the base 760 is open to allow access to on on-off switch at the bottom of the imaging device 750 and connections to power supplies (e.g. 110 volt AC electrical cord), firewire and any other external connections.
- power supplies e.g. 110 volt AC electrical cord
- FIG. 8 is a schematic diagram showing the top view of an exemplary embodiment of a TOADTM, with the casing 810 removed to show the upper surface of the stage 820 .
- Indentations 830 , 840 are shown in the top of the stage 820 , arranged to allow positioning of slides, microtiter wells or other devices over the CCD chip.
- a hole 860 in the center of the stage 820 allows for light transmission through the slide, microtiter well or other device and detection by the underlying CCD chip 850 . It will be apparent to the skilled artisan that the use of transparent or translucent devices, as discussed in more detail below, facilitates the use of a TOADTM apparatus with an optical detector located below the device to be optically read.
- the exemplary embodiment discussed above is designed for optical detection with samples that spontaneously emit light, for example using any known chemiluminescent or bioluminescent detection system, such as the luminol system disclosed below. In this case, no external source of excitatory light is needed to detect bound analytes.
- alternative systems may be utilized, such as fluorescently tagged detection molecules that bind to target analytes. Such systems are well known in the art.
- the use of a fluorescent detection system would necessitate additional components, such as an excitatory light source (e.g. laser, photodiode array, etc.), cutoff filters to screen the photodetector from excitatory light, and other such known components for fluorescent detection systems.
- an excitatory light source e.g. laser, photodiode array, etc.
- cutoff filters to screen the photodetector from excitatory light
- FootpadsTM may come in a variety of designs, an exemplary embodiment of which is shown in FIG. 9 .
- FIG. 9 illustrates an array of 12 FootpadsTM 910 contained in a FootpadTM holder 920 .
- a single FootpadsTM 910 has been removed from the array to illustrate its structure.
- the top end 930 of the FootpadsTM 910 may be designed for ease of handling, for example with a tapered, ridged shape as shown.
- a stem 940 may connect the handle 930 to the bottom 950 of the FootpadTM 910 .
- the lower surface of the FootpadsTM 910 may be coated with translucent nitrocellulose, rayon, cellophane or other known materials that may bind to probes, analytes or other ligands, as discussed below.
- the FootpadTM 910 may come prespotted with various probes, calibration spots and other spots, as discussed below. Alternatively the user may load any molecule of interest, such as antibodies or other probes, on the lower surface 950 of the FootpadTM 910 .
- FIG. 10 A side view of an array of FootpadsTM 910 inserted into a FootpadTM holder 920 is shown in FIG. 10 .
- the FootpadsTM 910 When inserted fully into the holder 920 , the FootpadsTM 910 are contained in wells that hold the FootpadsTM 910 firmly in place.
- the spacing of FootpadsTM 910 in the holder 920 is designed so that the entire array may be inserted into the wells of a standard 96 well microtiter plate.
- FIG. 11 shows that the bottom of the FootpadTM holder 920 is open, with space around the rim of the FootpadTM 910 to accomodate the well rims on a microtiter plate.
- a microtiter plate may be preloaded with reagents and the holder 920 with FootpadsTM 910 sequentially immersed in consecutive sets of corresponding microtiter wells.
- twelve or more FootpadsTM 910 may be exposed to appropriate reagents simultaneously.
- the holder 920 and FootpadsTM 910 may be transferred manually between different sets of wells of a microtiter plate.
- the holder 920 and/or FootpadsTM 910 may be designed to be handled robotically.
- a standard 96 well plate with a flat bottom optical surface may be used with pre-loaded reagents and FootpadsTM on a bioluminescent TOADTM detector.
- a packaged kit may include a labeled, foil sealed 96 well plate with 12 TOADTM FootpadsTM and reagents.
- Super signal reagents Luminol and peroxide may be mixed immediately before a test and added to the “optical” reservoir H before beginning the test ( FIG. 1 ). The test sample may be placed in the A reservoir ( FIG. 1 ). As indicated in FIG.
- sample is placed in column A wells, blocking solution (100 ⁇ L) in column B wells, wash solutions (100 ⁇ L) in columns C, E and G wells, antibody cocktail (200 ⁇ L) in column D wells, HRP-SA solution (100 ⁇ L) in column F wells and luminol solution (100 ⁇ L) in column H wells of a 96 well microtiter plate format.
- blocking solution 100 ⁇ L
- wash solutions 100 ⁇ L
- E and G wells antibody cocktail
- HRP-SA solution 100 ⁇ L
- luminol solution 100 ⁇ L
- FootpadTM holder may be manipulated accordingly.
- Luminol-peroxide reagent is a solution containing luminol and peroxide that is prepared and used on the same day tests are initiated. Luminol in the presence of HRP (horse radish peroxidase) and peroxide forms an unstable intermediate that produces light (see below). In the process it is consumed. Because it is in abundant excess relative to the amount of HRP trapped in a microspot on the surface of a slide or in a microplate well, light emission may be sustained for several hours. The Luminol and peroxide may be dispensed and mixed in equal volumes. The solution is then diluted using dilution buffer equivalent to the total volume in the first mixture (50% dilution). For example, if 1 ml of Luminol is combined with 1 ml of peroxide, then 2 ml of dilution buffer may be used to dilute the reagent to produce 4 mL of solution for testing.
- HRP hydrogen radish peroxidase
- a stage may be fitted to the TOADTM detector to accommodate the 96 well plate (see FIG. 8 ).
- the stage should securely fix the microplate so that 4 of the “H” reservoirs ( FIG. 1 ), which span 25 mm, fit the optical window of the instrument.
- the first 4 “optical” H 1 , 2 , 3 , and 4 reservoirs ( FIG. 1 ) are positioned over the target area.
- the well plates are then shifted in increments of 4 “optical windows” so that alignment and imaging can accommodate all 12 of the H reservoirs in 3 steps.
- the three positions of interest are shown and labeled in the diagram as position # 1 , # 2 , or # 3 ( FIG. 1 ).
- Embodiments involving plates pre-loaded with reagents and FootpadsTM sealed with foil allow the operator to conveniently run from 1 to 12 test samples by loading only luminol-peroxide and sample into the microplate.
- Each row 1 through 12 represents a single sample process. With a breakaway row and seal the packaged kit can be used for incremental tests until all 12 rows are consumed, providing the stage adjusts to lock the “optical” well H on the target imager.
- Each FootpadTM in an arrayed format accommodates up to 24 spotted probes ( FIG. 2 ) and allows for the possibility of multiplexing a single sample.
- FIG. 2 illustrates an exemplary embodiment, with an Eppendorf pipet tip 210 affixed to the top of a FootpadTM with a probe binding surface on the bottom 220 , the Eppendorf tip surrounded by a reservoir with fluid 230 .
- the FootpadTM surface 220 is about 7 mm in diameter.
- An exemplary pattern of capture antibodies (200 ⁇ M spots) and index spot is also shown 240 .
- a “blank” non-arrayed FootpadTM in a 96 well microplate with an empty “antibody cocktail” reservoir allows the user to test for any targets of interest. This is accomplished by either manually spotting primary antibodies onto a pre-treated FootpadTM, or affixing a robotically spotted cellophane, translucent nitrocellulose, rayon or other array of spots to the FootpadTM. The operator then fills the empty reservoir with the biotinylated secondary antibodies, the H reservoir with luminol-peroxide, and the A reservoir with sample for testing ( FIG. 1 ).
- one format for the bioluminescent TOADTM may include a stage to accommodate the 96 well plate in the manner indicated.
- samples may be analyzed using the methods and apparatus disclosed herein, including virtually any type of environmental, clinical, veterinary, pathologic or medical sample.
- samples may be analyzed after collection without any sample treatment whatsoever.
- samples may be processed after collection and before analysis.
- Samples may be processed in various ways, including without limitation cooling, freezing, heating, homogenization, organic phase extraction, detergent extraction, enzymatic digestion, centrifugation, filtration, ultracentrifugation, ultrafiltration, lyophilization or various well known chromatographic procedures.
- solid samples may be treated by homogenization and, if necessary, crude filtration, such as filtering the sample through a nylon or other filter with a pore size of approximately 100 ⁇ m or less.
- TOADTM FootpadTM are cylinders measuring 7 mm in height and 7 mm in diameter, fitting with the lower flat coated surface resting on the flat bottom of the well reservoir ( FIG. 2 ).
- the exposed upper surface may be used to affix an inverted eppendorf pipet tip, handle or appendage so that the pad may be moved easily from one reservoir to the next.
- the lower surface of the FootpadTM is coated with an appropriate binding medium and may be either blank or pre-arrayed (spotted) with capture antibodies (probes). Each pad may be marked with an index calibration spot ( FIG. 2 ) serving two purposes.
- the index when placed in luminol-peroxide provides a reference for luminosity based on a standard spot. It also serves to identify any other spots that react in a test since the position relative to the index is always known. It does not matter if the pad rotates in the reservoir, since capture probe spots are identified in spatial relationship to the index calibration spot. All positions are correctly readable as long as the pad is placed face (treated surface) down in a reservoir.
- a total of 24 spots may be affixed to a single FootpadTM without exceeding a density of 100 spots per square cm.
- a binary ID code may be affixed to a FootpadTM, for exampole using the first two rows of spots, and used to provide a tracking lot ID number.
- the lower surface of the FootpadTM may be used to accept and firmly affix probes.
- the composition of the surface may be important for optimized probe binding and analyte detection and quantification. Depending upon how the array or spotting is done, the composition may vary.
- the lower surface of the FootpadTM is coated with a thin layer of translucent nitrocellulose.
- nitrocellulose Colloidal 1% nitrocellulose firmly affixes to nylon, and to a lesser extent to other plastics and glass.
- the translucent nitrocellulose surface formed after drying on these surfaces avidly binds proteins and other substrates, while preserving their functionality (e.g., enzyme activity, antibody-antigen binding, etc.)
- a FootpadTM of nylon to which translucent nitrocellulose has been applied may be used. This format works well for manual spotting on the pad but may be less useful for robotic arrayers, which are mostly designed to print on ordinary slides measuring 25 ⁇ 75 ⁇ 1 mm.
- a sheet of nylon coated with nitrocellulose may be used to print the array.
- the array may then be punched out and affixed to the lower surface of the FootpadTM with an adhesive.
- a device may be constructed to hold coated FootpadsTM firmly in position for robotic array work. Additional details of embodiments using translucent nitrocellulose layers for probe binding are disclosed below.
- functional FootpadsTM to bind probes may be manufactured out of rayon.
- cellophane printed discs may be affixed to the FootpadTM with an appropriate adhesive.
- the array may be printed on a thin sheet of cellophane before affixing it to glass, plastic, or any other solid support.
- the FootpadTM may be of any color and does not have to be translucent.
- a rayon or cellophane surface requires no solvent or drying step, making the manufacturing process less complicated than the colloidal nitrocellulose process for coating either slides or FootpadsTM.
- HRP-SA reagent refers to horse radish peroxidase conjugated with streptavidin in a solution formulated to enhance antigen detection.
- the solution is normally stable for at least 2 years from the time of formulation. Its activity can be verified in a test by placing one drop into 100 ⁇ L of luminol-peroxide solution. In a totally dark room, the faint blue light emitted shows that the light-producing reaction has begun.
- the FootpadsTM are either precoated and spotted with probes or precoated and blank (no spots on the pad), placed in the empty reservoir A column ( FIG. 1 ).
- the operator using a blank (non-pre-arrayed) package will conduct assays with probes and biotinylated antibodies that are provided by the user. Because the FootpadTM comes already prepared for manual spotting, the operator needs only to remove the FootpadTM, apply spots to its lower surface, fill the antibody D reservoir ( FIG. 1 ) with biotinylated antibodies, fill the luminol-peroxide H reservoir ( FIG. 1 ), block the FootpadTM, and begin the test.
- the following materials may be used for a pre-coated blank FootpadTM test.
- All reagents and materials may be assembled and identified before initiating a test.
- the user has elected to use antibodies for probes and secondary biotinylated antibodies to capture a target when using a blank FootpadTM.
- the procedure is illustrated in Table 1.
- All reagents and materials may be assembled and identified before initiating a test.
- the user has elected to use a pre-arrayed FootpadTM configuration, making the entire process considerably simpler and faster using spotted FootpadsTM. Only two solutions are loaded into well reservoirs.
- the luminol-peroxide reagent is mixed and added to reservoir H ( FIG. 1 ).
- the sample is placed in reservoir A ( FIG. 1 ). Processing begins after the FootpadTM has been adequately blocked, incubating 5 minutes in reservoir B. The procedure is illustrated in Table 2.
- Exemplary Kit Components of Potential Use with a FootpadTM Format are Indicated in Table 3.
- a binary code of spots may be used as an index to track production batches of pre-arrayed FootpadsTM, GRABBERTM slides or other items.
- An exemplary method of coding is disclosed herein.
- a binary code system to identify a production particular lot may be used in the first two rows of the FootpadTM ( FIG. 2 ).
- the reference spots are used to determine if the other spots in the adjacent rows and column are binary 1 or binary 0.
- a 4 th spot located at the coordinates for row 2 column 2 is a quality assurance check sum on the intended code for the lot number assigned.
- the other spots in the first two rows are either empty or filled with the biotin marker at the same concentration and volume as is used for calibration spots and are determined to be either 0 or 1 by comparison to the 3 binary reference marks.
- the binary 0 reference spot contains 1/10 th of the concentration of the biotin marker used in a standard calibration spot. If any of the spots used to set the binary code are measured with a luminosity of lower intensity than the binary 0 reference, they are assigned a value of 0. A spot measured with a greater luminosity than both the binary 0 reference and the binary 1 reference is assigned the value of 1. A spot with a measured luminosity in between the binary 0 and binary 1 reference spots registers as a defective FootpadTM and is reported as an error to the operator.
- the binary 1 reference spot contains 3/10 th of the concentration of the biotin marker used in a standard calibration spot. If any of the spots used to set the binary code are measured with a luminosity of greater intensity than the binary 1 reference, they are assigned a value of 1. A spot of lower luminosity than both the binary 1 reference and the binary 0 reference is assigned the value of 0. A spot measuring luminosity between the reference spots registers as a defective FootpadTM and is reported as an error to the operator.
- the date of production may serve as the Lot number assignment for that production.
- the date may be printed in a binary code format.
- the unique pattern for a particular production date may be determined when a request for a lot production run is made.
- a proprietary software program coding and assigning filled and empty spots may be used so that a user by entering the date for the production run will see the spots that are to be filled and those to be left empty.
- the program used for the pattern of filled spots in the ID code also generates the assignment for the check-sum validation reference.
- a reference spot at row 2 column 2 may be either completely filled or left empty as a validation of the binary code on the FootpadTM. If the sum of the value 1's in the binary code assigned for a particular date is an even number, then the value 0 (empty spot) may be assigned for the check sum validation spot. If the sum of the value 1's in the binary code assigned for a particular date is an odd number, then the value 1 (filled spot) may be assigned for the check sum validation spot.
- the check sum validation when read against the binary code reference spots will be either 0 or 1. If the value read fails to match the assigned value for a particular production date, the FootpadTM will be assumed to have been printed incorrectly and discarded.
- FIG. 3 illustrates an exemplary protocol for use with GRABBERTM slides, comprising affixing a primary antibodies to the slide 310 , drying the 2D array 320 , blocking the slide 330 (10 min), capturing antigen with the primary antibodies 340 (10 min), forming an immunocomplex with secondary biotinylated antibodies 350 (10 min), forming HRP-SA complexes 360 (10 min), adding luminol reagent 370 and capturing an image (10 min).
- the luminescent reaction catalyzed by HRP is as indicated in the bottom of FIG. 3 .
- GRABBERTM slides provide for an easy to use method for detecting and identifying one or more targets of interest in a solution assayed on the surface of a slide.
- Slides may be provided pre-spotted with capture probes (e.g., antibodies) affixed ready for immediate testing.
- capture probes e.g., antibodies
- users who want to prepare their own 2D-spotted array may in 1 hour prepare a manual array for testing.
- the method of detection utilizes a primary antibody capturing an antigen target to form an immunocomplex with a second antibody that is biotinylated or otherwise labeled.
- the first antibody probe is affixed to a translucent nitrocellulose slide (GRABBERTM) and during the entire procedure remains affixed to the surface of the slide.
- the immunocomplex if formed, may be detected using a well-known enzyme activated bioluminescent process.
- Horseradish peroxidase (HRP) catalyzes the breakdown of peroxide and produces an intense light if luminol is added to the solution during the breakdown process. Luminol forms an unstable free radical intermediate that results in the release of photons at 430 nm ( FIG. 3 ).
- HRP horseradish peroxidase
- SA streptavidin
- the immunocomplex may be detected with an appropriate and sensitive photon detector. Biotin and streptavidin rapidly combine to form this light producing complex.
- Typical protein (e.g., antibody) probes may be spotted with 1 to 5 nL per spot at a concentration of 0.05 to 0.2 ⁇ G/mL.
- secondary tagged antibody such as biotinylated antibody
- the optimized concentration may be determined empirically by the user.
- Secondary antibodies may be diluted in dilution buffer to a concentration typically in the range of 5 to 30 ⁇ G/mL.
- a TOADTM total optical assay device
- TOADTM total optical assay device
- proprietary software to allow the user the means to read, interpret and record signals at the surface of a slide.
- An image file and report may be saved or printed for subsequent analysis and comparisons.
- the user may provide a sample that is placed in an incubation sleeve ( FIG. 6 ) affixed to the slide and allowed to react for 10 minutes before it is discarded (see below).
- GRABBERTM slides may be coated with a translucent nitrocellulose substrate (see U.S. patent application Ser. No. 10/373,546, filed Feb. 24, 2003) that avidly and immediately binds proteins, carbohydrates and/or oligonucleotides, strongly affixing them to the coated surface while preserving the functionality and 3D structure of the bound molecule. No other chemical process is required to affix the probes to the slide surface, making the 2D array procedure simple and fast.
- the hydrophobic surface with a superior contact angle is well suited for compact robotically printed arrays.
- the bioluminescent reaction is long lasting and the signal may be acquired over prolonged periods, allowing for extraordinary sensitivity in detection. Many targets may be simultaneously identified in a single sample.
- the proper primary probe antibody and biotinylated secondary antibody should strongly interact with the target for adequate detection.
- Preprinted slides and reagents provided are optimized to produce high quality detection.
- FIG. 6 shows an exemplary set of GRABBERTM slides, along with an incubation sleeve for performing the binding, washing and other procedures on the slide.
- the exemplary incubation sleeve shown in FIG. 6 contains four separate reaction chambers for use with GRABBERTM slides.
- Non-limiting exemplary kit materials for use with GRABBERTM slides are also listed in Table 7, along with exemplary sources for the materials.
- a kit may be provided with all the materials needed to complete an assay. The user may assemble gloves, forceps, a timer, waste container for spent material, and eppendorf tips for spotting an array. A sample for testing should be acquired before beginning the assay. If the array is pre-spotted, testing may begin with the blocking as shown in FIG. 3 .
- pre-spotted arrays ready for testing are obtained.
- Slides have incubation sleeves ( FIG. 6 ) affixed to the nitrocellulose surface and secondary biotinylated antibodies are provided ready for use.
- An exemplary protocol for use with pre-spotted arrays is disclosed in Table 4.
- the user may elect to provide primary antibodies for probes and secondary biotinylated antibodies to detect a target when using a pre-coated non-arrayed slide.
- An exemplary protocol is shown in Table 5.
- a TOADTM may comprise one or more alternative detection units.
- Optical signals may be produced when analytes bind to probes and HRP-conjugated secondary antibodies in the presence of luminol, as disclosed above.
- the signals may be detected by the detection unit.
- the detection unit may comprise one or more detectors, such as a spectrometer, monochromator, CCD device, CCD camera, photomultiplier tube, photodiode, avalanche photodiode or any other device known in the art that can detect an optical signal.
- An optical signal may comprise any form of electromagnetic radiation, emission, or absorption, although in preferred embodiments the optical signal comprises visible light.
- the device may comprise a data analysis and storage unit, such as a computer or microprocessor. Suitable devices are well known in the art and the present invention is not limiting as to the type of data analysis and storage unit used.
- the data analysis and storage unit may be operably coupled to the detection unit, so that optical signals are collected, processed and stored.
- the data analysis and storage unit may store information on each sample collected, including the sample source, geographical location and any other data collected on the sample. The unit may further identify each analyte detected in the sample and store that data as well.
- the device may comprise an interface for downloading data to a remote location, either directly (for example by an incorporated radio transmitter or modem) or indirectly (for example, by downloading to diskette or other storage device or by printing a hard copy).
- one or more optical components may be interposed between the spot containing surface and detector, such as a lens or lens array to focus optical signals from each spot.
- detector such as a lens or lens array to focus optical signals from each spot.
- a non-limiting example of a detector may comprises a CMOS camera sensor or equivalent unit, such as a PixeLink model AL633 CMOS imager (Vitana Corp., Ottawa, Canada).
- a nylon slide or other matrix array may be secured on a stage.
- a CMOS imager may be used to capture the light signals.
- the CMOS chip may be located beneath the slide and aligned so that spots on the slide are directly above the imager and are sharply focused on the imager surface with optical lenses and apertures. Additional details of a CMOS imaging system and data analysis method of use are disclosed in U.S. patent application Ser. No. 10/373,408, by Lawrence R. Green, entitled “Image Sensor Optimization,” filed on Feb. 24, 2003, incorporated herein by reference.
- probes for the detection of analytes.
- the probes are antibodies, it is contemplated that virtually any molecule or aggregate that can bind to a target analyte with sufficient affinity and specificity to allow its detection may be used. Standard procedures for the production of monoclonal or polyclonal antibodies are known (see, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1988; incorporated herein by reference).
- Polyclonal antibodies are prepared by immunizing an animal with an immunogen and collecting antisera from the immunized animal.
- a wide range of animal species can be used for the production of antisera.
- Typical animals used for production of anti-antisera include, for example, rabbits, mice, rats, hamsters, pigs or horses. Because of the relatively large blood volume of rabbits, a rabbit is a preferred choice for production of polyclonal antibodies.
- Antibodies both polyclonal and monoclonal, may be prepared using conventional immunization techniques, as will be generally known to those of skill in the art.
- a composition containing antigenic epitopes of an analyte can be used to immunize one or more experimental animals, such as a rabbit or mouse, which will then proceed to produce specific antibodies against the analyte.
- Polyclonal antisera may be obtained, after allowing time for antibody generation, simply by bleeding the animal and preparing serum samples from the whole blood.
- a given composition may vary in its immunogenicity. It is often necessary, therefore, to boost the host immune system, as may be achieved by coupling an immunogen to a carrier.
- exemplary and preferred carriers are keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). Other albumins such as ovalbumin, mouse serum albumin or rabbit serum albumin also can be used as carriers.
- KLH keyhole limpet hemocyanin
- BSA bovine serum albumin
- Other albumins such as ovalbumin, mouse serum albumin or rabbit serum albumin also can be used as carriers.
- Means for conjugating an analyte to a carrier protein are well known in the art and include glutaraldehyde, m-maleimidobenzoyl-N-hydroxysuccinimide ester, carbodiimide and bis-biazotized benzidine.
- the immunogenicity of a particular immunogen composition can be enhanced by the use of non-specific stimulators of the immune response, known as adjuvants.
- adjuvants include complete.
- Freund's adjuvant a non-specific stimulator of the immune response containing killed Mycobacterium tuberculosis
- incomplete Freund's adjuvants and aluminum hydroxide adjuvant.
- the amount of immunogen composition used in the production of polyclonal antibodies varies, depending upon the nature of the immunogen as well as the animal used for immunization.
- a variety of routes can be used to administer the immunogen (subcutaneous, intramuscular, intradermal, intravenous and intraperitoneal).
- the production of polyclonal antibodies may be monitored by sampling blood of the immunized animal at various points following immunization. A second, booster, injection also may be given. The process of boosting and titering is repeated until a suitable titer is achieved.
- the immunized animal can be bled and the serum isolated and stored, and/or the animal can be used to generate monoclonal antibodies.
- Monoclonal antibodies may be readily prepared through use of well-known techniques, such as those exemplified in U.S. Pat. No. 4,196,265, incorporated herein by reference.
- this technique involves immunizing a suitable animal with a selected immunogen composition, e.g., a purified or partially purified composition comprising an analyte.
- the immunizing composition is administered in a manner effective to stimulate antibody producing cells.
- Cells from rodents such as mice and rats are preferred, however, the use of rabbit, sheep or frog cells is also possible.
- somatic cells with the potential for producing antibodies, specifically B-lymphocytes (B-cells), are selected for use in the mAb generating protocol.
- B-cells B-lymphocytes
- These cells may be obtained from biopsied spleens, tonsils or lymph nodes, or from a peripheral blood sample. Spleen cells and peripheral blood cells are preferred, the former because they are a rich source of antibody-producing cells that are in the dividing plasmablast stage, and the latter because peripheral blood is easily accessible.
- a panel of animals will have been immunized and the spleen of the animal with the highest antibody titer will be removed and the spleen lymphocytes obtained by homogenizing the spleen with a syringe.
- a spleen from an immunized mouse contains approximately 5 ⁇ 10 7 to 2 ⁇ 10 8 lymphocytes.
- the antibody-producing B lymphocytes from the immunized animal are then fused with cells of an immortal myeloma cell, generally one of the same species as the animal that was immunized.
- Myeloma cell lines suited for use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have high fusion efficiency, and enzyme deficiencies that render then incapable of growing in certain selective media which support the growth of only the desired fused cells (hybridomas).
- any one of a number of myeloma cells may be used, as are known to those of skill in the art.
- the immunized animal is a mouse
- P3-X63/Ag8.653, NS1/1.Ag 4 1, Sp210-Ag14, FO, NSO/U, MPC-11, MPC11-X45-GTG 1.7 and S194/5XX0 Bul for rats, one may use R210.RCY3, Y3-Ag 1.2.3, IR983F and 4B210; and U-266, GM1500-GRG2, LICR-LON-HMy2 and UC729-6 are all useful in connection with cell fusions.
- Methods for generating hybrids of antibody-producing spleen or lymph node cells and myeloma cells usually comprise mixing somatic cells with myeloma cells in a 2:1 ratio, though the ratio may vary from about 20:1 to about 1:1, respectively, in the presence of an agent or agents (chemical or electrical) that promote the fusion of cell membranes.
- Fusion methods using Sendai virus Kinohler and Milstein, Nature, 256:495-497, 1975; Eur. J. Immunol., 6: 511-519, 1976
- PEG polyethylene glycol
- the use of electrically induced fusion methods is also appropriate (Goding, In: Monoclonal Antibodies: Principles and Practice, 2d ed., Academic Press, Orlando, Fla., pp. 60-61, and 71-74, 1986).
- Fusion procedures usually produce viable hybrids at low frequencies, around 1 ⁇ 10 ⁇ 6 to 1 ⁇ 10 ⁇ 8 .
- the viable, fused hybrids may be differentiated from the parental, unfused cells by culturing in a selective medium that contains an agent that inhibits cell growth for unfused cells.
- agents are aminopterin, methotrexate, and azaserine. Where aminopterin or methotrexate are used, the medium is supplemented with hypoxanthine and thymidine as a source of nucleotides (HAT medium). Where azaserine is used, the medium is supplemented with hypoxanthine.
- a preferred selection medium is HAT. Only cells capable of operating nucleotide salvage pathways are able to survive in HAT medium. The myeloma cells are defective in key enzymes of the salvage pathway, e.g., hypoxanthine phosphoribosyl transferase (HPRT), and they cannot survive.
- the B-cells can operate this pathway, but they have a limited life span in culture and generally die within about two weeks. Therefore, the only cells that can survive in the selective media are those hybrids formed from myeloma and B-cells.
- This culturing provides a population of hybridomas from which specific hybridomas are selected.
- selection of hybridomas is performed by culturing the cells by single-clone dilution in microtiter plates, followed by testing the individual clonal supernatants (after about two to three wk) for the desired reactivity.
- the assay should be sensitive, simple and rapid, such as radioimmunoassays, enzyme immunoassays, cytotoxicity assays, plaque assays, dot immunobinding assays, and the like.
- the selected hybridomas would then be serially diluted and cloned into individual antibody-producing cell lines, which clones can then be propagated indefinitely to provide mAbs.
- the cell lines may be exploited for mAb production in two basic ways.
- a sample of the hybridoma can be injected (often into the peritoneal cavity) into a histocompatible animal of the type that was used to provide the somatic and myeloma cells for the original fusion.
- the injected animal develops tumors secreting the specific monoclonal antibody produced by the fused cell hybrid.
- the body fluids of the animal such as serum or ascites fluid, can then be tapped to provide mAbs in high concentration.
- the individual cell lines also could be cultured in vitro, where the mAbs are naturally secreted into the culture medium from which they can be readily obtained in high concentrations.
- Monoclonal antibodies produced by either means may be further purified, if desired, using filtration, centrifugation, and various chromatographic methods such as HPLC or affinity chromatography.
- Non-antibody probes that may be used include, for example, aptamers (e.g., U.S. Pat. Nos. 5,270,163; 5,567,588; 5,670,637; 5,696,249; and 5,843,653, incorporated herein by reference), peptide libraries (e.g., U.S. Pat. Nos. 5,565,332, 5,596,079, 6,031,071 and 6,068,829, incorporated herein by reference), and various receptor proteins, binding proteins, cell surface proteins, and other non-antibody peptides or proteins known in the art.
- aptamers e.g., U.S. Pat. Nos. 5,270,163; 5,567,588; 5,670,637; 5,696,249; and 5,843,653, incorporated herein by reference
- peptide libraries e.g., U.S. Pat. Nos. 5,565,332, 5,596,079, 6,031,071 and 6,068,829,
- labeled probes may be prepared by any methods known in the art.
- a label moiety may be incorporated into a probe (e.g., peptide, protein, oligonucleotide) during synthesis.
- labels may be attached by covalent, noncovalent, ionic, van der Waals, hydrogen bonding or other forces following probe synthesis. Methods for attaching fluorescent or other labels to probe molecules are known in the art and any such known method may be used to make labeled probes within the scope of the present invention.
- a probe molecule may be biotinylated and may bind to an avidin or streptavidin-conjugated fluorophore. Fluorophores and conjugated fluorophores may be obtained from commercial sources, such as Molecular Probes, Inc. (Eugene, Oreg.).
- Labels of use may comprise any composition detectable by electrical, optical, spectrophotometric, photochemical, biochemical, immunochemical, or chemical techniques. Labels may include, but are not limited to, conducting, luminescent, fluorescent, chemiluminescent, bioluminescent and phosphorescent labels, chromogens, enzymes or substrates.
- Fluorescent molecules suitable for use as labels include, but are not limited to, dansyl chloride, rhodamineisothiocyanate, Alexa 350, Alexa 430, AMCA, BODIPY 630/650, BODIPY 650/665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, Cascade Blue, Cy2, Cy3, Cy5,6-FAM, fluorescein, HEX, 6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, ROX, TAMRA, TET, Tetramethylrhodamine, and Texas Red.
- a variety of other known fluorescent or luminescent labels may be-utilized. (See, e.g., U.S. Pat. No. 5,800,992; U.S. Pat. No. 6,319,668.)
- images such as images for bioanalyte detection may be captured by an imager.
- the signal data may be corrected for sensitivity variation in the imager.
- the corrected data may then subjected to a leveling process.
- FIG. 12 illustrates an embodiment of an imaging operation 1205 .
- the operation provides for imaging bioanalyte detection.
- the process begins with capturing and processing calibration images 1210 .
- the process of capturing and processing calibration images provides for a calibration of the imaging system to adjust for differences in sensitivities for pixels or regions of the imager.
- a number of images such as images 1 through k, are captured.
- Each of the k images has a known exposure level for calibration.
- the k images have varying exposure levels that represent an even distribution over a particular range of exposure levels.
- the calibration process is performed at least once for an imager, but may be performed as often as needed.
- an interpolation function is created between exposure levels and average pixel signal values.
- the function may be expressed as F_Average(exposure).
- An interpolation function may also be created between exposure levels and the resulting signals produced by each pixel of the imager.
- the function for the nth pixel of the image may be expressed as Func[n](exposure).
- the results produced by the average interpolation function F_Average (exposure) and the interpolation functions for each pixel Func[it] (exposure) may be based on linear interpolation.
- the optical signal analysis is not limited to any particular method of interpolation. A different method of interpolation may be implemented and may provide more precise results in certain circumstances.
- a test image may be captured 115 .
- the image may be captured using a particular test exposure level (TestExposure).
- the capture of the test image results in the production of a pixel signal value for each pixel in the imager.
- the pixel signal values provide data regarding the radiation reaching the imager.
- the sensitivity of the pixels may vary.
- the process provides for correction of sensitivity deviation of imager areas 120 .
- a correction coefficient may be calculated.
- the coefficient for a pixel is equal to the average interpolation function shown in equation [1] divided by the interpolation function for the pixel as shown in equation [2].
- level transformation for a test image may include creation of a histogram of the image that reflects the number of pixels that provide each corrected pixel signal value.
- An end-in-search contrast stretching method may then be applied to the histogram.
- this method includes applying a constant percentage value P to saturate the image to full white and black. The method then provides for parsing through the histogram to find the high and low thresholds for the image.
- a particular signal depth value (such as 255, reflecting an eight-bit value) may be utilized.
- the leveled signal (LeveledTestSignalCorrected) for each pixel may be produced by comparing the corrected test signal with the High and Low thresholds. If the corrected value is less than the low threshold, the leveled signal is set to zero. If the corrected value is greater than the high threshold, the leveled signal is set to the depth value, such as, for example, 255. If the corrected value is between the high and low thresholds (or equal to the high or low threshold), the corrected value is set to the depth times the difference between the corrected signal value and the low threshold divided by the difference between the high and low thresholds.
- FIG. 13 is an exemplary flowchart illustrating an embodiment of an imaging process.
- the embodiment shown in FIG. 13 assumes that a calibration is made of an imager followed by the capture of a test image.
- calibration ( 1305 - 1315 ) includes capturing a certain number of calibration images 1305 using an imager.
- the calibration images are of varying exposure levels, with pixel values being captured for each such calibration image.
- An interpolation function (F_Average) is created 1310 to produce an average interpolated signal value for any exposure level.
- An interpolation function is created 1315 for each pixel (or region) of the imager to produce an interpolated signal value for any exposure level.
- a test image may be captured 1320 .
- the capture of the test image produces signal values for each pixel of imager, but such values are based upon the varying sensitivity of each pixel.
- the captured signal values are corrected for sensitivity ( 1325 - 1330 ).
- a coefficient is calculated for each pixel 1325 , with the coefficient being the average interpolation function value for the test exposure level divided by the pixel interpolation function for the test exposure level, such as shown in equation [3].
- Corrected signals are calculated for each pixel 1330 , with the corrected signal equaling the test signal produced by the pixel times the coefficient for the pixel, such as shown in equation [4].
- the corrected signals then may provided to any automated analysis 1360 .
- the corrected signal values may be subjected to a level transformation ( 1340 - 1355 ).
- a histogram is produced 1340 based upon the relation between each corrected pixel signal value and the number of pixels producing such corrected pixel signal value.
- a contrast stretching method is applied 1345 , which may include a constant percentage being saturated to full white and black.
- the histogram is then searched to determine the High threshold and Low threshold for the histogram 1350 .
- a leveled corrected test signal is produced for each signal 1355 , which is shown in more detail in FIG. 14 .
- the data may be provided to visual control 1365 .
- FIG. 14 is an exemplary flowchart illustrating an embodiment of producing leveled corrected test signals for an imager.
- N pixels which, for simplicity of explanation, are numbered 1 through N.
- j is a counter variable used in the process.
- the counter j is initially set to 1 ( 1405 ).
- the leveled signal value is set to zero 1415 . If not, there is a determination whether the corrected signal is between (or equal to either of) the Low threshold and the High threshold.
- the leveled value is set to the depth value for the imager times the difference between the corrected signal value and the Low threshold, divided by the difference between the High threshold and the Low threshold 1425 . If not, the corrected signal value is greater than the High threshold and the leveled value is set to the depth value for the imager 1430 .
- the counter j is then incremented 1435 and there is a determination whether the counter value is less or equal to than the number of pixels N 1440 . If so, the process continues for the next pixel 1440 . If not, then all pixels have been processed and the leveled signal values have been produced 1445 .
- FIG. 15 is block diagram of an exemplary computer 1500 that may be utilized in connection with an embodiment of the invention.
- FIG. 15 contains a possible embodiment of a computer, but embodiments of the invention may be implemented using many different general and special purpose computers.
- the computer 1500 includes a bus 1505 or other for transferring data and communicating.
- the bus may include multiple buses utilized for different purposes.
- the computer 1500 includes a processor 1510 to process information.
- the processor 1510 may include one or more individual processors or coprocessors.
- the computer 1500 may include an input 1515 coupled with the bus 1505 .
- the input is used for communicating information and providing commands.
- the input 1515 may include a keyboard, a keypad, a touch-screen, a voice-activated process, or other input devices.
- the computer may include a mouse or other cursor control 1520 to control cursor placement and to provide commands.
- the computer 1500 may include a display 1525 , such a CRT (cathode ray tube) or LCD (liquid crystal display) screen to display information.
- the display 1525 may include a device to produce sound, such as a speaker.
- the computer 1500 includes a main memory 1530 , such as random access memory (RAM), to store data.
- the computer 1500 may include read only memory (ROM) 1535 or other similar storage for storing static data.
- the computer 1500 may include data storage 1540 , such as a magnetic disk (hard disk or floppy disk), an optical disk (CD-ROM or DVD), flash memory, or other memory systems.
- the computer 1545 may include communication 1545 .
- the communication 1545 may include a wired or cable interface (including but not limited to Firewire, USB, parallel, and serial cables), a wireless interface, a network interface card, a radio transceiver, or other interface.
- the computer 1500 may be connected to a network or to other computers, devices, or instruments using the communication 1545 .
- the data analysis scheme disclosed above is a non-limiting example of methods of data analysis of use for analyte detection with the disclosed apparatus. In alternative embodiments, different methods of data analysis may be utilized, either alone or in conjunction with the above-disclosed method.
- the data analysis methods disclosed below are of particular use where detected light signals are not monochromatic.
- an image sensor When used for analytic purposes, the accuracy of an image sensor in detecting and recording the photon flux striking the image sensor is important.
- the use of an image sensor to produce visually pleasing results is not important for analysis, but is a design factor of modern image sensors that may be used for analytic purpose.
- signals generated by an image sensor as a result of light striking the image sensor are optimized to produce data that more closely represents the actual photon flux.
- the outputs of pixels of the image sensor are normalized to correlate with photon flux.
- a larger current will be produced by the photodiode at a first wavelength than a second wavelength if the QE for the photodiode is higher for the first wavelength than the second wavelength.
- CMOS imager sensors are fundamentally different from charge-coupled devices and are increasingly used in microscopy and diagnostic instruments because they are cheaper to build and require considerably less power to operate. CCD cameras are no longer clearly superior in low intensity light situations, which had been true in the past.
- CMOS images now rival traditional color imaging methods on film and are easily manipulated.
- the images may be transferred from one processor to another as a digital file in a variety of formats preserving the arrayed data pixel address.
- Manufacturers have devoted considerable energy reproducing “life-like” color image sensors using various color filters and interpolation methods to enhance a digital image rendering colors very close to the human eye experience.
- the pleasing “life-like” color pictures obtained with a color CMOS image sensor are not as useful for analytic procedures. Similar issues exist with monochromatic images unless the image is produced by light at single wavelength, which is rarely true.
- FIG. 16 is a simplified illustration of an example of a color CMOS image sensor that may be utilized in connection with an embodiment of the invention. Not all components and features of CMOS imagers are illustrated. FIG. 16 and the remaining figures below are for illustration and are not necessarily drawn to scale.
- an image sensor 1600 includes an imaging array 1610 .
- the imaging array is comprised of a large number of pixels arranged in a two-dimensional array. As shown in the magnified pixel array 1620 of a particular area of the array 1620 , there is a filter associated with each of the pixels in the imaging array 1610 .
- the image sensor 1600 will also generally contain electronics relating to the processing and transmission of signals generated by the imaging array 1610 , including analog signal processing 1640 , analog to digital conversion 1650 , and digital logic 1660 .
- the photodiode array in a CMOS color image sensor is blanketed by an ordered thin layer of polymeric filters, such as in a conventional Bayer RGB (red-green-blue) two-dimensional array.
- Each filter is sized to fit over an individual photodiode in a sequential (Bayer) pattern to capture color information from a broad bandwidth of incident illumination.
- a heavy emphasis is placed on the green filters to address the human visual maximal response at 550 nm. There are 2 green filters for every red and for every blue filter. However, even though the human eye is more attuned to the green 550 nm region, yellow is generally a better choice with regards to QE factor.
- CMOS image sensors and the integrated circuits that define the active pixel array are inherently monochromatic (black and white) devices that respond only to the total number of electrons striking the photodiodes, not to the color of light. Color is detected either by passing the light through a sequential series of filters (such as red, green, and blue filters), or with miniature transparent polymeric thin-film filters that are deposited over the pixel array.
- filters such as red, green, and blue filters
- each pixel or imaging element
- each pixel includes a triad of transistors on its surface that convert accumulated electron charge to a measurable voltage, reset the photodiode, and transfer voltage to a vertical column bus.
- the photodiode thus occupies only a fraction of the pixel area.
- the photodiode area encompasses an area equal to 30 to 80 percent of the total pixel area for most CMOS sensors. This area occupied by the photodiode is the area that absorbs photons, while the other parts of the pixel are relatively opaque, blocking, reflecting, or absorbing light.
- the photodiode area or window is referred to as the “aperture” or “fill factor” of the pixel or image sensor.
- a small aperture or fill factor results in a significant loss of sensitivity and a corresponding reduction in the signal to noise ratio and leads to a reduction in the dynamic range of the sensor.
- CMOS image sensors can be utilized to produce pictures based upon the signals produced when photons strike the photodiode surface associated with each pixel in an active pixel sensor array.
- the pixel signals are processed to form the total picture either in monochrome (black and white) or color.
- Monochrome CMOS imager sensors do not have color filters over the photodiode portion of the pixel.
- color CMOS imagers even with standard Bayer pattern filters, generally are more sensitive than monochromatic CMOS imagers. While it may appear that inherently monochromatic CMOS photodiode without filters would be more sensitive because some light passing through a filter is absorbed and never reaches the photodiode in a color filtered photodiode, this is not generally true. This assumption does not fully take into account the effect a filter has on the QE for a photodiode, which might enhance certain signals, and ignores the advantages provided by microlenses in color photodiode architecture, which are described below.
- Monochromatic CMOS image sensors do not have a color filter and they do not normally have a microlenses over each pixel. These are important factors that make monochromatic imagers less attractive than color CMOS image sensors with regard to imager sensitivity.
- FIG. 17 illustrates a small section of an imaging array of a color image sensor that may be utilized in connection with an embodiment of the invention.
- the illustrated section repeats throughout the imaging array.
- the section 1700 is comprised of four pixels, each having a filter.
- the filters 1720 - 1750 have colors based on the choices made for the array.
- Below the filters 1710 illustrates the structure of the individual pixels. For each pixel, such as pixel 1760 , there is a portion that comprises the photodiode 1770 , the area of the photodiode being only a fraction of the total area.
- the image sensor will detect only the portion of the light falling on the photodiode area.
- CMOS imagers used in analysis, one possible approach would be to construct imagers by carefully selecting filters and photodiodes to produce QE factors for a given bandwidth that is approximately constant. By combining an appropriate number of photodiodes in an array with chosen filters, the measurement of light energy would be more accurate.
- the filters chosen could assist in leveling and improving upon the QE factors.
- the filters and photodiodes are chosen for other purposes, with a goal of producing the most visually pleasing images.
- CMOS manufacturers use color filter arrays based on the primary subtractive colors, cyan, magenta, and yellow (CMY), instead of the standard additive primaries red, green, and blue (RGB).
- CMOS image manufacturers generally use either Bayer RGB or Bayer CMY patterns that have been selected for photographic imaging.
- FIG. 18 is an illustration of RGB and CMY filters.
- an imaging array is divided into small arrays of filters, with each such array of filters having the same filter pattern.
- An RBG filter array 1800 contains two-by-two arrays of filters, with each array containing a red filter and a blue filter for two diagonal pixels and two green filters for the remaining two diagonal pixels.
- a CMY filter array 1800 also contains two-by-two arrays of filters, with each array containing a cyan filter and a magenta filter for two diagonal pixels and two yellow filters for the remaining two diagonal pixels. While the illustrated filters are the most common filter arrangements, many other filter colors and patterns are possible, and any filter pattern may be used in conjunction with an embodiment of the invention.
- color CMOS image sensors In contrast to monochrome image sensors, color CMOS image sensors also contain microlenses that effectively direct photons to the photodiode aperture.
- the bubble lens generally including an anti-reflective coating, can effectively increase the surface area of a photodiode by a significant amount, approximately 60 percent in certain applications.
- the microlenses substantially increase the effective fill factor and may more than compensate for filters that cut down on the total light that can reach the photodiode.
- FIG. 19 is a simplified illustration of microlenses in an image sensor.
- Each pixel contains an active portion 1910 , with the active portion including only a portion of the pixel area.
- each of the pixels 1905 has an associated microlens 1920 .
- the function of each microlens 1920 is to focus more light energy on the active portion 1910 and thus to allow measurement of a larger percentage of the incident photon flux. For example, light 1930 strikes a microlens 1920 and is focused on the active portion 1905 of the pixel 1910 .
- absorption, reflection, and transmission Three primary mechanisms that reduce or hamper photon collection by the photosensitive area of an image sensor are absorption, reflection, and transmission. These factors are wavelength-dependent in nature, and define in part the quantum efficiency (QE) of the image sensor. For example, reflection and transmission of incident light occurs as a function of wavelength, with a high percentage of shorter wavelengths below 400 nm being reflected. Shorter wavelengths are absorbed in the first few microns of the photosensitive region but the longest wavelengths exceeding 650 nm often pass through the photosensitive region.
- QE quantum efficiency
- FIG. 20 illustrates a typical quantum efficiency spectral response for an image sensor.
- a Bayer CMY filter is evaluated.
- the spectral response 500 illustrates the quantum efficiency of the image sensor for various wavelengths of light incident on the image sensor.
- Each curve has peaks and valleys at different wavelengths of incident light.
- the output signal proportional to the photon flux can be determined for any wavelength or interval of interest, including those pixels for a monochromatic image sensor.
- every pixel in an array is essentially identical to its neighbor except for the kind of filter (CMY, RGB, other pattern, or no filter).
- the effect of a filter is either to increase or to reduce the photodiode energy output for a given photon flux.
- the effect on the signal is wavelength dependent.
- the QE is the variable in the output signal that should be factored out of the equation if fair comparisons are to be made across the imaging array for each and every pixel.
- raw data can be normalized according to the appropriate QE
- digital values can be created that may be used in subsequent analysis.
- the pixel value for a color CMOS image sensor is obtained before on chip conversion occurs and the value is normalized by multiplying each signal value for a particular color filter by the inverse QE.
- the QE may be treated as a constant depending upon the wavelength and filter type used.
- the Bayer CMY pattern over the range 550 to 650 nm for a Kodak 1310 color CMOS image sensor provides a QE of approximately 46 percent, and then drops linearly from 650 nm to 5 percent at 990 nm, approximately 0.6 percent every 5 nm.
- the Magenta and Yellow filters are very similar over the range from 630 nm to 990 nm.
- the QE values are as shown in Table 9.
- a pixel with a yellow filter would have its digital raw data multiplied by 2.38, a magenta filter pixel by 2.27, and a cyan filter pixel by 7.69.
- the signal for every pixel is effectively transformed to a numeric value that is directly proportional to the actual photon flux.
- Table 9 only contains the QE for the image sensor when light of a particular wavelength (670 nm) strikes the image sensor. The QE for any other wavelength of light will vary, as shown in FIG. 20 .
- Corrections to account for differences in QE may be made based upon known QE factors for a particular filter type and wavelength. (For example, see the data contained in Table 8 and Table 9.) However, an image sensor may also be utilized to automatically correct for differences in pixel QE. Under an embodiment of the invention, each area of a sensor array, such as each filter quadrant, is normalized to render every pixel in the quadrant optimally tuned for photon flux in real time.
- no corrections are made if the pixels and filters are all of the same type, as, for example, the YYYY, MMMM, and CCCC filter patterns shown in Table 8.
- a correction is made if there are two or more filter types in the array (e.g. filter patterns such as YYYC, RGB Bayer, or modified CMY Bayer).
- a method of auto correcting for QE can be used for any combination of two or more filter and photodiode types and such method corrects to normalize the 4 pixels in a quadrant so that each pixel produces an equivalent output signal.
- an array of an image sensor comprises multiple filter quadrants. Two or more filters are used in each quadrant of 4 pixels. In each quadrant of 4 pixels, the average analog to digital converted signal output for each filter and photodiode type is determined. If, for example, there are 3 yellow filtered pixels and 1 cyan filtered pixel in the quadrant, the average for the 3 yellow pixels is determined first. The output value for the yellow pixels is then compared to the value for the cyan pixel to determine which output is numerically greater. Under the embodiment, there is an assumption that all 4 pixels receive equivalent photon flux. The highest output value is assigned to all four pixels in the quadrant. The next quadrant in the array may then be corrected in the same manner, with the process continuing until the entire array has been assigned corrected output values to correlate with photon flux.
- the process of auto correction is repeated over time as an image sensor is used to record images.
- the wavelength of light received by an image sensor may change from a first wavelength to a second wavelength.
- a first type of filter may provide the highest QE for the first wavelength, while a second type of filter provides the highest QE for the second wavelength.
- the change in wavelength is included in the calculation process and therefore auto correction for changing light can be made in real time.
- the digital signals produced by an image sensor auto corrected for photon flux may be rendered to a gray scale image for subsequent visualization in a monochromatic representation.
- the optimization of an image sensor can first be calibrated.
- the calibration may be accomplished by illuminating the color filters and photodiodes with light of known wavelength and intensity.
- the raw data for each filter is obtained and compared to expected values. From the resulting comparison, the QE and the multiplier (normalization factor) that is required to obtain the equivalent output signal for each color filter used for each and every pixel in the array may be obtained.
- Optimized signals obtained using QE factor conversions can more accurately relate the signal to the photon flux, and therefore more precisely characterize events, such as the optical events related to excitation-emission spectra or absorption phenomena in a chemical reaction. Both sensitivity and accuracy are enhanced by properly converting the signal to account for QE factors.
- raw data produced may be processed for signal optimization.
- the signal is converted to a numeric value that correlates with the photon flux incident upon the imager. This process may be applied to either a color or monochromatic CMOS imager sensor to render the signal proportional to photon flux.
- Data processed according to this embodiment may be rendered for visualization, such as via a gray scale standard (0 to 255 monochromatic) to producing a black and white image that correlates with the actual photon flux.
- the visual image of the data is superficially equivalent to a gray scale monochromatic image sensor, but for an equivalent luminance will be more intense than a image produced by a monochromatic non-transformed CMOS counterpart because color CMOS chips are generally more sensitive than monochrome chips.
- a color image sensor generally provides a better signal and is more sensitive than a monochromatic imager because the pixel photodiode filters improve upon the QE for the photodiode.
- the filtering of light by a color image sensor may be corrected using the QE factors to convert the signal to a number that is directly proportional to the photon flux.
- FIG. 21 is an illustration of an embodiment of correction of QE factors for an image sensor.
- the correction process 2100 an image of an event is captured with an image sensor.
- the image sensor is a color sensor containing an array of pixels, with each pixel having a filter.
- the filters are arranged in quadrants, with each quadrant having a particular filter pattern.
- embodiments of the invention are not limited to any particular type of image sensor or filter arrangement.
- the outputs of each of the pixels within a first quadrant of the array are obtained 2110 .
- the average output of for each filter type in the quadrant is then determined.
- a filter quadrant is CMY pattern containing a cyan filter, a magenta filter, and two yellow filters
- the cyan output, the magenta output, and the average of the two yellow outputs are determined.
- the outputs are then compared and which output is highest is determined 2120 .
- the highest output is then assigned to each pixel in the quadrant 2125 .
- the average yellow output is the highest output for the CMY quadrant, indicating that, under the particular conditions, the yellow filter has the highest QE factor
- the average yellow output is assigned to each of the pixels in the quadrant. If there are more quadrants in the array 2130 , the output of the next quadrant is obtained 2135 and the process continues. Once the final quadrant has been corrected the process is completed 2140 and the corrected output for the array is available. The process can then be repeated over time to allow real time QE factor correction for the image sensor.
- FIG. 22 is an illustration of an embodiment of a process for calibration for optimization of an image sensor.
- a light of a known wavelength and intensity is produced 2205 .
- the photon flux on each pixel is known, which would be the output if the QE of a pixel were 100 percent.
- the known light is directed on an image sensor 2210 .
- the output of each pixel of the image sensor is obtained 2215 .
- the output of the image sensor may then be compared with the actual photon flux 2220 . Using the comparison, the quantum efficiency of the pixel may be calculated 2225 , and then a normalization factor may be calculated based upon the quantum efficiency 2230 .
- the comparison and calculation may be done for each filter color, resulting in a normalization factor for each filter color. In other embodiments, the comparison and calculation may be made for each pixel of an image sensor or for sectors of pixels of an image sensor, resulting in normalization factors that apply for certain portions of the image sensor. As the normalization factor varies for each wavelength of light that strikes the image sensor, the wavelength of the known light is varied 2235 and the process repeated for each needed wavelength.
- FIG. 23 is a flowchart illustrating an embodiment of the optimization of an image sensor.
- an image of an event is captured with an image sensor 2305 .
- the image sensor is a color CMOS image sensor utilizing a filter pattern such as a Bayer RGB or CMY pattern.
- the raw data for the image of the event may be obtained from the image sensor 2310 .
- the raw data is non-optimized data that, due to the nature of the image sensor, will generally vary greatly from the actual photon flux that struck the image sensor.
- the normalization factor depends on the wavelength of light, the wavelength is determined 2320 .
- the appropriate normalization factor may be determined for each pixel based upon the wavelength of light.
- a normalization factor for each lens color may be used in normalization.
- the normalization factors may vary based on other factors.
- the raw data may then converted using the appropriate normalization factors for the pixels of the image sensor 2325 , thus producing an optimized data set that approximates the actual photon flux for the captured image of the event.
- an image may be produced using the converted data 2330 .
- FIG. 24 is block diagram of an exemplary computer that may be used in conjunction with an image sensor in an embodiment of the invention. While FIG. 24 illustrates a computer that may be connected to the image sensor, in other embodiments the function of the components shown may be structured in varying manner or may be performed by different systems. In some embodiments some signal processing functions may be performed by the image sensor or by components coupled with the image sensor. In some embodiments an imaging system may include most or all functions in a single unit. Not all computers are structured as shown in FIG. 24 . In addition, certain computers may utilize elements shown in FIG. 24 as auxiliary devices that are external from the computer.
- a computer 2400 comprises a bus 2405 or other communication means for communicating information, and a processing means such as a processor 2410 coupled with the bus 2405 for processing information.
- the computer 2400 further comprises a random access memory (RAM) or other dynamic storage device as a main memory 2415 for storing information and instructions to be executed by the processor 2410 .
- Main memory 2415 also may be used for storing temporary variables or other intermediate information during execution of instructions by the processor 2410 .
- the computer 2400 also may comprise a read only memory (ROM) 2420 and/or other static storage device for storing static information and instructions for the processor 2410 .
- ROM read only memory
- a data storage device 2425 may also be coupled to the bus 2405 of the computer 2400 for storing information and instructions.
- the data storage device 2425 may include a magnetic disk or optical disc and its corresponding drive, flash memory or other nonvolatile memory, or other memory device.
- the computer 2400 may also be coupled via the bus 2405 to a display device 2430 , such as a liquid crystal display (LCD) or other display technology, for displaying information to an end user.
- the display device may be a touch-screen that is also utilized as at least a part of an input device.
- display device 2430 may be or may include an auditory device, such as a speaker for providing auditory information.
- An input device 2440 may be coupled to the bus 2405 for communicating information and/or command selections to the processor 2410 .
- input device 2440 may be a keyboard, a keypad, a touch-screen and stylus, a voice-activated system, or other input device, or combinations of such devices.
- cursor control device 2445 such as a mouse, a trackball, or cursor direction keys for communicating direction information and command selections to processor 2410 and for controlling cursor movement on display device 2430 .
- a communication device 2450 may also be coupled to the bus 2405 .
- the communication device 2450 may include a transceiver, a wireless modem, a network interface card, or other interface device.
- the computer 2400 may be linked to a network or to other devices using the communication device 2450 , which may include links to the Internet, a local area network, or another environment.
- Fluorophores are frequently used to detect the presence or absence of a coupled reaction on a glass or other surface. Fluorescence detectors measure the intensity of the evanescent wave produced when a fluorophore is excited with a laser or other light source. Typically the laser is used to excite the fluorophore at its absorption peak and the detector is tuned to read the emission signal at a longer emission wavelength, which is characteristic of that particular fluorophore. The shift in wavelength between absorption and emission is referred to as the Stokes shift. Most fluorescence detection methods use fluorophores with a large Stokes shift so that the emission and absorption curves are well separated.
- filters eliminate most of the signal from the excitatory light source, they also cut out a significant portion of the evanescent (emitted) signal. Most band pass filters cut out as much as 40 to 50% of the emission signal. Long pass filters may cut an additional 10% of the emission signal.
- Fluorescent detection is used in a number of common test methods. DNA hybridization is commonly analyzed in this manner, using an appropriate fluorophore coupled to a set of known oligonucleotides that hybridize to capture oligonucleotides affixed to a slide. Sandwich immunoassays also employ this method of analysis, either using a tagged secondary antibody that binds to a primary antibody, or using a secondary biotinylated antibody and an avidin-fluorophore as the tag. Many variations on this method are well known.
- Various other types of light interference may occur in fluorescent detection.
- Light scatter occurs by reflection of the excitation beam, while light dispersion occurs by reflection and bending of the excitation beam. Scatter and dispersion may represent a large part of the light striking a detector.
- a substance such as a protein, nucleic acid or other biomolecule
- the amount of surface covered and the mass or density of the attached material may greatly affect the amount of scattered light.
- the chemical composition of proteins, oligonucleotides or polymers attached to the surface may also affect the scattered light (see FIG. 25 ).
- the material attached to the surface material may itself fluoresce.
- the glass or other material used may also have surface irregularities that can affect the signals received by the detector. The energy absorbed across the surface may vary from one spot to another, making signal analysis very problematic. Such problems require the use of novel methods of fluorescent detection and/or data analysis.
- Evanescent signals are generally very weak and light scatter is intense, making accurate quantitative detection of analytes problematic. Light scatter is frequently assumed to be eliminated by filters. However, scattered light is almost always present and can be a significant part of the total signal reaching a detector. Filters used to remove light scatter also remove much of the target emission signal, thereby decreasing detector sensitivity. Filters may also transmit a small amount of scattered light. If the scattered light is relatively large compared to the evanescent emitted light, the detected signal will be a combination from several sources, only one of which represents target molecule binding.
- Two spots e.g., different antibodies
- the other spot reacts with a target, such as a bacterial pathogen and/or other reagents.
- Target binding to the reactive antibody increases the mass attached to the spot and results in a larger surface area and a change in molecular structure at the spot. A mass effect has occurred.
- the light scatter from the reactive spot will be different from the light scatter before target molecule binding.
- a sensitive photon-counting detector could detect this difference in scatter.
- a variety of instruments, such as certain flow cytometers and turbidity meters take advantage of scatter to quantify the amount of material in a solution.
- Those instruments measure the angle of scatter for a beam of light impinging on a target material.
- the change in signal is the difference between the reference signal (S ref ) and signal 2 (S 2 ).
- the S 2 signal is shown as having two components, a modified scatter signal plus a mass effect signal of the coupled pathogen.
- the signal from the reactive spot changes while the signal from the non-reactive spot signal is constant.
- ⁇ S (non-reactive spot) 0
- S (reactive spot) Modified ( S p )+ M 1 ⁇ S ref
- the mass effect is sufficient to cause a large scatter effect, the fluorophore used for target detection could be eliminated.
- the mass attached to a surface using standard oligonucleotide probes may be increased by a factor of 2 or more upon binding of target nucleic acids.
- Such a large change in mass may be detectable by monitoring light scatter instead of evanescent waves.
- another mass effect occurs when the biotinylated antibody binds to the pathogen.
- a third mass effect occurs when avidin-conjugated fluorophore binds to biotin.
- the most sensitive signal may be obtained by subtracting the initial reference signal from the final captured signal, obtained after the fluorophore has been attached and excited. That signal represents the modified accumulated mass effects and the emission signal for the reactive spot.
- ⁇ S (reactive spot) Modified accumulated mass effects+Emission ⁇ S ref
- This method of analysis may be used with a CMOS imager or any known digital imaging method that allows storage of pixel images for subsequent processing.
- the signal obtained from each spot will contain more useful information and will show a more intense change upon target binding if a proper subtraction method is used.
- the scatter effect may be turned to an advantage in detecting target binding. Moreover, it is unnecessary to have fluorophore emission and absorption curves well separated, since spurious signals are subtracted out of the image.
- the full intensity of an emission signal may be measured without reducing emitted light by with filters.
- a subtraction method also eliminates artifacts and defects that may derive, for example, from inhomogeneity (chips, flaws) in the slide surface.
- the non-reactive spots completely blank out and do not appear as a signal.
- CMOS imagers and pixel capturing devices in general exhibit a random, very low level noise there are limits as to what kinds of signals can be detected.
- the baseline reference may exhibit a random number of spikes. A weak signal falling between two spikes would not normally be detected against this background noise.
- the signal-to-noise problem may be improved if numerous images are captured and added one upon the other. Because the random spikes inherent in a detector such as a CMOS imager are constantly shifting about, accumulating the frame images will tend to average out the random noise. However a weak signal from the emission of an excited fluorophore does not change its pixel location. Therefore, an accumulated signal caused by target binding will increase with time. This method is similar to taking a photoimage of a distant star or galaxy, by tracking the object as it moves across the sky. The object of interest appears brighter against the background with time because the signal has accumulated at the same spot on the detector, while the background light averages out.
- a glass slide or other matrix array is secured on a stage.
- a fluidic cube or other device is attached to the surface of the glass and used to deliver samples, second antibodies and other reagents.
- an excitatory laser is focused on one end of the glass slide at an inclined angle about 30 to 40 degrees.
- the glass slide acts as a waveguide to conduct the excitatory light to spots, containing bound primary antibody, on the glass surface.
- a CMOS imager is used to capture the light signals.
- the CMOS chip is located beneath the glass slide and is aligned so that spots on the slide are directly above the imager and are sharply focused on the imager surface with optical lenses and apertures.
- Each picture represents a single frame. For example 10 frames are taken using a 50 millisecond exposure. The exposure is selected so that the amount of light captured in a single frame is within the sensitive range, for the camera. The 10 digital frames are then added to provide a reference set that is used for subtraction of unwanted (background) signals. The accumulated image is referred to as the calibration slide.
- the fluidic cube is used to expose primary antibody to a sample, bind any target molecules to the first antibody, and bind second antibody to the target.
- the process ends with binding of avidin-fluorophore to the biotinylated second antibody and a final set of washes.
- the same number of frames used to obtain the reference slide image are taken of the sample slide, using the same exposures.
- the cumulative set of frames is referred to as the sample slide image.
- the luminescent signal for each spot is determined by subtracting the reference slide image from the sample slide image. This process essentially eliminates background noise and matrix array artifacts, resulting in very sensitive detection of target molecules.
- pictures may be obtained in either still frame or video mode.
- a typical video frame runs at 2000 ms and captures 100 frames each for the reference and sample analysis. This method removes artifacts and non-reactive spots, leaving only those signals that represent target molecule binding to the array.
- the present invention may include various processes.
- the processes of the present invention may be performed by hardware components or may be embodied in machine-executable instructions, which may be used to cause a general-purpose or special-purpose processor or logic circuits programmed with the instructions to perform the processes.
- the processes may be performed by a combination of hardware and software.
- Portions of the present invention may be provided as a computer program product, which may include a machine-readable medium having stored thereon instructions, which may be used to program a computer (or other electronic devices) to perform a process according to the present invention.
- the machine-readable medium may include, but is not limited to, floppy diskettes, optical disks, CD-ROMs, and magneto-optical disks, ROMs, RAMs, EPROMs, EEPROMs, magnet or optical cards, flash memory, or other type of media/machine-readable medium suitable for storing electronic instructions.
- the present invention may also be downloaded as a computer program product, wherein the program may be transferred from a remote computer to a requesting computer by way of data signals embodied in a carrier wave or other propagation medium via a communication link (e.g., a modem or network connection).
- a communication link e.g., a modem or network connection
- Colloidal nitrocellulose slides may be spotted with probes using any known methods for microarray production. Methods for spotting proteins, peptides, oligonucleotides and nucleic acids onto nitrocellulose surfaces are well known in the art. Antibodies and biotinylated bovine serum albumin were used to determine the colloidal nitrocellulose binding capacity. The estimated protein binding capacity for the initial matrix arrays was in the range of 100 to 200 ⁇ g/cm 2 .
- CMOS imaging system that detected light emissions through the translucent nitrocellulose matrix arrays was used with a Cy5-streptavidin indicator dye.
- a Cy5-streptavidin indicator dye See, e.g., U.S. patent application Ser. No. 09/974,089, filed Oct. 1, 2001.
- biotinylated BSA was reproducibly detected at least down to 10 to 20 picograms of protein.
- Optimal CMOS images were obtained using a protein concentration range of about 20 to 100 ⁇ g/mL biotinylated BSA.
- the CMOS imaging data was confirmed using a 24 hour colloidal gold stain BioRad, Hercules, Calif.) of the spot arrayed translucent nitrocellulose slides.
- the ability of the colloidal nitrocellulose matrix to maintain antibody binding activity was confirmed by spotting a variety of antibodies on the translucent surface. A concentration range of 20 to 200 ⁇ g/mL was used. Nonspecific protein binding sites on the nitrocellulose membrane were blocked with 0.1% BSA in buffer solution. The antibodies were then exposed to solutions containing the appropriate target antigen. Binding was detected using biotinylated second antibodies and Cy5-streptavidin indicator.
- a 2D array spotted with 5 nanoliters per spot of primary goat anti-mouse antibody solution and was developed using a secondary mouse Listeria monoclonal antibody and a secondary biotinylated goat anti-mouse antibody.
- the primary and secondary goat anti-mouse antibodies bound to different epitopes of the secondary mouse antibody.
- the two secondary antibodies were thus used to detect primary antibody bound to the array.
- the primary antibody could be detected down to a level of 100 picograms or less of antibody.
- the CMOS data was confirmed on the same slides using colloidal gold staining.
- Rous sarcoma virus was titered using primary antibody probe binding and HRP-SA bioluminescent detection as disclosed above. Prespotted slides containing anti-RSV antibodies were prepared for RSV. RSV was serially diluted 10 fold with each dilution to finally reach a lower limit of detection where no further spots were detected. A lower limit of detection was estimated at is 0.000091 IU/mL for bioluminescent detection (10 13 fold dilution from the initial stock titer).
- Place test sample (step 7) in reservoir A. Place footpad face down into reservoir A, and allow 10 minutes 10 incubation. Remove footpad from A reservoir, immerse briefly in B to wash the 10 surface. Then move directly to reservoir C and briefly immerse and wash the surface, then place the footpad in D to incubate 10 minutes. Remove the footpad from D reservoir, wash in E briefly, and place it in 10 reservoir F to incubate 10 minutes. Remove the footpad from F reservoir, wash in G briefly, and place it in reservoir H. Immediately place the microplate on the TOAD stage and begin imaging. Imaging may take 15 minutes for very low level detection. 15 1 ProClin 0.05%.
- wash ⁇ 1 the incubation chamber with wash solution by completely filling and 1 then emptying the reservoir chamber.
- Wash ⁇ 1 the incubation chamber with wash solution by completely filling and 1 then emptying the reservoir chamber.
- Block the prepared slide by filling the incubation sleeve chamber with blocking 10 solution and allowing 10 minutes for complete blocking. Then remove and dispose of in a waste container. Place test sample into the incubation chamber and allow 10 minutes for probe 10 binding. Then empty the reservoir contents and dispose of in a waste container. Wash ⁇ 1 the incubation chamber with wash solution by completely filling and 1 then emptying the reservoir chamber.
Abstract
The present invention concerns methods and compositions relating to translucent matrix arrays. In certain embodiments, the arrays are reconfigurable. Reconfigurable arrays may be produced using small linker molecules, such as aptamers or affibodies, which preferably bind to an IgG specific portion of antibodies. Such arrays may be used to detect any target that binds selectively or specifically to an IgG. Translucent matrix arrays may utilize cellophane, rayon or a translucent, colloidal form of nitrocellulose to coat the substrate. Other embodiments concern methods of data analysis and apparatus for analyte detection. Certain embodiments concern a total optical assay device (TOAD™), which may be used with GRABBER™ slides and/or FOOTPAD™ microtiter well assay devices.
Description
- The present application claims the benefit of U.S. patent application Ser. No. 10/373,546 and Ser. No. 10/373,408, each filed on Feb. 24, 2003, and claims the benefit under 35 U.S.C. §119(e) of Provisional U.S. patent application Ser. No. ______, entitled “Methods and Apparatus for Total Optical Assay Device, by Lawrence R. Green, filed on Jan. 29, 2004. The entire text of each above-listed application is incorporated herein by reference.
- 1. Field of the Invention
- The present invention relates to the field of microarray analysis. More particularly, the present invention concerns methods, compositions and apparatus relating to translucent, solid, matrix assay devices for microarray analysis. In certain embodiments of the invention, the microarray may be a reconfigurable microarray. In some embodiments, the methods concern methods of data analysis for optical detection of analytes. Still other embodiments concern apparatus, compositions and methods of use of a total optical assay device (TOAD™), which in preferred embodiments may be used with translucent coated slides or microtiter well plates.
- 2. Description of Related Art
- Detection of trace amounts of various analytes, such as proteins, nucleic acids, lipids, metabolites, toxins, wastes, contaminants, poisons, hormones, pharmaceuticals, drugs, explosives, pathogens, biohazards, hazardous chemicals, viruses, bacteria, cells, diseased cells, etc. is extremely important for many applications in epidemiology, public health, biowarfare, environmental health and safety, forensics, disease detection and treatment and numerous other fields. Bioanalytes in particular pose numerous problems in analyte detection. Many bioanalytes, such as protein variants, may be structurally similar to other related compounds, resulting in cross-reactivity and false positive detection. Other bioanalytes may be relatively unreactive to detection reagents, causing low detection sensitivity and false negative detection.
- Numerous methods for detection of proteins and other bioanalytes have been developed, primarily based on some type of immunological assay. Western blots, ELISA assays, sandwich immunoassays, immunoadsorption, etc. all rely upon a binding interaction between an antibody or antibody fragment, such as a monoclonal or polyclonal antibody, and an analyte to be detected. The antibody-analyte complex is then detected, often by addition of a labeled secondary antibody. One format developed for bioanalyte detection has involved the use of microarrays of use for simultaneous analysis of multiple analytes on a single chip format.
- Microarray analysis involves the attachment of capture molecules, such as antibodies or oligonucleotides, to a solid matrix. Typically, the array is designed so that capture molecules specific for particular target analytes are attached to identifiable locations on the matrix. After exposure to a sample suspected of containing one or more target analytes, the matrix is analyzed to determine if substances in the sample bind to the capture molecules at one or more locations on the array.
- Two-dimensional microarrays have proven useful for a wide range of applications, such as genomic research. Arrays of oligonucleotide probes may be used to determine the match or mismatch for a given sample of DNA or RNA, as in the detection of disease-associated single nucleotide polymorphisms (SNPs). Gene expression-profiling with microarrays containing probes against target gene mRNAs has been used to identify genes that are up- or down-regulated in response to disease, drug treatment, developmental stage and other conditions. Microarrays have also been of use for applications in protein research. However, proteins are more difficult to attach to a solid matrix and far more complex than oligonucleotides. Thus, techniques for use with protein (antibody) microarrays often require modifications compared to the more simple nucleic acid microarrays. (See, e.g., Constans, The Scientist, 16:28, 2002.)
- Many clinical diagnostic devices have been built around microarray platforms incorporating an appropriate solid matrix. These often contain capture molecules that have been printed or otherwise permanently affixed to the matrix. One of the problems with such fixed arrays is that they are static. Once an array has been printed, it cannot be changed or adapted to conduct any tests other than the ones that it was originally designed for. A reconfigurable microarray would be very advantageous in allowing flexibility of use.
- Existing microarrays face additional problems. For example, the type of solid matrix used may affect the results obtained, depending on the method of analysis and the materials used. Most microarrays are produced using covalent, electrostatic or hydrophobic binding to attach capture probes to the surface of a solid matrix. The capture probes remain attached to the surface during sample analysis. Bound target molecules may be detected in a variety of ways. Most commonly, one or more fluorophore tags are attached to the target molecules or cells that are to be bound by a capture molecule. Once binding is complete the tags may be spectrophotometrically detected. Scanners, CCD cameras or similar detectors may be used to determine the location and signal intensity of fluorescent tags bound to matrix arrays.
- The amount of probe material that can be affixed on a matrix surface depends on the composition of the solid matrix. If insufficient amounts of probe are affixed to the matrix, the resulting fluorescent signal will be so weak that it cannot be detected even if the probe captures a tagged target molecule. It is also not sufficient to bind high concentrations of probe molecules to the surface of a solid matrix, if the matrix does not provide sufficient conformational or steric freedom to allow probes to bind to target molecules.
- The solid matrix must also preserve the functional activity of the probe. Proteins, such as antibodies, attached to a solid matrix may undergo denaturation over time, rendering antibodies inactive or enzymes dysfunctional. In such cases, the signal strength (and the amount of target protein identified in a sample) may vary by the length of time following matrix array manufacture. Although such time-dependent processes may be compensated for in part by the use of external standard proteins, the denaturation rates for different antibodies or enzymes affixed to the same matrix may not be identical.
- Other characteristics of the solid matrix used for 2D arrays may also be important. For example, the opacity of the solid matrix may render it useless for certain kinds of analysis. Opaque materials only allow sample analysis to occur on the same side of the solid matrix as the probe array. This prevents the use of see-through optics that detect light from the opposite side of the matrix. For example, a matrix array may be opposed to a fluidic cube or other fluidic device, with probe molecules attached to the array within a cavity formed by the fluidics cube. Detection of real-time binding of target molecules to the probes would be greatly facilitated if emitted light could be detected from the opposite surface of the array. This is not feasible if the array is opaque to the emitted light. A need exists for a translucent solid matrix that could be used with a variety of optical detection systems. Such translucent matrix materials should also allow for binding of high concentrations of probe molecules, while maintaining probe molecules in an active state.
- Microarrays may be used in combination with optical image sensors for detection of analytes. Among possible analytic uses for image sensors is the evaluation and characterization of light interactions between one or more substances on a surface or in a reaction vessel. Light emitted by the object of interest or absorbed by the object when a beam of light passes through it may be detected and quantified.
- Most modern light detectors are designed to capture a spectral signal by presenting a two-dimensional array of sensitive photodiodes towards a target. The photodiodes are designed to produce current when exposed to light, and the resulting current may be analyzed in various ways. Modern sensors convert the analog photodiode signal to a digital signal format that may then be stored and processed for later analysis.
- Image sensors are often sensitive and responsive, acting to minimize background noise and interference. Image sensors are capable of accurately recording data regarding light striking the photodiode array of the sensor. High-resolution digital pictures may be produced pixel by pixel with an appropriate source of light, an optical system, an image sensor, and a computer. Using such a system, photographic pictures may be obtained in either monochromatic or color formats.
- However, a photodiode will produce an analog output signal that correlates with the energy striking the photodiode array only in special circumstances, such as when the target is illuminated by monochromatic light at a particular wavelength. Even though the output signal of a photodiode is essentially linear with respect to the illumination applied to the photodiode, the signal value for a pixel does not generally correlate accurately with the photon flux. This is because the quantum efficiency (QE) for converting the photon flux to a photodiode electrical energy varies with certain factors. In addition, in most cases more than a single wavelength of light will strike a photodiode.
- Every photodiode has a certain QE factor that will vary with factors such as wavelength and temperature. Photon flux represents the electromagnetic energy striking the surface of a two-dimensional array, and the QE represents the capability of the photodiode to convert that energy into electrical energy. QE is usually expressed as a percentage of the energy flux, equaling some percentage less than 100 percent. Because QE varies greatly with the wavelength of light illuminating a photodiode, comparisons of a signal at one wavelength to that at another are difficult to interpret unless the QE factors are known for all wavelengths that apply.
- Further, most image sensors are designed by manufacturers to produce images that approximate the equivalent of what would be seen on a film or by the human eye. Manufacturers are interested in reproducing “life-like” pictures and colors. Manufacturers may provide access to the raw digital information for every pixel, but image sensors generally process that information before it is available for analysis to better render the “life-like” colors and intensities that represent human visual expectations.
- For these reasons, the data produced by an image sensor generally does not directly relate to the photon flux that impinges upon the photodiode array of the sensor. This factor limits the usefulness of image sensors for analytic purposes.
- The present invention resolves a long-standing need in the art by providing compositions for and methods of production and use of translucent solid 2D matrix arrays. In certain embodiments of the invention, the matrix arrays are microarrays, with binding molecule spots of between 1 μm and 999 μm in size. In particular embodiments, the spots may be between 100 and 500 μm in size. More particularly, the spots may be about 300 μm in size. In specific embodiments, the microarrays may be reconfigurable. Exemplary microarrays of potential use in the claimed methods are disclosed, for example in U.S. patent application Ser. No. 10/035,367, filed Dec. 28, 2001, the entire contents of which are incorporated herein by reference.
- In various embodiments of the invention, the solid matrix arrays may exhibit one or more of the following characteristics: [1] inexpensive to produce; [2] long term stability (retain characteristic features over time); [3] ease of manufacture; [4] reproducible target molecule detection and/or quantification between lots; [5] bind high levels of probes; [6] do not interfere with probe functionality (e.g., binding affinity for target molecules); [7] translucent; and [8] do not interfere with probe-target molecule interaction. Such characteristics of the disclosed solid matrix arrays are advantageous compared to previously known solid matrix arrays.
- Certain embodiments of the invention concern efficient methods for producing a translucent (optically clear) nitrocellulose matrix supported on a solid substrate. Such translucent matrices are ideally suited for 2D microarray analysis. The translucent nitrocellulose matrix preserves protein (antibody) functionality and exhibits many of the characteristics listed above, such as high binding capacity. The translucent nitrocellulose solid matrix is suitable for genomic and proteomic work and can be used in a variety of diagnostic formats. Because it is translucent, it is suitable for use with see-through optics that detect light from the opposite side of the matrix from the capture molecules. A non-limiting example of a fluidics cube type biosensor of use with the claimed methods and compositions is disclosed in U.S. patent application Ser. No. 09/974,089, filed Oct. 1, 2001, the entire contents of which are incorporated herein by reference.
- Other embodiments of the invention concern methods for producing a translucent, optically clear signal using small linker molecules bound to the surface of a solid matrix substrate. Aptamers, affibodies (e.g. U.S. Pat. No. 5,831,012), or other linkers that exhibit a high affinity for the Fc portion of certain antibodies may be used to attach antibodies or antibody fragments to a solid matrix. The use of such linkers overcomes the tendency for the solid matrix to display a lower binding capacity for larger molecules (e.g., antibodies). The methods may be used in combination with optically clear nitrocellulose matrix substrates to create reconfigurable microarrays. Alternatively, the methods may be used with traditional translucent substrates such as glass microscope slides.
- Still other embodiments concern methods of data processing and analysis for optical detection systems, for example to use with detection and/or quantification of analyte binding to 2-D matrix arrays.
- Certain embodiments of the invention concern methods, compositions and apparatus for a total optical assay device (TOAD™). In particular embodiments, the TOAD™ may be used with nylon slides coated with a layer of translucent nitrocellulose, rayon or cellophane (GRABBER™ slides) or with coated microtiter well plates (FOOTPADS™).
- The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
-
FIG. 1 shows an exemplary 96 Well Microplate Reagent and Footpad™ Format -
FIG. 2 illustrates an exemplary Footpad™, showing an array with index spot and positioning in a reservoir with an inverted eppendorf pipet tip. -
FIG. 3 illustrates an exemplary method of use of a TOAD™ apparatus with a translucent nitrocellulose-coated slide (GRABBER™). -
FIG. 4 illustrates an illustrative example of a Total Optical Assay Device (TOAD™). -
FIG. 5 shows an exemplary kit for use with a TOAD™. In this non-limiting example, GRABBER™ slides are included for analyte detection. Alternative embodiments of kits may comprise 96 well microtiter plates -
FIG. 6 illustrates an exemplary set of GRABBER™ slides, along with an incubation sleeve with four reaction chambers. -
FIG. 7 shows a schematic diagram, illustrating the components of an exemplary TOAD™ apparatus. -
FIG. 8 shows a schematic of the upper surface of a TOAD™ apparatus with thecasing 810 removed to show thestage 820. -
FIG. 9 shows a non-limiting exemplary embodiment of an array ofFootpads™ 910 contained in aFootpad™ holder 920. -
FIG. 10 shows a side view of an array ofFootpads™ 910 in aholder 920. -
FIG. 11 shows a bottom view of an array ofFootpads™ 910 in aholder 920. -
FIG. 12 illustrates an embodiment of an imaging operation. -
FIG. 13 is a flowchart illustrating an embodiment of an imaging process. -
FIG. 14 is a flowchart illustrating an embodiment of a leveling process. -
FIG. 15 illustrates an embodiment of a computer environment. -
FIG. 16 is an illustration of a CMOS image sensor; -
FIG. 17 is an illustration of a Bayer color filter mosaic array; -
FIG. 18 is an illustration of possible filter arrangements for an image sensor; -
FIG. 19 is an illustration of microlens operation in an image sensor; -
FIG. 20 is a graph of quantum efficiency of an exemplary image sensor, -
FIG. 21 is a flow chart illustrating an embodiment of correction of QE factors; -
FIG. 22 is a flow chart illustrating an embodiment of calibration for image sensor optimization; -
FIG. 23 is a flow chart illustrating an embodiment of image sensor optimization; -
FIG. 24 is a block diagram illustrating an exemplary computer that may be utilized in connection with an embodiment of the invention; and -
FIG. 25 is an illustration of light scattering detection. - Definitions
- Terms that are not otherwise defined herein are used in accordance with their plain and ordinary meaning.
- As used herein, “a” or “an” may mean one or more than one of an item.
- As used herein, the terms “analyte,” “target” and “target analyte” mean any compound, molecule or aggregate of interest for detection. Non-limiting examples of analytes include a protein, peptide, carbohydrate, polysaccharide, glycoprotein, lipid, hormone, growth factor, cytokine, receptor, antigen, allergen, antibody, substrate, metabolite, cofactor, inhibitor, drug, pharmaceutical, nutrient, toxin, poison, biowarfare agent, biohazardous agent, infectious agent, prion, vitamin, waste product, or any other molecule or atom, without limitation as to size. “Analytes” are not limited to single molecules or atoms, but may also comprise complex aggregates, such as a virus, bacterium, Salmonella, Streptococcus, Legionella, E. coli, Giardia, Cryptosporidium, Rickettsia, spore, mold, yeast, algae, amoebae, dinoflagellate, unicellular organism, pathogen or cell. In certain embodiments, cells exhibiting a particular characteristic or disease state, such as a cancer cell, may be target analytes. Virtually any chemical or biological compound, molecule or aggregate could be a target analyte. “Bioanalytes” are “analytes” that are associated with, part of, contained within, incorporated into, metabolites of and/or products of biological systems (e.g., organisms, cells, bacteria, viruses, etc.)
- As used herein, “capture molecule” or “probe” refers to a molecule or aggregate that has binding affinity for one or more targets. Within the scope of the present invention virtually any molecule or aggregate that has a binding affinity for some target of interest may be a “probe.” “Probes” include, but are not limited to, polyclonal antibodies, monoclonal antibodies, antibody fragments, FAb fragments, humanized antibodies, single-chain antibodies, chimeric antibodies, affibodies, oligonucleotides, polynucleotides, nucleic acids, aptamers, nucleic acid ligands and any other known ligand that can bind to at least one target molecule. In certain embodiments, the capture molecule is specific for binding to a single target, although in other embodiments the capture molecule may bind to multiple targets that exhibit similar structures or binding domains. In preferred embodiments, the capture molecule is an antibody. Primary antibodies for detection of one or more targets of interest may be provided on a pre-spotted slide or may be selected by the user to load onto a slide or other array.
- The terms “detection” and “detecting” are used herein to refer to an assay or procedure that is indicative of the presence of one or more specific analytes in a sample, or that predicts a disease state or a medical or environmental condition associated with the presence of one or more specific analytes in a sample. It will be appreciated by those of skill in the art that all assays exhibit a certain level of false positives and false negatives. Even where a positive result in an assay is not invariably associated with the presence of a target analyte, the result is of use as it indicates the need for more careful monitoring of an individual, a population, or an environmental site. An assay is diagnostic of a disease state or a medical or environmental condition when the assay results show a statistically significant association or correlation with the ultimate manifestation of the disease or condition
- In a non-limiting embodiment, “GRABBER™ slides” refer to nylon slides coated with a layer of translucent nitrocellulose, as discussed in more detail below. The nitrocellulose may be applied to a surface with an icon relief. Spotting may be done using a spotting template with the icon in a corner (e.g., the upper left or lower right corner) of the template and the nitrocellulose surface exposed. The invention is not limited to the illustrated preferred embodiments and the skilled artisan will realize that other types of slides, including but not limited to glass or other types of plastic slides, may be used in the practice of the claimed methods and apparatus.
- A “spotting template” refers to a tool that may hold slides (e.g., up to 6 slides at a time) when applying probes to the surface of a slide. The template may be used to accurately place spots in the proper field that will be obtained in imaging. In an exemplary embodiment, slides may be provided with diamond marker points. Spotting of probes in the region between the diamond points provides for accurate imaging.
- In certain embodiments, a “focus template slide” is a glass slide with a semi-translucent template grid pattern identical to the spotting template. The slide may be used on the stage of the TOAD™ to confirm that the test slide has been properly positioned for imaging. It is also useful in helping the user identify the position of a particular spot in the image.
- In some embodiments, “index marking solution” refers to a ready formulated index protein with biotin affixed that when spotted on the surface of a slide, serves as a convenient position marker and positive control. The solution may be used without dilution by spotting onto the surface of the slide a column or row of spots in the same manner as is used in affixing primary probe antibodies.
- An “incubation sleeve” may refer to a sleeve with a sticky surface that is applied to a nitrocellulose surface, forming an incubation chamber. In certain embodiments, there are two openings on a diagonal in the window that may be used to fill and or empty the chamber during incubation. The sleeve may be affixed to a slide after the 2D array is formed, but before blocking, and may remain in place throughout the test, even during the imaging procedure. Just before imaging, after the luminol test solution is placed in the sleeve incubator, the thin surface outer window sheet may be peeled away to present a totally clear window during imaging.
- “TOAD™ bioilluminator” refers to an imaging apparatus, equipped with a stage to accommodate a prepared slide, set of microtiter wells or other device to be optically imaged. The slide or other device may be placed on the stage so that a sleeve incubator (face up) is positioned accurately in the field for imaging. This may be confirmed in advance using a focus template slide and imager. Generally when an array is spotted between the diamond points on a template, the sleeve will be centered directly above the lens in the slotted stage. The apparatus is not limited to the disclosed preferred embodiments, and other types of devices besides slides or microtiter wells may be utilized for analyte detection with a TOAD™ bioilluminator.
- Traditional Translucent Slides
- Glass or plastic microscope slides have commonly been used as solid matrix supports for microarray analysis. Probe molecules have been attached to glass or plastic surfaces using cross-linking compounds. (See, e.g., Schena, Microarray Analysis. J. Wiley & Sons, New York, N.Y., 648 pp., 2002.) Probes may be printed as 2D arrays of spots, each of about 100 to 500 μm in diameter. The cross-linking compounds and any coating used to attach probes to the glass surface form a solid matrix, on top of the glass substrate. Many different kinds of cross-linkers are known, depending on the type of reactive moieties (e.g., sulfhydryl, amino, carboxyl, phenyl, hydroxyl, aldehyde, etc.) available on the probe molecules that can be cross-linked to the surface without affecting probe functionality (e.g., target molecule binding).
- A problem with previous methods for probe attachment is that the capacity for attachment is limited. As probe size is increased, the number of possible binding sites for prospective target molecules is generally decreased. If the binding sites for the probe are saturated at a level below the threshold for detection, a signal will not be observed even if binding has occurred between probe and target molecule.
- Attempts have been made to attach probes to the glass surface using avidin-coated slides and biotin-conjugated probe molecules. Alternatively, silanes, such as aminosilane or 3-glycidoxypropyltrimethoxysilane, have been coated onto the glass surface, with the silane moiety attached to the glass and the reactive moiety cross-linked to probe molecules. Other approaches have utilized slides coated with reactive substrates with functional aldehyde, carboxyl, epoxy, or amine groups that can form a covalent bond with the probe molecules, affixing them permanently to the glass surface.
- Although these methods work moderately well for small probe molecules, they tend to work poorly for larger probe molecules (e.g., antibodies) where functionality (binding) may depend on probe orientation, flexibility and degree of cross-linking. Covalent attachment methods also tend to bind very little material to the matrix surface. Consequently, probe concentration is low and signal detection is difficult. Because relatively little probe is available on the surface of the 2D array, such systems show a low signal-to-noise ratio for a positive binding reaction between probe and target.
- Protein or peptide target molecules are often detected using antibodies as capture molecules. Two-dimensional arrays used in clinical diagnostics or proteomics frequently utilize antibodies as probes for protein or peptide target molecules. Although antibodies tend to be highly specific for their target antigens, they are not easily attached to glass surfaces with cross-linking agents and standard methods. This is because of the limited amount of material that can be affixed to the matrix with known chemistries, resulting in weak signals generated upon target binding. Another problem is that antibody specific binding cannot be maintained without adequate hydration and support in the matrix. Thus, long term stability of antibody-coupled solid matrix arrays tends to be limited, with inconsistent results obtained depending on the age of the array.
- Attempts have been made to solve this problem by creating an environment that stabilizes the protein and preserves its functional probe features. For example, Prolinx Inc. (Bothell, Wash.) has developed a chemical affinity system using standard glass slides with a polymer brush format affixed to their surface. The system relies upon the interaction between two synthetic small molecules that form a stable complex, phenyldiboronic acid (PDBA) and salicylhydroxamic acid (SHA). (E.g., Stolowitz et al., Bioconjugate Chem. 12:229-239, 2001.) PDBA is first conjugated with protein probes. The conjugated probes then link to SHA attached to the polymer brush to form a 3D functional array. This method is limited by the amount of antibody that can be bound to the surface. More importantly, the target antigen must be sufficiently small to diffuse through the brush border in order to react with antibodies affixed to the matrix. Such methods are not suitable for identifying and/or quantifying larger targets, such as whole cells or bacteria.
- Opaque Slides
- Methods to stabilize and increase the amount of probe attached to matrix arrays are highly desirable. Such methods generally lead to opaque slides, since the matrix materials used to increase probe binding and preserve stability typically involve non-translucent gels, hydro-gels, agars, and other materials coated on the glass surface. Proteins attached to such opaque matrix materials are stabilized by hydrophobic and electrostatic interactions in a three-dimensional array.
- Most scanners in current use for genomic and proteomic microarrays read the slides from the same side as the bound probe and target molecules, using opaque matrix arrays. Opaque matrix-coating materials used to produce microarrays include nylon, PVDF (polyvinylidene fluoride) and nitrocellulose. Nitrocellulose, a traditional polymer substrate in use for more than 50 years, is a substrate with very attractive properties for microarray applications. (E.g., Tonkinson and Stillman, Frontiers in Bioscience 7:c1-12, 2002.)
- Opaque nitrocellulose has been extensively used to immobilize proteins and nucleic acids for biomolecular analysis. Nitrocellulose immobilizes molecules of interest in near quantitative fashion and allows for short and long term storage. Nitrocellulose also allows for solution phase target species to efficiently bind to immobilized capture molecules. Diagnostic devices using ELISA methods have employed nitrocellulose membranes with a lateral flow process to bind capture reagents to the membrane (Jones, IVD Technology, 5(2):32, 1999).
- Traditional opaque membrane materials have a number of attractive features. They are inexpensive to construct, bind more than 100 times the amount of protein that can be bound by linker coated glass slides, and are generally easy to work with. This is particularly true for opaque nitrocellulose membranes, which have a long history of use.
- Nitrocellulose is normally produced in a microporous form that may be applied to the surface of glass slides to form an opaque surface. Probes may then be attached to the opaque nitrocellulose membranes in microarrays, using standard nitrocellulose binding methods. Such slides have been used with radioactive, fluorescent and chemiluminescent detection systems (e.g., Brush, The Scientist 14[9]:21, 2000).
- Traditional nitrocellulose membranes are also very brittle in the absence of a supporting structure or foundation, leading to frequent cracking or fragmentation. For this reason, opaque nitrocellulose has been used in a microporous form bound to plastic sheets. Such sheets are always opaque, due to the microporous form, and require a supporting structure (e.g. acetate or cellulose) to avoid damage during handling.
- Although opaque nitrocellulose membranes exhibit high binding capacity, stability and reasonably low interference with target-capture molecule interactions, they are not suitable for use with optical detection systems designed to work from the opposite side of a matrix array.
- Translucent Nitrocellulose Slides
- The methods and compositions disclosed herein may be used to produce translucent surface coatings of colloidal nitrocellulose that retain advantageous binding characteristics of opaque nitrocellulose membranes. The interaction between probe and target molecules can be observed directly on a translucent nitrocellulose solid matrix.
- In some embodiments of the invention, translucent nitrocellulose matrix arrays may be used in combination with a flow cell, fluidics cube or capillary system (e.g., U.S. patent application Ser. No. 09/974,089). In such embodiments, the translucent nitrocellulose matrix may be attached to one side of a glass or plastic slide. Probes may be attached to the nitrocellulose and the interaction between probe and target molecules observed through the glass with a sensor or camera.
- The nitrocellulose material is totally translucent if formed according to the disclosed methods. Light signals may thus be observed without scatter or interference from opaque materials. This allows a greater signal-to-noise ratio and ease of detection of target molecules, compared to opaque microporous nitrocellulose matrix arrays. Such opaque matrix arrays can obscure portions of the light or reaction indicator species (e.g., dye) produced upon binding of target molecules.
- Nitrocellulose in the form of a colloid in an amyl acetate solvent has been used by electron microscopists to make castings for specimens. Colloidal nitrocellulose is formed by casting as an ultra-thin film on a water surface. The film may then be picked up on a transmission electron microscopy (TEM) grid and used as a support film for TEM specimens. Because the film must be very clean and uniform, great care is exercised in its production. Colloidal nitrocellulose is readily soluble in amyl acetate. The amyl acetate is water soluble and evaporates evenly to form uniform films. It is supplied as a 1% solution of very pure nitrocellulose.
- High purity nitrocellulose in EM grade amyl acetate (Collodion) may be purchased from commercial sources. The amyl acetate is purified by refluxing over calcium oxide to remove all moisture. Soluble and suspended material is removed by slow distillation. The removal of all traces of moisture from the solvent permits the formation of very strong colloidal nitrocellulose films with virtually no holes.
- In an exemplary embodiment of the invention, Collodion was obtained in bulk from Ernest P Fullam, Inc. (Latham, N.Y.) and used to manufacture high quality translucent nitrocellulose matrix arrays. An aliquot of 200 μL of 1% Collodion solution was pipetted onto the surface of freshly cleaned standard 25×75 mm glass slides. The Collodion was evenly spread to the edges of the glass slide surface in a dust free area. After drying for 2 hours at room temperature, the slides were heated for an additional hour or more at approximately 60° C. Dried slides were labeled and stored for production of microarrays.
- When using a glass array surface, the edges of each slide were sealed with lacquer (e.g. nail polish) or other adhesive to prevent the ultra-thin nitrocellulose substrate from separating from the glass upon exposure to aqueous solutions. When colloidal nitrocellulose is applied to acetate film, nylon slides or other plastic surfaces, it requires no adhesive and binds avidly. Slides may be composed of almost any translucent material as long as the amyl acetate does not react with the surface to discolor it or alter its properties. Certain types of plastics become opaque when exposed to amyl acetate and are not suitable for use with that solvent system. In alternative embodiments of the invention, the colloidal nitrocellulose may be suspended in other volatile organic solvents besides amyl acetate before application to a glass or other translucent slide.
- The colloidal nitrocellulose slides may be spotted with probes using any known methods for microarray production. Methods for spotting proteins, peptides, oligonucleotides and nucleic acids onto nitrocellulose surfaces are well known in the art. Antibodies and biotinylated bovine serum albumin were used to determine the colloidal nitrocellulose binding capacity. The estimated protein binding capacity for the initial glass matrix arrays was in the range of 100 to 200 μg/cm2.
- A CMOS imaging system that detected light emissions through the translucent nitrocellulose matrix arrays was used with a Cy5-streptavidin indicator dye. (See, e.g., U.S. patent application Ser. No. 09/974,089, filed Oct. 1, 2001.) At a loading volume of approximately 5 nanoliters per spot, biotinylated BSA was reproducibly detected at least down to 10 to 20 picograms of protein. Optimal CMOS images were obtained using a protein concentration range of about 20 to 100 μg/mL biotinylated BSA. The CMOS imaging data was confirmed using a 24 hour colloidal gold stain (BioRad, Hercules, Calif.) of the spot arrayed translucent nitrocellulose slides.
- The ability of the colloidal nitrocellulose matrix to maintain antibody binding activity was confirmed by spotting a variety of antibodies on the translucent surface. A concentration range of 20 to 200 μg/mL was used. Nonspecific protein binding sites on the nitrocellulose membrane were blocked with 0.1% BSA in buffer solution. The antibodies were then exposed to solutions containing the appropriate target antigen. Binding was detected using biotinylated second antibodies and Cy5-streptavidin indicator.
- A 2D array spotted with 5 nanoliters per spot of primary goat anti-mouse antibody solution and was developed using a secondary mouse Listeria monoclonal antibody and a secondary biotinylated goat anti-mouse antibody. In this assay, the primary and secondary goat anti-mouse antibodies bound to different epitopes of the secondary mouse antibody. The two secondary antibodies were thus used to detect primary antibody bound to the array. Using a CMOS imaging system, the primary antibody could be detected down to a level of 100 picograms or less of antibody. The CMOS data was confirmed on the same slides using colloidal gold staining.
- An advantage of the translucent nitrocellulose surface is that the progress of the probe binding reaction can be examined by looking through the translucent lower surface of the slide. This allows more effective probe binding to occur. The slide may also be adapted for use with a fluidic cube to mix and deliver samples to the surface. The progress of the probe-target binding reaction may also be monitored in real time through the underside of the slide.
- Reconfigurable Microarrays
- In certain embodiments of the invention, reconfigurable microarrays may be produced by using small linker molecules, such as aptamers or affibodies, bound to the surface of a solid matrix. Aptamers are oligonucleotides derived by an in vitro evolutionary process called SELEX (e.g., Brody and Gold, Molecular Biotechnology 74:5-13, 2000). Aptamers may be produced by known methods (e.g., U.S. Pat. Nos. 5,270,163; 5,567,588; 5,670,637; 5,696,249; 5,843,653) or obtained from commercial sources (e.g, Somalogic, Boulder, Colo.). Aptamers are relatively small molecules on the order of 7 to 50 kDa. Because they are small, stable and not as easily damaged as proteins, they may be bound in higher numbers to the surface of a solid matrix. This effectively amplifies the number of probe reactive sites on the surface of an array.
- Affibody® ligands (U.S. Pat. No. 5,831,012) are highly specific affinity proteins that may be designed and used like aptamers. Affibodies may be produced or purchased from commercial sources (Affibody AB, Bromma, Sweden). Aptamers and affibodies may be used in combination with antibodies to increase the functional avidity of translucent or non-translucent solid matrices for probe molecule binding. Increased binding in turn results in an increased signal strength, greater signal-to-noise ratio, more reproducible target molecule detection and greater sensitivity of detection.
- Reconfigurable microarrays may be used in combination with two antibodies and a capture probe. The capture probe may be an affibody, aptamer or any other probe capable of binding one of the antibodies. Both antibodies should selectively bind to a target cell, molecule or antigen.
- The effectiveness of binding is increased if the capture probe binds to a portion of an antibody characteristic of the IgG class. Such probes would only require a small part of the antibody structure to be present in order to react and bind to an antibody-target complex. Larger targets, such as microbes or cells are covered with numerous antigens that may form very large complexes with antibodies. However, truncated IgG antibody fragments could interact with such large targets and still bind to an aptamer or affibody probe on the slide surface.
- Antibodies are most stable in solution and optimal antigen-target molecule binding occurs with antibodies in solution, not attached to a solid matrix. In preferred embodiments of the invention, the two antibodies may be allowed to bind to the target in solution. Once target-antibody complexes are formed, the complex may be exposed to aptamer or affibody probe molecules on the reconfigurable matrix array. The probes may bind to a first antibody, while the second antibody may be conjugated to a fluorescent tag or other marker. The tagged complex may then be detected on the surface of the matrix array, using optical detection or any other known detection method.
- For example, an aptamer may be tailored to specifically bind to the Fc portion of mouse IgG with high affinity. Samples containing target molecules of interest may be allowed to interact in solution with a mouse antibody specific for an antigen of interest. The sample may be mixed with a different biotinylated or otherwise tagged second (non-mouse) antibody that binds to a different epitope on the same antigen. The target antigen bound to the first and second antibodies may be exposed to the aptamer microarray. The anti-mouse aptamer affixes the complex to the solid matrix. After extensive washing to remove unbound tagged antibodies, the complex containing tagged antibody that is attached to the matrix array surface may be detected.
- In some embodiments of the invention, multiple analytes may be simultaneously detected on a reconfigurable microarray. Such multiplex assays require that each second antibody specific for a different target antigen be labeled with a distinguishable label. For example, three different second antibodies may be tagged with red, green or blue fluorophores. Using anti-mouse aptamers, mouse antibodies specific for three different targets may be added to a sample and mixed with the target molecules and second antibodies. After exposure to the aptamer array, the presence of each target may be determined by the presence of red, green or blue fluorophores attached to the matrix. The skilled artisan will realize that the invention is not limited to optically distinguishable fluorophore tags and that any known identifiable tag moieties, such as radioactive, fluorescent, luminescent, enzymatic, etc. may be used. The number of target analytes that may be simultaneously detected is limited only by the number of distinguishable tags that may be attached to the second antibody.
- The skilled artisan will realize that many variations on this scheme may be used within the scope of the claimed methods. For example, in alternative embodiments of the invention, a first antibody may be used in conjunction with multiple tagged second antibodies, each of which binds to a different epitope of the target molecule. This may occur, for example, where the available second antibodies are polyclonal antibodies. Alternatively, use of more than one second antibody with affinity for the same antigen may improve the sensitivity of detection. In another alternative, one second antibody may bind to a class of targets (for example, all E. coli bacteria) while a second antibody binds to a specific subclass (e.g., E. coli strain O157:H7).
- In a non-limiting example, the aptamer detection method may be used to detect microbes in a food sample. An aptamer that exhibits high affinity and specific binding for mouse IgG may be obtained. Such aptamers may be rapidly and readily obtained using SELEX. The anti-mouse IgG aptamer may be attached to a slide using standard methods, preferably with a translucent solid matrix. Non-specific binding sites on the matrix may be blocked and the slide washed before testing.
- To detect Listeria monocytogenes, an IgG mouse anti-Listeria m. antibody may be incubated with a food sample of interest at an appropriate concentration (typically 1 to 50 μg/mL). A rabbit (or other non-mouse) biotinylated secondary anti-Listeria m. antibody (1 to 50 μg/mL) and incubated for 5 to 30 minutes. The sample with both antibodies may then be applied to the array containing anti-mouse IgG aptamers. After a short interval (approximately 15 minutes) the array may be washed so that only mouse IgG and rabbit biotinylated antibody complexed with Listeria m. is retained on the array. A solution of Cy5-strepavidin or other indicator applied to the surface may then reveal the presents or absence of an anti-Listeria m. antibody complex affixed to the surface.
- A single aptamer with high selectivity for IgG mouse antibodies may be used as a universal extender to capture and detect a variety of microbes. The only requirement would be that the mouse antibody to the microbe or antigen reacts only with the target and the aptamer, while the biotinylated second antibody reacts only with the target and not with the aptamer.
- Such an aptamer array is reconfigurable and is dependent only upon the nature of the solutions delivered to its surface. For example, an aptamer array that binds to mouse IgG antibodies may in principal be used to detect any target for which a mouse IgG is available. It is far more cost effective to construct such a reconfigurable array, compared to constructing a series of fixed pattern arrays, each of which may only detect a limited number of targets. Thus, the present invention provides significant cost advantages for use in proteomic and genomic work.
- Although the methods disclosed in this section may be used with opaque arrays, they are most effectively used with a translucent matrix where solutions are delivered on one side and examined for reactivity from the opposite side of the array. A fluidic cube, total optical assay device (TOAD™) or the equivalent may be attached to the reactive surface to deliver fluids to various parts of the array, allowing the user to determine which test results will be obtained for a given sample.
- Aptamers are more stable than antibodies and large proteins. They are also smaller and bind in higher concentrations to reactive surfaces. Thus, aptamer-based systems extend the avidity of an array for target molecules beyond what could be achieved using larger proteins for array binding. Although the present example is presented with regard to aptamers, the skilled artisan will realize that affibodies or other small ligands could be used in the practice of the claimed methods.
- TOAD™ Bioilluminator
-
FIG. 4 illustrates a non-limiting exemplary embodiment of a Total Optical Assay Device (TOAD™). In this example, the TOAD™ comprises a light-tight casing 410 with a hingedlid 420. When thelid 420 is closed, thecasing 410 blocks external light from the interior of the TOAD™, allowing highly sensitive detection of bioluminescence or other emitted light from samples to be analyzed. Thelid 420 is opened to show astage 430. Devices to be imaged, including but not limited to GRABBER™ slides or FOOTPAD™ microtiter well devices, may be positioned on top of thestage 430. Underneath the stage is a single focusing lens (not shown) that sits on top of a CCD (charge coupled device) chip or other light sensor (not shown). The slide or microtiter wells may be positioned on thestage 430 by aligning them with corresponding shaped depressions (seeFIG. 8 ) on the top of thestage 430. Thecasing 410 may comprise depressions, handles or other features to facilitate moving the TOAD™. -
FIG. 7 illustrates a schematic view of an exemplary embodiment of a TOAD™, with the body of thecasing 710 displaced to show the internal components. Thelid 720 overlies a stage 730, which is used to position slides, microtiter wells or other devices over a CCD chip located at the top of animaging device 750. In a non-limiting example, theimaging device 750 is a QICAM 10-bit mono cooled CCD camera (Qimaging™, Burnaby, B.C., Canada, catalog #QIC-M-10-C). However, the TOAD™ is not limited to the exemplary embodiment and it is contemplated that other known types ofimaging devices 750 may be utilized. A single focusing lens (not shown) is interposed between the CCD chip and the stage 730 and may be attached to the top of theimaging device 750, for example using a C-mount adaptor. - In the exemplary embodiment the
imaging device 750 contains, in addition to a CCD chip, a Peltier heat exchange element surrounding the CCD chip. The rest of theimaging device 750 contains electronic components for processing the signals detected by the CCD chip, along with connections for a power supply, software interface and external data port, such as a 6-pin firewire connector. The Peltier heat exchanger removes heat from theCCD camera 750 and releases it inside thecasing 710. In order to prevent the TOAD™ from overheating, a separate fan drivencooling device 740 is positioned adjacent to the top of theimaging device 750. Thecooling device 740 drives hot air out of the casing through a light-tight vent at the back of the casing 710 (not shown) and circulates cool air through the casing 710 interior. During standard operation, thecooling device 740 operates efficiently enough that theCCD camera 750 may be operated continuously without overheating. Overheating of theCCD camera 750 results in substantial increase in background noise, producing random bursts of apparent light detection throughout the optical field of the CCD chip. - The
imaging device 750 rests on top of a base 760 that holds theimaging device 750 in position relative to the stage 730. The bottom of thebase 760 is open to allow access to on on-off switch at the bottom of theimaging device 750 and connections to power supplies (e.g. 110 volt AC electrical cord), firewire and any other external connections. A non-limiting list of components that may be incorporated into a TOAD™, including exemplary embodiments and sources of such components, is included in Table 6. -
FIG. 8 is a schematic diagram showing the top view of an exemplary embodiment of a TOAD™, with thecasing 810 removed to show the upper surface of thestage 820.Indentations stage 820, arranged to allow positioning of slides, microtiter wells or other devices over the CCD chip. Ahole 860 in the center of thestage 820 allows for light transmission through the slide, microtiter well or other device and detection by theunderlying CCD chip 850. It will be apparent to the skilled artisan that the use of transparent or translucent devices, as discussed in more detail below, facilitates the use of a TOAD™ apparatus with an optical detector located below the device to be optically read. - The exemplary embodiment discussed above is designed for optical detection with samples that spontaneously emit light, for example using any known chemiluminescent or bioluminescent detection system, such as the luminol system disclosed below. In this case, no external source of excitatory light is needed to detect bound analytes. The skilled artisan will realize that alternative systems may be utilized, such as fluorescently tagged detection molecules that bind to target analytes. Such systems are well known in the art. The use of a fluorescent detection system would necessitate additional components, such as an excitatory light source (e.g. laser, photodiode array, etc.), cutoff filters to screen the photodetector from excitatory light, and other such known components for fluorescent detection systems. The illustrative embodiment discussed above possesses the advantages of simplicity of construction and use, low cost, and sensitive detection of target analytes with minimal background noise.
- Footpads™
- Certain embodiments concern apparatus and methods of use of devices called Footpads™. Footpads™ may come in a variety of designs, an exemplary embodiment of which is shown in
FIG. 9 .FIG. 9 illustrates an array of 12Footpads™ 910 contained in aFootpad™ holder 920. Asingle Footpads™ 910 has been removed from the array to illustrate its structure. Thetop end 930 of theFootpads™ 910 may be designed for ease of handling, for example with a tapered, ridged shape as shown. Astem 940 may connect thehandle 930 to thebottom 950 of theFootpad™ 910. The lower surface of theFootpads™ 910 may be coated with translucent nitrocellulose, rayon, cellophane or other known materials that may bind to probes, analytes or other ligands, as discussed below. TheFootpad™ 910 may come prespotted with various probes, calibration spots and other spots, as discussed below. Alternatively the user may load any molecule of interest, such as antibodies or other probes, on thelower surface 950 of theFootpad™ 910. - A side view of an array of
Footpads™ 910 inserted into aFootpad™ holder 920 is shown inFIG. 10 . When inserted fully into theholder 920, theFootpads™ 910 are contained in wells that hold theFootpads™ 910 firmly in place. The spacing ofFootpads™ 910 in theholder 920 is designed so that the entire array may be inserted into the wells of a standard 96 well microtiter plate.FIG. 11 shows that the bottom of theFootpad™ holder 920 is open, with space around the rim of theFootpad™ 910 to accomodate the well rims on a microtiter plate. As discussed below, a microtiter plate may be preloaded with reagents and theholder 920 withFootpads™ 910 sequentially immersed in consecutive sets of corresponding microtiter wells. Thus, twelve ormore Footpads™ 910 may be exposed to appropriate reagents simultaneously. Theholder 920 andFootpads™ 910 may be transferred manually between different sets of wells of a microtiter plate. Alternatively, theholder 920 and/orFootpads™ 910 may be designed to be handled robotically. - Footpad™ Kits
- In certain embodiments, a standard 96 well plate with a flat bottom optical surface may be used with pre-loaded reagents and Footpads™ on a bioluminescent TOAD™ detector. A packaged kit may include a labeled, foil sealed 96 well plate with 12 TOAD™ Footpads™ and reagents. Super signal reagents Luminol and peroxide may be mixed immediately before a test and added to the “optical” reservoir H before beginning the test (
FIG. 1 ). The test sample may be placed in the A reservoir (FIG. 1 ). As indicated inFIG. 1 , in certain embodiments, sample is placed in column A wells, blocking solution (100 μL) in column B wells, wash solutions (100 μL) in columns C, E and G wells, antibody cocktail (200 μL) in column D wells, HRP-SA solution (100 μL) in column F wells and luminol solution (100 μL) in column H wells of a 96 well microtiter plate format. The skilled artisan will realize that the disclosed methods and apparatus are not limited to a 96-well format and other formats may be used. Using the 12 Footpad™ holder disclosed above, each column comprising 4 Footpads™ may be sequentially exposed to the solutions in columns A-H ofFIG. 1 , starting with the first column of 4 Footpads™ immersed in the column A (sample) wells and moving theholder 1 column at a time through the B-H wells. Where solutions are present in less than all 8 columns of the microtiter plate, as discussed below, the Footpad™ holder may be manipulated accordingly. - Luminol-peroxide reagent is a solution containing luminol and peroxide that is prepared and used on the same day tests are initiated. Luminol in the presence of HRP (horse radish peroxidase) and peroxide forms an unstable intermediate that produces light (see below). In the process it is consumed. Because it is in abundant excess relative to the amount of HRP trapped in a microspot on the surface of a slide or in a microplate well, light emission may be sustained for several hours. The Luminol and peroxide may be dispensed and mixed in equal volumes. The solution is then diluted using dilution buffer equivalent to the total volume in the first mixture (50% dilution). For example, if 1 ml of Luminol is combined with 1 ml of peroxide, then 2 ml of dilution buffer may be used to dilute the reagent to produce 4 mL of solution for testing.
- A stage may be fitted to the TOAD™ detector to accommodate the 96 well plate (see
FIG. 8 ). The stage should securely fix the microplate so that 4 of the “H” reservoirs (FIG. 1 ), which span 25 mm, fit the optical window of the instrument. In a 96 well microplate format, the first 4 “optical” H1, 2, 3, and 4 reservoirs (FIG. 1 ) are positioned over the target area. The well plates are then shifted in increments of 4 “optical windows” so that alignment and imaging can accommodate all 12 of the H reservoirs in 3 steps. The three positions of interest are shown and labeled in the diagram asposition # 1, #2, or #3 (FIG. 1 ). - Embodiments involving plates pre-loaded with reagents and Footpads™ sealed with foil allow the operator to conveniently run from 1 to 12 test samples by loading only luminol-peroxide and sample into the microplate. Each
row 1 through 12 represents a single sample process. With a breakaway row and seal the packaged kit can be used for incremental tests until all 12 rows are consumed, providing the stage adjusts to lock the “optical” well H on the target imager. Each Footpad™ in an arrayed format accommodates up to 24 spotted probes (FIG. 2 ) and allows for the possibility of multiplexing a single sample.FIG. 2 illustrates an exemplary embodiment, with anEppendorf pipet tip 210 affixed to the top of a Footpad™ with a probe binding surface on the bottom 220, the Eppendorf tip surrounded by a reservoir withfluid 230. With a 96-well format, theFootpad™ surface 220 is about 7 mm in diameter. An exemplary pattern of capture antibodies (200 μM spots) and index spot is also shown 240. - Using a “blank” non-arrayed Footpad™ in a 96 well microplate with an empty “antibody cocktail” reservoir allows the user to test for any targets of interest. This is accomplished by either manually spotting primary antibodies onto a pre-treated Footpad™, or affixing a robotically spotted cellophane, translucent nitrocellulose, rayon or other array of spots to the Footpad™. The operator then fills the empty reservoir with the biotinylated secondary antibodies, the H reservoir with luminol-peroxide, and the A reservoir with sample for testing (
FIG. 1 ). - Since 96 well plates are easily obtained, inexpensive, and optically suitable for a bioluminescent assay, and because preloading the plate is straight forward, one format for the bioluminescent TOAD™ may include a stage to accommodate the 96 well plate in the manner indicated.
- A variety of samples may be analyzed using the methods and apparatus disclosed herein, including virtually any type of environmental, clinical, veterinary, pathologic or medical sample. In different embodiments, samples may be analyzed after collection without any sample treatment whatsoever. In other embodiments, samples may be processed after collection and before analysis. Samples may be processed in various ways, including without limitation cooling, freezing, heating, homogenization, organic phase extraction, detergent extraction, enzymatic digestion, centrifugation, filtration, ultracentrifugation, ultrafiltration, lyophilization or various well known chromatographic procedures. In certain embodiments, it is anticipated that solid samples may be treated by homogenization and, if necessary, crude filtration, such as filtering the sample through a nylon or other filter with a pore size of approximately 100 μm or less.
- Exemplary Footpad™ and Spotting Pattern
- In certain embodiments, TOAD™ Footpad™ are cylinders measuring 7 mm in height and 7 mm in diameter, fitting with the lower flat coated surface resting on the flat bottom of the well reservoir (
FIG. 2 ). The exposed upper surface may be used to affix an inverted eppendorf pipet tip, handle or appendage so that the pad may be moved easily from one reservoir to the next. The lower surface of the Footpad™ is coated with an appropriate binding medium and may be either blank or pre-arrayed (spotted) with capture antibodies (probes). Each pad may be marked with an index calibration spot (FIG. 2 ) serving two purposes. - The index when placed in luminol-peroxide provides a reference for luminosity based on a standard spot. It also serves to identify any other spots that react in a test since the position relative to the index is always known. It does not matter if the pad rotates in the reservoir, since capture probe spots are identified in spatial relationship to the index calibration spot. All positions are correctly readable as long as the pad is placed face (treated surface) down in a reservoir.
- A total of 24 spots may be affixed to a single Footpad™ without exceeding a density of 100 spots per square cm. A binary ID code may be affixed to a Footpad™, for exampole using the first two rows of spots, and used to provide a tracking lot ID number.
- Translucent Nitrocellulose Binding Surface Affixed to the Footpad™
- The lower surface of the Footpad™ may be used to accept and firmly affix probes. The composition of the surface may be important for optimized probe binding and analyte detection and quantification. Depending upon how the array or spotting is done, the composition may vary. In preferred embodiments, the lower surface of the Footpad™ is coated with a thin layer of translucent nitrocellulose.
- Colloidal 1% nitrocellulose firmly affixes to nylon, and to a lesser extent to other plastics and glass. As shown herein, the translucent nitrocellulose surface formed after drying on these surfaces avidly binds proteins and other substrates, while preserving their functionality (e.g., enzyme activity, antibody-antigen binding, etc.) A Footpad™ of nylon to which translucent nitrocellulose has been applied may be used. This format works well for manual spotting on the pad but may be less useful for robotic arrayers, which are mostly designed to print on ordinary slides measuring 25×75×1 mm.
- In some embodiments, a sheet of nylon coated with nitrocellulose may be used to print the array. The array may then be punched out and affixed to the lower surface of the Footpad™ with an adhesive. In alternative embodiments, a device may be constructed to hold coated Footpads™ firmly in position for robotic array work. Additional details of embodiments using translucent nitrocellulose layers for probe binding are disclosed below.
- Rayon and Cellophane Substrates
- We have shown that 100% rayon thread, when immersed in a phosphate buffer with biotinylated BSA, affixes the B-BSA and produces a strong signal easily seen in the HRP-SA Luminol-peroxide format on the bioluminescent detector. The signal is intense and specific for biotin affixed to the thread, as can be demonstrated by first blocking the thread with 0.1% BSA. No signal is evident if the thread is blocked first before adding HRP-SA and Luminol-peroxide. It appears that rayon, a naturally occurring cellulose polymer, behaves in a manner similar to nitrocellulose. Untreated “raw” cellophane is identical to 100% rayon and can be obtained in translucent thin sheets. It is abundant and inexpensive.
- In some embodiments, functional Footpads™ to bind probes may be manufactured out of rayon. Alternatively, cellophane printed discs may be affixed to the Footpad™ with an appropriate adhesive. The array may be printed on a thin sheet of cellophane before affixing it to glass, plastic, or any other solid support.
- The Footpad™ may be of any color and does not have to be translucent. A rayon or cellophane surface requires no solvent or drying step, making the manufacturing process less complicated than the colloidal nitrocellulose process for coating either slides or Footpads™.
- 96 Well Microplate Procedure
- In the following discussion, HRP-SA reagent refers to horse radish peroxidase conjugated with streptavidin in a solution formulated to enhance antigen detection. The solution is normally stable for at least 2 years from the time of formulation. Its activity can be verified in a test by placing one drop into 100 μL of luminol-peroxide solution. In a totally dark room, the faint blue light emitted shows that the light-producing reaction has begun.
- The Footpads™ are either precoated and spotted with probes or precoated and blank (no spots on the pad), placed in the empty reservoir A column (
FIG. 1 ). The operator using a blank (non-pre-arrayed) package will conduct assays with probes and biotinylated antibodies that are provided by the user. Because the Footpad™ comes already prepared for manual spotting, the operator needs only to remove the Footpad™, apply spots to its lower surface, fill the antibody D reservoir (FIG. 1 ) with biotinylated antibodies, fill the luminol-peroxide H reservoir (FIG. 1 ), block the Footpad™, and begin the test. - Material List Using Pre-Coated Blank Footpad™ Test
- The following materials may be used for a pre-coated blank Footpad™ test.
- Pre-coated blank Footpad™ 96 well kit
- Spotting buffer
- Primary antibody for target of interest
- Secondary biotinylated antibody to form the sandwich immunocomplex
- Antibody dilution buffer with stabilizer
- Index marking solution
- Luminol-peroxide reagent
- Sample for testing
- TOAD™ bioilluminator
- Desktop computer and software
- Material List Pre-Arrayed Blank Footpad™ Test
- For pre-arrayed Footpad™ tests, the following materials may be used.
- Pre-arrayed Footpad™ 96 well kit
- Luminol-peroxide reagent
- Sample for testing
- TOAD™ bioilluminator
- Desktop computer and software
- Pre-Coated Blank Footpad™ Procedure
- All reagents and materials may be assembled and identified before initiating a test. In this embodiment, the user has elected to use antibodies for probes and secondary biotinylated antibodies to capture a target when using a blank Footpad™. The procedure is illustrated in Table 1.
- Pre-Arrayed Footpad™ Procedure
- All reagents and materials may be assembled and identified before initiating a test. In this embodiment, the user has elected to use a pre-arrayed Footpad™ configuration, making the entire process considerably simpler and faster using spotted Footpads™. Only two solutions are loaded into well reservoirs. The luminol-peroxide reagent is mixed and added to reservoir H (
FIG. 1 ). The sample is placed in reservoir A (FIG. 1 ). Processing begins after the Footpad™ has been adequately blocked, incubating 5 minutes in reservoir B. The procedure is illustrated in Table 2. - Component Configuration
- Exemplary Kit Components of Potential Use with a Footpad™ Format are Indicated in Table 3.
- Binary ID Code
- A binary code of spots may be used as an index to track production batches of pre-arrayed Footpads™, GRABBER™ slides or other items. An exemplary method of coding is disclosed herein. A binary code system to identify a production particular lot may be used in the first two rows of the Footpad™ (
FIG. 2 ). There are 3 reference spots in the first calibrator position. The reference spots are used to determine if the other spots in the adjacent rows and column are binary 1 orbinary 0. A 4th spot located at the coordinates forrow 2column 2 is a quality assurance check sum on the intended code for the lot number assigned. The other spots in the first two rows are either empty or filled with the biotin marker at the same concentration and volume as is used for calibration spots and are determined to be either 0 or 1 by comparison to the 3 binary reference marks. -
Binary 0 Reference Spot - The binary 0 reference spot contains 1/10th of the concentration of the biotin marker used in a standard calibration spot. If any of the spots used to set the binary code are measured with a luminosity of lower intensity than the binary 0 reference, they are assigned a value of 0. A spot measured with a greater luminosity than both the binary 0 reference and the binary 1 reference is assigned the value of 1. A spot with a measured luminosity in between the binary 0 and
binary 1 reference spots registers as a defective Footpad™ and is reported as an error to the operator. -
Binary 1 Reference Spot - The binary 1 reference spot contains 3/10th of the concentration of the biotin marker used in a standard calibration spot. If any of the spots used to set the binary code are measured with a luminosity of greater intensity than the binary 1 reference, they are assigned a value of 1. A spot of lower luminosity than both the binary 1 reference and the binary 0 reference is assigned the value of 0. A spot measuring luminosity between the reference spots registers as a defective Footpad™ and is reported as an error to the operator.
- Binary Code and Lot Number Assignments
- For each production of a Footpad™ there is a lot production date. The date of production may serve as the Lot number assignment for that production. The date may be printed in a binary code format. The unique pattern for a particular production date may be determined when a request for a lot production run is made.
- A proprietary software program coding and assigning filled and empty spots may be used so that a user by entering the date for the production run will see the spots that are to be filled and those to be left empty. The program used for the pattern of filled spots in the ID code also generates the assignment for the check-sum validation reference.
- Check Sum Validation Spot
- A reference spot at
row 2column 2 may be either completely filled or left empty as a validation of the binary code on the Footpad™. If the sum of thevalue 1's in the binary code assigned for a particular date is an even number, then the value 0 (empty spot) may be assigned for the check sum validation spot. If the sum of thevalue 1's in the binary code assigned for a particular date is an odd number, then the value 1 (filled spot) may be assigned for the check sum validation spot. The check sum validation when read against the binary code reference spots will be either 0 or 1. If the value read fails to match the assigned value for a particular production date, the Footpad™ will be assumed to have been printed incorrectly and discarded. - GRABBER™ Slides
- Embodiments of the invention concerning a microtiter well format are discussed above (Footpad™). Alternative embodiments concern devices and methods of use of translucent coated slides (GRABBER™) (
FIG. 3 ).FIG. 3 illustrates an exemplary protocol for use with GRABBER™ slides, comprising affixing a primary antibodies to theslide 310, drying the2D array 320, blocking the slide 330 (10 min), capturing antigen with the primary antibodies 340 (10 min), forming an immunocomplex with secondary biotinylated antibodies 350 (10 min), forming HRP-SA complexes 360 (10 min), addingluminol reagent 370 and capturing an image (10 min). The luminescent reaction catalyzed by HRP is as indicated in the bottom ofFIG. 3 . - GRABBER™ slides provide for an easy to use method for detecting and identifying one or more targets of interest in a solution assayed on the surface of a slide. Slides may be provided pre-spotted with capture probes (e.g., antibodies) affixed ready for immediate testing. Alternatively, users who want to prepare their own 2D-spotted array may in 1 hour prepare a manual array for testing.
- In preferred embodiments, the method of detection utilizes a primary antibody capturing an antigen target to form an immunocomplex with a second antibody that is biotinylated or otherwise labeled. The first antibody probe is affixed to a translucent nitrocellulose slide (GRABBER™) and during the entire procedure remains affixed to the surface of the slide.
- The immunocomplex, if formed, may be detected using a well-known enzyme activated bioluminescent process. Horseradish peroxidase (HRP) catalyzes the breakdown of peroxide and produces an intense light if luminol is added to the solution during the breakdown process. Luminol forms an unstable free radical intermediate that results in the release of photons at 430 nm (
FIG. 3 ). By conjugating HRP to streptavidin (SA), the immunocomplex may be detected with an appropriate and sensitive photon detector. Biotin and streptavidin rapidly combine to form this light producing complex. - Typical protein (e.g., antibody) probes may be spotted with 1 to 5 nL per spot at a concentration of 0.05 to 0.2 μG/mL. Where primary antibodies are attached to a slide, matrix array or other surface, secondary tagged antibody, such as biotinylated antibody, may be provided in a dilution buffer premixed at an optimized concentration for target detection with pre-spotted slides. The optimized concentration may be determined empirically by the user. Secondary antibodies may be diluted in dilution buffer to a concentration typically in the range of 5 to 30 μG/mL.
- A TOAD™ (total optical assay device) may be provided with proprietary software to allow the user the means to read, interpret and record signals at the surface of a slide. An image file and report may be saved or printed for subsequent analysis and comparisons.
- The user may provide a sample that is placed in an incubation sleeve (
FIG. 6 ) affixed to the slide and allowed to react for 10 minutes before it is discarded (see below). - GRABBER™ slides may be coated with a translucent nitrocellulose substrate (see U.S. patent application Ser. No. 10/373,546, filed Feb. 24, 2003) that avidly and immediately binds proteins, carbohydrates and/or oligonucleotides, strongly affixing them to the coated surface while preserving the functionality and 3D structure of the bound molecule. No other chemical process is required to affix the probes to the slide surface, making the 2D array procedure simple and fast. The hydrophobic surface with a superior contact angle is well suited for compact robotically printed arrays.
- The bioluminescent reaction is long lasting and the signal may be acquired over prolonged periods, allowing for extraordinary sensitivity in detection. Many targets may be simultaneously identified in a single sample. The proper primary probe antibody and biotinylated secondary antibody should strongly interact with the target for adequate detection. Preprinted slides and reagents provided are optimized to produce high quality detection.
- Materials List
- All of the disposable slides, reagents and other materials needed to assay for analytes using GRABBER™ slides with a TOAD™ bioilluminator may be provided in kit form, as illustrated in
FIG. 5 .FIG. 6 shows an exemplary set of GRABBER™ slides, along with an incubation sleeve for performing the binding, washing and other procedures on the slide. The exemplary incubation sleeve shown inFIG. 6 contains four separate reaction chambers for use with GRABBER™ slides. - The following exemplary materials may be used to perform a pre-coated nitrocellulose slide assay. Non-limiting exemplary kit materials for use with GRABBER™ slides are also listed in Table 7, along with exemplary sources for the materials. A kit may be provided with all the materials needed to complete an assay. The user may assemble gloves, forceps, a timer, waste container for spent material, and eppendorf tips for spotting an array. A sample for testing should be acquired before beginning the assay. If the array is pre-spotted, testing may begin with the blocking as shown in
FIG. 3 . -
- GRABBER™ pre-coated slide
- Spotting buffer
- Spotting template
- Focus Template slide
- Primary antibody for target of interest
- Secondary biotinylated antibody to form the sandwich immunocomplex
- Antibody dilution buffer with stabilizer
- Index marking solution
- HRP-SA reagent
- Luminol-peroxide reagent
- Sample for testing
- Incubation sleeve
- TOAD™ bioilluminator
- Desktop computer and software
- Disposable dispensers
- Timer
- Dust free latex gloves
- Forceps
- Pre-Spotted Array Protocol
- All reagents and materials may be assembled and identified before initiating an assay. In certain embodiments, pre-spotted arrays ready for testing are obtained. Slides have incubation sleeves (
FIG. 6 ) affixed to the nitrocellulose surface and secondary biotinylated antibodies are provided ready for use. An exemplary protocol for use with pre-spotted arrays is disclosed in Table 4. - Protocol for User Prepared 2D Array
- In an alternative embodiment, the user may elect to provide primary antibodies for probes and secondary biotinylated antibodies to detect a target when using a pre-coated non-arrayed slide. An exemplary protocol is shown in Table 5.
- Detection Unit
- The discussion above illustrates the use of a TOAD™ containing an exemplary CCD based optical detection system. The apparatus and methods are not limited to the disclosed preferred embodiments. In certain embodiments, a TOAD™ may comprise one or more alternative detection units. Optical signals may be produced when analytes bind to probes and HRP-conjugated secondary antibodies in the presence of luminol, as disclosed above. The signals may be detected by the detection unit. The detection unit may comprise one or more detectors, such as a spectrometer, monochromator, CCD device, CCD camera, photomultiplier tube, photodiode, avalanche photodiode or any other device known in the art that can detect an optical signal. An optical signal may comprise any form of electromagnetic radiation, emission, or absorption, although in preferred embodiments the optical signal comprises visible light.
- In preferred embodiments, the presence of analyte attached to one or more probes is indicated by a bioluminescent spot on the surface of the slide, 96-well microplate or other surface. In various embodiments, the device may comprise a data analysis and storage unit, such as a computer or microprocessor. Suitable devices are well known in the art and the present invention is not limiting as to the type of data analysis and storage unit used. The data analysis and storage unit may be operably coupled to the detection unit, so that optical signals are collected, processed and stored. In alternative embodiments, the data analysis and storage unit may store information on each sample collected, including the sample source, geographical location and any other data collected on the sample. The unit may further identify each analyte detected in the sample and store that data as well. In certain embodiments, the device may comprise an interface for downloading data to a remote location, either directly (for example by an incorporated radio transmitter or modem) or indirectly (for example, by downloading to diskette or other storage device or by printing a hard copy).
- In certain embodiments, one or more optical components may be interposed between the spot containing surface and detector, such as a lens or lens array to focus optical signals from each spot. A non-limiting example of a detector may comprises a CMOS camera sensor or equivalent unit, such as a PixeLink model AL633 CMOS imager (Vitana Corp., Ottawa, Canada).
- In an exemplary embodiment, a nylon slide or other matrix array may be secured on a stage. A CMOS imager may be used to capture the light signals. The CMOS chip may be located beneath the slide and aligned so that spots on the slide are directly above the imager and are sharply focused on the imager surface with optical lenses and apertures. Additional details of a CMOS imaging system and data analysis method of use are disclosed in U.S. patent application Ser. No. 10/373,408, by Lawrence R. Green, entitled “Image Sensor Optimization,” filed on Feb. 24, 2003, incorporated herein by reference.
- Probes
- Various embodiments concern the use of probes for the detection of analytes. Although in preferred embodiments the probes are antibodies, it is contemplated that virtually any molecule or aggregate that can bind to a target analyte with sufficient affinity and specificity to allow its detection may be used. Standard procedures for the production of monoclonal or polyclonal antibodies are known (see, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1988; incorporated herein by reference).
- Polyclonal antibodies are prepared by immunizing an animal with an immunogen and collecting antisera from the immunized animal. A wide range of animal species can be used for the production of antisera. Typical animals used for production of anti-antisera include, for example, rabbits, mice, rats, hamsters, pigs or horses. Because of the relatively large blood volume of rabbits, a rabbit is a preferred choice for production of polyclonal antibodies.
- Antibodies, both polyclonal and monoclonal, may be prepared using conventional immunization techniques, as will be generally known to those of skill in the art. A composition containing antigenic epitopes of an analyte can be used to immunize one or more experimental animals, such as a rabbit or mouse, which will then proceed to produce specific antibodies against the analyte. Polyclonal antisera may be obtained, after allowing time for antibody generation, simply by bleeding the animal and preparing serum samples from the whole blood.
- A given composition may vary in its immunogenicity. It is often necessary, therefore, to boost the host immune system, as may be achieved by coupling an immunogen to a carrier. Exemplary and preferred carriers are keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). Other albumins such as ovalbumin, mouse serum albumin or rabbit serum albumin also can be used as carriers. Means for conjugating an analyte to a carrier protein are well known in the art and include glutaraldehyde, m-maleimidobenzoyl-N-hydroxysuccinimide ester, carbodiimide and bis-biazotized benzidine.
- The immunogenicity of a particular immunogen composition can be enhanced by the use of non-specific stimulators of the immune response, known as adjuvants. Exemplary and preferred adjuvants include complete. Freund's adjuvant (a non-specific stimulator of the immune response containing killed Mycobacterium tuberculosis), incomplete Freund's adjuvants and aluminum hydroxide adjuvant.
- The amount of immunogen composition used in the production of polyclonal antibodies varies, depending upon the nature of the immunogen as well as the animal used for immunization. A variety of routes can be used to administer the immunogen (subcutaneous, intramuscular, intradermal, intravenous and intraperitoneal). The production of polyclonal antibodies may be monitored by sampling blood of the immunized animal at various points following immunization. A second, booster, injection also may be given. The process of boosting and titering is repeated until a suitable titer is achieved. When a desired level of immunogenicity is obtained, the immunized animal can be bled and the serum isolated and stored, and/or the animal can be used to generate monoclonal antibodies.
- Monoclonal antibodies may be readily prepared through use of well-known techniques, such as those exemplified in U.S. Pat. No. 4,196,265, incorporated herein by reference. Typically, this technique involves immunizing a suitable animal with a selected immunogen composition, e.g., a purified or partially purified composition comprising an analyte. The immunizing composition is administered in a manner effective to stimulate antibody producing cells. Cells from rodents such as mice and rats are preferred, however, the use of rabbit, sheep or frog cells is also possible.
- Following immunization, somatic cells with the potential for producing antibodies, specifically B-lymphocytes (B-cells), are selected for use in the mAb generating protocol. These cells may be obtained from biopsied spleens, tonsils or lymph nodes, or from a peripheral blood sample. Spleen cells and peripheral blood cells are preferred, the former because they are a rich source of antibody-producing cells that are in the dividing plasmablast stage, and the latter because peripheral blood is easily accessible. Often, a panel of animals will have been immunized and the spleen of the animal with the highest antibody titer will be removed and the spleen lymphocytes obtained by homogenizing the spleen with a syringe. Typically, a spleen from an immunized mouse contains approximately 5×107 to 2×108 lymphocytes.
- The antibody-producing B lymphocytes from the immunized animal are then fused with cells of an immortal myeloma cell, generally one of the same species as the animal that was immunized. Myeloma cell lines suited for use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have high fusion efficiency, and enzyme deficiencies that render then incapable of growing in certain selective media which support the growth of only the desired fused cells (hybridomas).
- Any one of a number of myeloma cells may be used, as are known to those of skill in the art. For example, where the immunized animal is a mouse, one may use P3-X63/Ag8, P3-X63-Ag8.653, NS1/1.Ag 4 1, Sp210-Ag14, FO, NSO/U, MPC-11, MPC11-X45-GTG 1.7 and S194/5XX0 Bul; for rats, one may use R210.RCY3, Y3-Ag 1.2.3, IR983F and 4B210; and U-266, GM1500-GRG2, LICR-LON-HMy2 and UC729-6 are all useful in connection with cell fusions.
- Methods for generating hybrids of antibody-producing spleen or lymph node cells and myeloma cells usually comprise mixing somatic cells with myeloma cells in a 2:1 ratio, though the ratio may vary from about 20:1 to about 1:1, respectively, in the presence of an agent or agents (chemical or electrical) that promote the fusion of cell membranes. Fusion methods using Sendai virus (Kohler and Milstein, Nature, 256:495-497, 1975; Eur. J. Immunol., 6: 511-519, 1976), and those using polyethylene glycol (PEG), such as 37% (v/v) PEG, have been disclosed (Gefter et al., Somatic Cell Genet., 3: 231-236, 1977). The use of electrically induced fusion methods is also appropriate (Goding, In: Monoclonal Antibodies: Principles and Practice, 2d ed., Academic Press, Orlando, Fla., pp. 60-61, and 71-74, 1986).
- Fusion procedures usually produce viable hybrids at low frequencies, around 1×10−6 to 1×10−8. However, the viable, fused hybrids may be differentiated from the parental, unfused cells by culturing in a selective medium that contains an agent that inhibits cell growth for unfused cells. Exemplary agents are aminopterin, methotrexate, and azaserine. Where aminopterin or methotrexate are used, the medium is supplemented with hypoxanthine and thymidine as a source of nucleotides (HAT medium). Where azaserine is used, the medium is supplemented with hypoxanthine.
- A preferred selection medium is HAT. Only cells capable of operating nucleotide salvage pathways are able to survive in HAT medium. The myeloma cells are defective in key enzymes of the salvage pathway, e.g., hypoxanthine phosphoribosyl transferase (HPRT), and they cannot survive. The B-cells can operate this pathway, but they have a limited life span in culture and generally die within about two weeks. Therefore, the only cells that can survive in the selective media are those hybrids formed from myeloma and B-cells.
- This culturing provides a population of hybridomas from which specific hybridomas are selected. Typically, selection of hybridomas is performed by culturing the cells by single-clone dilution in microtiter plates, followed by testing the individual clonal supernatants (after about two to three wk) for the desired reactivity. The assay should be sensitive, simple and rapid, such as radioimmunoassays, enzyme immunoassays, cytotoxicity assays, plaque assays, dot immunobinding assays, and the like.
- The selected hybridomas would then be serially diluted and cloned into individual antibody-producing cell lines, which clones can then be propagated indefinitely to provide mAbs. The cell lines may be exploited for mAb production in two basic ways. A sample of the hybridoma can be injected (often into the peritoneal cavity) into a histocompatible animal of the type that was used to provide the somatic and myeloma cells for the original fusion. The injected animal develops tumors secreting the specific monoclonal antibody produced by the fused cell hybrid. The body fluids of the animal, such as serum or ascites fluid, can then be tapped to provide mAbs in high concentration. The individual cell lines also could be cultured in vitro, where the mAbs are naturally secreted into the culture medium from which they can be readily obtained in high concentrations. Monoclonal antibodies produced by either means may be further purified, if desired, using filtration, centrifugation, and various chromatographic methods such as HPLC or affinity chromatography.
- Although the methods and compositions disclosed herein allow for the production of novel antibodies against analytes, it is contemplated that previously characterized antibodies or commercially available antibodies may be used to bind to and detect any analyte of interest.
- Non-antibody probes that may be used include, for example, aptamers (e.g., U.S. Pat. Nos. 5,270,163; 5,567,588; 5,670,637; 5,696,249; and 5,843,653, incorporated herein by reference), peptide libraries (e.g., U.S. Pat. Nos. 5,565,332, 5,596,079, 6,031,071 and 6,068,829, incorporated herein by reference), and various receptor proteins, binding proteins, cell surface proteins, and other non-antibody peptides or proteins known in the art.
- Probe Labels
- In various embodiments of the invention, labeled probes may be prepared by any methods known in the art. In certain embodiments, a label moiety may be incorporated into a probe (e.g., peptide, protein, oligonucleotide) during synthesis. In other embodiments of the invention, labels may be attached by covalent, noncovalent, ionic, van der Waals, hydrogen bonding or other forces following probe synthesis. Methods for attaching fluorescent or other labels to probe molecules are known in the art and any such known method may be used to make labeled probes within the scope of the present invention. In particular embodiments of the invention, a probe molecule may be biotinylated and may bind to an avidin or streptavidin-conjugated fluorophore. Fluorophores and conjugated fluorophores may be obtained from commercial sources, such as Molecular Probes, Inc. (Eugene, Oreg.).
- Labels of use may comprise any composition detectable by electrical, optical, spectrophotometric, photochemical, biochemical, immunochemical, or chemical techniques. Labels may include, but are not limited to, conducting, luminescent, fluorescent, chemiluminescent, bioluminescent and phosphorescent labels, chromogens, enzymes or substrates. Fluorescent molecules suitable for use as labels include, but are not limited to, dansyl chloride, rhodamineisothiocyanate,
Alexa 350,Alexa 430, AMCA, BODIPY 630/650,BODIPY 650/665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, Cascade Blue, Cy2, Cy3, Cy5,6-FAM, fluorescein, HEX, 6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, ROX, TAMRA, TET, Tetramethylrhodamine, and Texas Red. A variety of other known fluorescent or luminescent labels may be-utilized. (See, e.g., U.S. Pat. No. 5,800,992; U.S. Pat. No. 6,319,668.) - Methods of Optical Signal Analysis
- According to an embodiment of the invention, images such as images for bioanalyte detection may be captured by an imager. The signal data may be corrected for sensitivity variation in the imager. The corrected data may then subjected to a leveling process.
-
FIG. 12 illustrates an embodiment of an imaging operation 1205. Under a particular embodiment of the invention, the operation provides for imaging bioanalyte detection. In this illustration, the process begins with capturing andprocessing calibration images 1210. The process of capturing and processing calibration images provides for a calibration of the imaging system to adjust for differences in sensitivities for pixels or regions of the imager. In calibration, a number of images, such asimages 1 through k, are captured. Each of the k images has a known exposure level for calibration. In one embodiment, the k images have varying exposure levels that represent an even distribution over a particular range of exposure levels. The calibration process is performed at least once for an imager, but may be performed as often as needed. - Using the data obtained from the k images, an interpolation function is created between exposure levels and average pixel signal values. The function may be expressed as F_Average(exposure). The interpolation function provides an average signal value expected for any exposure level in the range, based on interpolation between the average results of the calibration images. For example, if an exposure level x produces an average interpolated pixel signal level of y, this may be expressed as:
F_Average(x)=y [1] - An interpolation function may also be created between exposure levels and the resulting signals produced by each pixel of the imager. The function for the nth pixel of the image may be expressed as Func[n](exposure). The interpolation function provides a signal value expected for a pixel for any exposure level in the range, based on interpolation between the results of the calibration images for each pixel. For example, if an exposure level x produces a pixel signal level z for the nth pixel of the image, this may be expressed as:
Func[n](x)=z [2] - The results produced by the average interpolation function F_Average (exposure) and the interpolation functions for each pixel Func[it] (exposure) may be based on linear interpolation. However, the optical signal analysis is not limited to any particular method of interpolation. A different method of interpolation may be implemented and may provide more precise results in certain circumstances.
- A test image may be captured 115. The image may be captured using a particular test exposure level (TestExposure). The capture of the test image results in the production of a pixel signal value for each pixel in the imager. The pixel signal values provide data regarding the radiation reaching the imager. However, the sensitivity of the pixels may vary. Under an embodiment of the invention, the process provides for correction of sensitivity deviation of imager areas 120. For each pixel of the imager, a correction coefficient may be calculated. The coefficient for a pixel is equal to the average interpolation function shown in equation [1] divided by the interpolation function for the pixel as shown in equation [2]. For pixel n and exposure level TestExposure:
Coefficient[n]=F_Average(TestExposure)/Func[n](TestExposure) [3] - While this embodiment provides for a coefficient for each pixel, other embodiments may provide for correction coefficients that are based on different regions or groups of pixels.
- A corrected test signal for the nth pixel may then be obtained by multiplying the received test signal (TestSignal[n]) by the coefficient for the pixel obtained from equation [3]:
TestSignalCorrected[n]=Coefficient[n]×TestSignal[n] [4] - The corrected data may then be provided for automated analysis 130. The corrected data may also be subjected to level transformation to improve the visual control of the test results 125. Under an embodiment of the invention, level transformation for a test image may include creation of a histogram of the image that reflects the number of pixels that provide each corrected pixel signal value. An end-in-search contrast stretching method may then be applied to the histogram. In an embodiment of the invention, this method includes applying a constant percentage value P to saturate the image to full white and black. The method then provides for parsing through the histogram to find the high and low thresholds for the image. A particular signal depth value (such as 255, reflecting an eight-bit value) may be utilized. The leveled signal (LeveledTestSignalCorrected) for each pixel may be produced by comparing the corrected test signal with the High and Low thresholds. If the corrected value is less than the low threshold, the leveled signal is set to zero. If the corrected value is greater than the high threshold, the leveled signal is set to the depth value, such as, for example, 255. If the corrected value is between the high and low thresholds (or equal to the high or low threshold), the corrected value is set to the depth times the difference between the corrected signal value and the low threshold divided by the difference between the high and low thresholds.
- Under an embodiment of the invention, assuming that Low is the Low threshold and High is the High threshold obtained from a histogram, the production of the leveled signal for the nth pixel may be expressed in the following pseudocode:
IF TestSignalCorrected[n]<Low THEN LeveledTestSignalCorrected[n]=0
ELSE IF Low←TestSignalCorrected[n]←High THEN LeveledTestSignalCorrected[n]=0
ELSE LeveledTestSignalCorrected[n]=Depth -
FIG. 13 is an exemplary flowchart illustrating an embodiment of an imaging process. The embodiment shown inFIG. 13 assumes that a calibration is made of an imager followed by the capture of a test image. In this embodiment, calibration (1305-1315) includes capturing a certain number ofcalibration images 1305 using an imager. The calibration images are of varying exposure levels, with pixel values being captured for each such calibration image. An interpolation function (F_Average) is created 1310 to produce an average interpolated signal value for any exposure level. An interpolation function is created 1315 for each pixel (or region) of the imager to produce an interpolated signal value for any exposure level. - Upon calibrating the imager, a test image may be captured 1320. The capture of the test image produces signal values for each pixel of imager, but such values are based upon the varying sensitivity of each pixel. Under an embodiment of the invention, the captured signal values are corrected for sensitivity (1325-1330). A coefficient is calculated for each
pixel 1325, with the coefficient being the average interpolation function value for the test exposure level divided by the pixel interpolation function for the test exposure level, such as shown in equation [3]. Corrected signals are calculated for eachpixel 1330, with the corrected signal equaling the test signal produced by the pixel times the coefficient for the pixel, such as shown in equation [4]. The corrected signals then may provided to anyautomated analysis 1360. - Under an embodiment of the invention, the corrected signal values may be subjected to a level transformation (1340-1355). A histogram is produced 1340 based upon the relation between each corrected pixel signal value and the number of pixels producing such corrected pixel signal value. A contrast stretching method is applied 1345, which may include a constant percentage being saturated to full white and black. The histogram is then searched to determine the High threshold and Low threshold for the
histogram 1350. Using such data, a leveled corrected test signal is produced for eachsignal 1355, which is shown in more detail inFIG. 14 . Upon producing the leveled data, the data may be provided tovisual control 1365. -
FIG. 14 is an exemplary flowchart illustrating an embodiment of producing leveled corrected test signals for an imager. In this illustration, it is assumed that there are N pixels, which, for simplicity of explanation, are numbered 1 through N. For illustration, j is a counter variable used in the process. The counter j is initially set to 1 (1405). For the jth pixel, there is a determination whether the corrected signal value is less than theLow threshold 1410. If so, the leveled signal value is set to zero 1415. If not, there is a determination whether the corrected signal is between (or equal to either of) the Low threshold and the High threshold. If so, the leveled value is set to the depth value for the imager times the difference between the corrected signal value and the Low threshold, divided by the difference between the High threshold and theLow threshold 1425. If not, the corrected signal value is greater than the High threshold and the leveled value is set to the depth value for theimager 1430. - The counter j is then incremented 1435 and there is a determination whether the counter value is less or equal to than the number of
pixels N 1440. If so, the process continues for thenext pixel 1440. If not, then all pixels have been processed and the leveled signal values have been produced 1445. -
FIG. 15 is block diagram of anexemplary computer 1500 that may be utilized in connection with an embodiment of the invention.FIG. 15 contains a possible embodiment of a computer, but embodiments of the invention may be implemented using many different general and special purpose computers. - Under an embodiment of the invention, the
computer 1500 includes abus 1505 or other for transferring data and communicating. The bus may include multiple buses utilized for different purposes. Thecomputer 1500 includes aprocessor 1510 to process information. Theprocessor 1510 may include one or more individual processors or coprocessors. - The
computer 1500 may include aninput 1515 coupled with thebus 1505. The input is used for communicating information and providing commands. Theinput 1515 may include a keyboard, a keypad, a touch-screen, a voice-activated process, or other input devices. The computer may include a mouse or other cursor control 1520 to control cursor placement and to provide commands. Thecomputer 1500 may include adisplay 1525, such a CRT (cathode ray tube) or LCD (liquid crystal display) screen to display information. Thedisplay 1525 may include a device to produce sound, such as a speaker. - The
computer 1500 includes amain memory 1530, such as random access memory (RAM), to store data. Thecomputer 1500 may include read only memory (ROM) 1535 or other similar storage for storing static data. Thecomputer 1500 may includedata storage 1540, such as a magnetic disk (hard disk or floppy disk), an optical disk (CD-ROM or DVD), flash memory, or other memory systems. - The
computer 1545 may includecommunication 1545. Thecommunication 1545 may include a wired or cable interface (including but not limited to Firewire, USB, parallel, and serial cables), a wireless interface, a network interface card, a radio transceiver, or other interface. Thecomputer 1500 may be connected to a network or to other computers, devices, or instruments using thecommunication 1545. - Analysis using Image Sensors
- The data analysis scheme disclosed above is a non-limiting example of methods of data analysis of use for analyte detection with the disclosed apparatus. In alternative embodiments, different methods of data analysis may be utilized, either alone or in conjunction with the above-disclosed method. The data analysis methods disclosed below are of particular use where detected light signals are not monochromatic.
- When used for analytic purposes, the accuracy of an image sensor in detecting and recording the photon flux striking the image sensor is important. The use of an image sensor to produce visually pleasing results is not important for analysis, but is a design factor of modern image sensors that may be used for analytic purpose. Under an embodiment of the invention, signals generated by an image sensor as a result of light striking the image sensor are optimized to produce data that more closely represents the actual photon flux. The outputs of pixels of the image sensor are normalized to correlate with photon flux.
- Image Sensor Operation
- Investigators using a photodiode detector may incorrectly assume that the digital data acquired from the detector correlates with the photon flux striking the detector because increases in the intensity of the signal out will generally directly correlate with increases in signal input in a particular wavelength or band-width. Because photodiodes are very linear in output, increases in the photon flux at different wavelengths over the photodiode surface will, over the photodiode's dynamic range, produce a linear output signal. However, the output data will not correlate with the photon flux if the QE is variable over the range of wavelengths that are striking the photodiode. For a particular number of photons striking a photodiode over a time period, a larger current will be produced by the photodiode at a first wavelength than a second wavelength if the QE for the photodiode is higher for the first wavelength than the second wavelength.
- Restricting a light source for analysis to a narrow band by filtering or by using a laser light source generally will not resolve accuracy issues. Emission spectra that are evaluated using image sensors may be very broad even if the excitation source has a narrow wavelength range. For this reason, the shape of the QE curve for a photodiode should be carefully considered in evaluating output data from an image sensor.
- With regard to the choice of image sensors, CMOS imager sensors are fundamentally different from charge-coupled devices and are increasingly used in microscopy and diagnostic instruments because they are cheaper to build and require considerably less power to operate. CCD cameras are no longer clearly superior in low intensity light situations, which had been true in the past.
- CMOS images now rival traditional color imaging methods on film and are easily manipulated. The images may be transferred from one processor to another as a digital file in a variety of formats preserving the arrayed data pixel address. Manufacturers have devoted considerable energy reproducing “life-like” color image sensors using various color filters and interpolation methods to enhance a digital image rendering colors very close to the human eye experience. However, the pleasing “life-like” color pictures obtained with a color CMOS image sensor are not as useful for analytic procedures. Similar issues exist with monochromatic images unless the image is produced by light at single wavelength, which is rarely true.
-
FIG. 16 is a simplified illustration of an example of a color CMOS image sensor that may be utilized in connection with an embodiment of the invention. Not all components and features of CMOS imagers are illustrated.FIG. 16 and the remaining figures below are for illustration and are not necessarily drawn to scale. InFIG. 16 , animage sensor 1600 includes animaging array 1610. The imaging array is comprised of a large number of pixels arranged in a two-dimensional array. As shown in the magnifiedpixel array 1620 of a particular area of thearray 1620, there is a filter associated with each of the pixels in theimaging array 1610. Theimage sensor 1600 will also generally contain electronics relating to the processing and transmission of signals generated by theimaging array 1610, includinganalog signal processing 1640, analog todigital conversion 1650, anddigital logic 1660. - The photodiode array in a CMOS color image sensor is blanketed by an ordered thin layer of polymeric filters, such as in a conventional Bayer RGB (red-green-blue) two-dimensional array. Each filter is sized to fit over an individual photodiode in a sequential (Bayer) pattern to capture color information from a broad bandwidth of incident illumination. In an RGB array, a heavy emphasis is placed on the green filters to address the human visual maximal response at 550 nm. There are 2 green filters for every red and for every blue filter. However, even though the human eye is more attuned to the green 550 nm region, yellow is generally a better choice with regards to QE factor.
- CMOS image sensors and the integrated circuits that define the active pixel array are inherently monochromatic (black and white) devices that respond only to the total number of electrons striking the photodiodes, not to the color of light. Color is detected either by passing the light through a sequential series of filters (such as red, green, and blue filters), or with miniature transparent polymeric thin-film filters that are deposited over the pixel array.
- Active pixel sensor (APS) technology is the most popular design for CMOS image detectors. In addition to a photodiode, each pixel (or imaging element) includes a triad of transistors on its surface that convert accumulated electron charge to a measurable voltage, reset the photodiode, and transfer voltage to a vertical column bus. The photodiode thus occupies only a fraction of the pixel area. The photodiode area encompasses an area equal to 30 to 80 percent of the total pixel area for most CMOS sensors. This area occupied by the photodiode is the area that absorbs photons, while the other parts of the pixel are relatively opaque, blocking, reflecting, or absorbing light. The photodiode area or window is referred to as the “aperture” or “fill factor” of the pixel or image sensor. A small aperture or fill factor results in a significant loss of sensitivity and a corresponding reduction in the signal to noise ratio and leads to a reduction in the dynamic range of the sensor.
- CMOS image sensors can be utilized to produce pictures based upon the signals produced when photons strike the photodiode surface associated with each pixel in an active pixel sensor array. The pixel signals are processed to form the total picture either in monochrome (black and white) or color.
- Monochrome CMOS imager sensors do not have color filters over the photodiode portion of the pixel. However, color CMOS imagers, even with standard Bayer pattern filters, generally are more sensitive than monochromatic CMOS imagers. While it may appear that inherently monochromatic CMOS photodiode without filters would be more sensitive because some light passing through a filter is absorbed and never reaches the photodiode in a color filtered photodiode, this is not generally true. This assumption does not fully take into account the effect a filter has on the QE for a photodiode, which might enhance certain signals, and ignores the advantages provided by microlenses in color photodiode architecture, which are described below. Monochromatic CMOS image sensors do not have a color filter and they do not normally have a microlenses over each pixel. These are important factors that make monochromatic imagers less attractive than color CMOS image sensors with regard to imager sensitivity.
-
FIG. 17 illustrates a small section of an imaging array of a color image sensor that may be utilized in connection with an embodiment of the invention. The illustrated section repeats throughout the imaging array. Thesection 1700 is comprised of four pixels, each having a filter. The filters 1720-1750 have colors based on the choices made for the array. Below thefilters 1710 illustrates the structure of the individual pixels. For each pixel, such aspixel 1760, there is a portion that comprises thephotodiode 1770, the area of the photodiode being only a fraction of the total area. The image sensor will detect only the portion of the light falling on the photodiode area. - In color imagers used in analysis, one possible approach would be to construct imagers by carefully selecting filters and photodiodes to produce QE factors for a given bandwidth that is approximately constant. By combining an appropriate number of photodiodes in an array with chosen filters, the measurement of light energy would be more accurate. The filters chosen could assist in leveling and improving upon the QE factors. However, in practice the filters and photodiodes are chosen for other purposes, with a goal of producing the most visually pleasing images. In order to improve upon the quantum efficiency and spectral response, several CMOS manufacturers use color filter arrays based on the primary subtractive colors, cyan, magenta, and yellow (CMY), instead of the standard additive primaries red, green, and blue (RGB). CMOS image manufacturers generally use either Bayer RGB or Bayer CMY patterns that have been selected for photographic imaging.
-
FIG. 18 is an illustration of RGB and CMY filters. For these filters, an imaging array is divided into small arrays of filters, with each such array of filters having the same filter pattern. AnRBG filter array 1800 contains two-by-two arrays of filters, with each array containing a red filter and a blue filter for two diagonal pixels and two green filters for the remaining two diagonal pixels. ACMY filter array 1800 also contains two-by-two arrays of filters, with each array containing a cyan filter and a magenta filter for two diagonal pixels and two yellow filters for the remaining two diagonal pixels. While the illustrated filters are the most common filter arrangements, many other filter colors and patterns are possible, and any filter pattern may be used in conjunction with an embodiment of the invention. Certain other alternative filter patterns that provide benefits in certain wavelength ranges are shown in Table 8.TABLE 8 Alterative Color Filters for a CMOS Color Imager Wavelength Range (nm) Filter Type Modified Bayer Pattern 510-810 Yellow Y, Y, Y, Y 610-810 Magenta M, M, M, M 490-550 Cyan C, C, C, C 490-810 Yellow, Cyan Y, Y, Y, C 350-550 None Monochrome pattern - In contrast to monochrome image sensors, color CMOS image sensors also contain microlenses that effectively direct photons to the photodiode aperture. The bubble lens, generally including an anti-reflective coating, can effectively increase the surface area of a photodiode by a significant amount, approximately 60 percent in certain applications. The microlenses substantially increase the effective fill factor and may more than compensate for filters that cut down on the total light that can reach the photodiode.
-
FIG. 19 is a simplified illustration of microlenses in an image sensor. Within the image sensor, there aremultiple pixels 1905. Each pixel contains anactive portion 1910, with the active portion including only a portion of the pixel area. In order to compensate in part for the light energy that would not normally strike any of theactive portions 1910, each of thepixels 1905 has an associatedmicrolens 1920. The function of eachmicrolens 1920 is to focus more light energy on theactive portion 1910 and thus to allow measurement of a larger percentage of the incident photon flux. For example, light 1930 strikes amicrolens 1920 and is focused on theactive portion 1905 of thepixel 1910. - Image Sensor Optimization
- Three primary mechanisms that reduce or hamper photon collection by the photosensitive area of an image sensor are absorption, reflection, and transmission. These factors are wavelength-dependent in nature, and define in part the quantum efficiency (QE) of the image sensor. For example, reflection and transmission of incident light occurs as a function of wavelength, with a high percentage of shorter wavelengths below 400 nm being reflected. Shorter wavelengths are absorbed in the first few microns of the photosensitive region but the longest wavelengths exceeding 650 nm often pass through the photosensitive region.
-
FIG. 20 illustrates a typical quantum efficiency spectral response for an image sensor. ForFIG. 20 , a Bayer CMY filter is evaluated. The spectral response 500 illustrates the quantum efficiency of the image sensor for various wavelengths of light incident on the image sensor. There is an individual response curve for a pixel with amagenta filter 2010, a pixel with acyan filter 2020, and a pixel with ayellow filter 2030. Each curve has peaks and valleys at different wavelengths of incident light. - By examining the QE wavelength dependence curves for each filter type used in an image sensor, the output signal proportional to the photon flux can be determined for any wavelength or interval of interest, including those pixels for a monochromatic image sensor.
- In many cases every pixel in an array is essentially identical to its neighbor except for the kind of filter (CMY, RGB, other pattern, or no filter). The effect of a filter is either to increase or to reduce the photodiode energy output for a given photon flux. The effect on the signal is wavelength dependent. The QE is the variable in the output signal that should be factored out of the equation if fair comparisons are to be made across the imaging array for each and every pixel.
- In a CMOS imager, the pixel signal is obtained for each pixel as raw data after the analog to digital converter transforms the value for a set time interval. If QE is expressed as a fraction, the pixel signal is directly proportional to the product of the QE and Photon Flux:
PIXEL SIGNAL=CONSTANT×QE×PHOTON FLUX - Under an embodiment of the invention, if raw data can be normalized according to the appropriate QE, digital values can be created that may be used in subsequent analysis. The pixel value for a color CMOS image sensor is obtained before on chip conversion occurs and the value is normalized by multiplying each signal value for a particular color filter by the inverse QE.
- For a relatively narrow bandwidth, the QE may be treated as a constant depending upon the wavelength and filter type used. In one example, the Bayer CMY pattern over the
range 550 to 650 nm for aKodak 1310 color CMOS image sensor provides a QE of approximately 46 percent, and then drops linearly from 650 nm to 5 percent at 990 nm, approximately 0.6 percent every 5 nm. In addition, the Magenta and Yellow filters are very similar over the range from 630 nm to 990 nm. - For a particular example with a
CMY pattern Kodak 1310 color image sensor at 670 nm, the QE values are as shown in Table 9. A pixel with a yellow filter would have its digital raw data multiplied by 2.38, a magenta filter pixel by 2.27, and a cyan filter pixel by 7.69. In this embodiment, the signal for every pixel is effectively transformed to a numeric value that is directly proportional to the actual photon flux. It is noted that Table 9 only contains the QE for the image sensor when light of a particular wavelength (670 nm) strikes the image sensor. The QE for any other wavelength of light will vary, as shown inFIG. 20 .TABLE 9 Quantum Efficiency and Normalization Factors for Kodak 1310 Image Sensor at 670 nmQuantum Normalization Filter Type Efficiency (%) Factor Yellow 43 2.38 Magenta 44 2.27 Cyan 13 7.69 Monochrome (no filter) 28 3.57 Red 35 2.86 Green 5 20.0 Blue 3 33.3 - QE Factor Correction
- Corrections to account for differences in QE may be made based upon known QE factors for a particular filter type and wavelength. (For example, see the data contained in Table 8 and Table 9.) However, an image sensor may also be utilized to automatically correct for differences in pixel QE. Under an embodiment of the invention, each area of a sensor array, such as each filter quadrant, is normalized to render every pixel in the quadrant optimally tuned for photon flux in real time.
- According to an embodiment, no corrections are made if the pixels and filters are all of the same type, as, for example, the YYYY, MMMM, and CCCC filter patterns shown in Table 8. A correction is made if there are two or more filter types in the array (e.g. filter patterns such as YYYC, RGB Bayer, or modified CMY Bayer). A method of auto correcting for QE can be used for any combination of two or more filter and photodiode types and such method corrects to normalize the 4 pixels in a quadrant so that each pixel produces an equivalent output signal.
- If the pixels are tightly packed in a quadrant relative to the change in photon flux over a given region of the array, then it can be assumed that the same number of photons are striking each pixel in the quadrant at any given moment. With the currently available high-resolution sensors, and with anticipated future improvements in resolution, the assumption that neighboring pixels in any given quadrant experience identical photon flux is appropriate. Using this assumption, each of the pixels in the quadrant should produce the same output. According to an embodiment, auto correction causes adjacent neighbors in each filter quadrant to be identical. The most sensitive pixel type in a quadrant is used to factor out QE and wavelength differences, which simplifies the problem of correcting for wavelength and bandwidth dependence. Auto correction also reduces or eliminates problems related to temperature variations for different filter and photodiode types.
- In one example, an array of an image sensor comprises multiple filter quadrants. Two or more filters are used in each quadrant of 4 pixels. In each quadrant of 4 pixels, the average analog to digital converted signal output for each filter and photodiode type is determined. If, for example, there are 3 yellow filtered pixels and 1 cyan filtered pixel in the quadrant, the average for the 3 yellow pixels is determined first. The output value for the yellow pixels is then compared to the value for the cyan pixel to determine which output is numerically greater. Under the embodiment, there is an assumption that all 4 pixels receive equivalent photon flux. The highest output value is assigned to all four pixels in the quadrant. The next quadrant in the array may then be corrected in the same manner, with the process continuing until the entire array has been assigned corrected output values to correlate with photon flux.
- The process of auto correction is repeated over time as an image sensor is used to record images. In an example, the wavelength of light received by an image sensor may change from a first wavelength to a second wavelength. A first type of filter may provide the highest QE for the first wavelength, while a second type of filter provides the highest QE for the second wavelength. The change in wavelength is included in the calculation process and therefore auto correction for changing light can be made in real time.
- Under an embodiment of the invention, it is not necessary to know in advance the QE for each filter type to auto correct for QE differences. Auto correcting the sensor based on the photon flux at the time an image is obtained optimizes the photo image to correlate with photon flux. This method of correcting the signal removes temperature and wavelength dependence differences for different filter types and can be implemented using software. Such method thus automatically corrects for a broad band signal impinging upon an image sensor.
- Under an embodiment of the invention, the digital signals produced by an image sensor auto corrected for photon flux may be rendered to a gray scale image for subsequent visualization in a monochromatic representation.
- Image Sensor Calibration
- Under an embodiment of the invention, the optimization of an image sensor can first be calibrated. The calibration may be accomplished by illuminating the color filters and photodiodes with light of known wavelength and intensity. For a color CMOS imager, the raw data for each filter is obtained and compared to expected values. From the resulting comparison, the QE and the multiplier (normalization factor) that is required to obtain the equivalent output signal for each color filter used for each and every pixel in the array may be obtained.
- Optimized signals obtained using QE factor conversions can more accurately relate the signal to the photon flux, and therefore more precisely characterize events, such as the optical events related to excitation-emission spectra or absorption phenomena in a chemical reaction. Both sensitivity and accuracy are enhanced by properly converting the signal to account for QE factors.
- Using a standard CMOS imager (such as a
Kodak 1310 color CMOS image sensor,) in an embodiment of the invention, raw data produced may be processed for signal optimization. The signal is converted to a numeric value that correlates with the photon flux incident upon the imager. This process may be applied to either a color or monochromatic CMOS imager sensor to render the signal proportional to photon flux. - Data processed according to this embodiment may be rendered for visualization, such as via a gray scale standard (0 to 255 monochromatic) to producing a black and white image that correlates with the actual photon flux. The visual image of the data is superficially equivalent to a gray scale monochromatic image sensor, but for an equivalent luminance will be more intense than a image produced by a monochromatic non-transformed CMOS counterpart because color CMOS chips are generally more sensitive than monochrome chips. A color image sensor generally provides a better signal and is more sensitive than a monochromatic imager because the pixel photodiode filters improve upon the QE for the photodiode. The filtering of light by a color image sensor may be corrected using the QE factors to convert the signal to a number that is directly proportional to the photon flux. Advantage then is taken of the color filter's microlens for every pixel, effectively amplifying the aperture for the photodiode.
- Illustrations of Processes
-
FIG. 21 is an illustration of an embodiment of correction of QE factors for an image sensor. In thecorrection process 2100, an image of an event is captured with an image sensor. In this illustration, the image sensor is a color sensor containing an array of pixels, with each pixel having a filter. In this case, the filters are arranged in quadrants, with each quadrant having a particular filter pattern. However, embodiments of the invention are not limited to any particular type of image sensor or filter arrangement. - In
FIG. 21 , the outputs of each of the pixels within a first quadrant of the array are obtained 2110. The average output of for each filter type in the quadrant is then determined. In one example, if a filter quadrant is CMY pattern containing a cyan filter, a magenta filter, and two yellow filters, the cyan output, the magenta output, and the average of the two yellow outputs are determined. The outputs are then compared and which output is highest is determined 2120. The highest output is then assigned to each pixel in thequadrant 2125. For example, if the average yellow output is the highest output for the CMY quadrant, indicating that, under the particular conditions, the yellow filter has the highest QE factor, then the average yellow output is assigned to each of the pixels in the quadrant. If there are more quadrants in thearray 2130, the output of the next quadrant is obtained 2135 and the process continues. Once the final quadrant has been corrected the process is completed 2140 and the corrected output for the array is available. The process can then be repeated over time to allow real time QE factor correction for the image sensor. -
FIG. 22 is an illustration of an embodiment of a process for calibration for optimization of an image sensor. In thecalibration process 2200, a light of a known wavelength and intensity is produced 2205. With a known intensity, the photon flux on each pixel is known, which would be the output if the QE of a pixel were 100 percent. The known light is directed on animage sensor 2210. The output of each pixel of the image sensor is obtained 2215. The output of the image sensor may then be compared with theactual photon flux 2220. Using the comparison, the quantum efficiency of the pixel may be calculated 2225, and then a normalization factor may be calculated based upon thequantum efficiency 2230. For a color CMOS image sensor, the comparison and calculation may be done for each filter color, resulting in a normalization factor for each filter color. In other embodiments, the comparison and calculation may be made for each pixel of an image sensor or for sectors of pixels of an image sensor, resulting in normalization factors that apply for certain portions of the image sensor. As the normalization factor varies for each wavelength of light that strikes the image sensor, the wavelength of the known light is varied 2235 and the process repeated for each needed wavelength. -
FIG. 23 is a flowchart illustrating an embodiment of the optimization of an image sensor. In theoptimization process 2300, an image of an event is captured with animage sensor 2305. Under one embodiment of the invention, the image sensor is a color CMOS image sensor utilizing a filter pattern such as a Bayer RGB or CMY pattern. The raw data for the image of the event may be obtained from theimage sensor 2310. The raw data is non-optimized data that, due to the nature of the image sensor, will generally vary greatly from the actual photon flux that struck the image sensor. As the normalization factor depends on the wavelength of light, the wavelength is determined 2320. The appropriate normalization factor may be determined for each pixel based upon the wavelength of light. For one embodiment utilizing a color CMOS image sensor, a normalization factor for each lens color may be used in normalization. Under other embodiments, the normalization factors may vary based on other factors. The raw data may then converted using the appropriate normalization factors for the pixels of theimage sensor 2325, thus producing an optimized data set that approximates the actual photon flux for the captured image of the event. Under an embodiment of the invention, an image may be produced using the converteddata 2330. - Computer Operation
-
FIG. 24 is block diagram of an exemplary computer that may be used in conjunction with an image sensor in an embodiment of the invention. WhileFIG. 24 illustrates a computer that may be connected to the image sensor, in other embodiments the function of the components shown may be structured in varying manner or may be performed by different systems. In some embodiments some signal processing functions may be performed by the image sensor or by components coupled with the image sensor. In some embodiments an imaging system may include most or all functions in a single unit. Not all computers are structured as shown inFIG. 24 . In addition, certain computers may utilize elements shown inFIG. 24 as auxiliary devices that are external from the computer. - Under an embodiment of the invention, a
computer 2400 comprises abus 2405 or other communication means for communicating information, and a processing means such as aprocessor 2410 coupled with thebus 2405 for processing information. Thecomputer 2400 further comprises a random access memory (RAM) or other dynamic storage device as amain memory 2415 for storing information and instructions to be executed by theprocessor 2410.Main memory 2415 also may be used for storing temporary variables or other intermediate information during execution of instructions by theprocessor 2410. Thecomputer 2400 also may comprise a read only memory (ROM) 2420 and/or other static storage device for storing static information and instructions for theprocessor 2410. - A
data storage device 2425 may also be coupled to thebus 2405 of thecomputer 2400 for storing information and instructions. Thedata storage device 2425 may include a magnetic disk or optical disc and its corresponding drive, flash memory or other nonvolatile memory, or other memory device. Thecomputer 2400 may also be coupled via thebus 2405 to adisplay device 2430, such as a liquid crystal display (LCD) or other display technology, for displaying information to an end user. In some environments, the display device may be a touch-screen that is also utilized as at least a part of an input device. In some environments,display device 2430 may be or may include an auditory device, such as a speaker for providing auditory information. Aninput device 2440 may be coupled to thebus 2405 for communicating information and/or command selections to theprocessor 2410. In various implementations,input device 2440 may be a keyboard, a keypad, a touch-screen and stylus, a voice-activated system, or other input device, or combinations of such devices. Another type of user input device that may be included is acursor control device 2445, such as a mouse, a trackball, or cursor direction keys for communicating direction information and command selections toprocessor 2410 and for controlling cursor movement ondisplay device 2430. - A
communication device 2450 may also be coupled to thebus 2405. Depending upon the particular implementation, thecommunication device 2450 may include a transceiver, a wireless modem, a network interface card, or other interface device. Thecomputer 2400 may be linked to a network or to other devices using thecommunication device 2450, which may include links to the Internet, a local area network, or another environment. - Fluorescence Detection
- Fluorophores are frequently used to detect the presence or absence of a coupled reaction on a glass or other surface. Fluorescence detectors measure the intensity of the evanescent wave produced when a fluorophore is excited with a laser or other light source. Typically the laser is used to excite the fluorophore at its absorption peak and the detector is tuned to read the emission signal at a longer emission wavelength, which is characteristic of that particular fluorophore. The shift in wavelength between absorption and emission is referred to as the Stokes shift. Most fluorescence detection methods use fluorophores with a large Stokes shift so that the emission and absorption curves are well separated. With fluorophores that have a small Stokes shift, it is necessary to excite at a shorter wavelength than the optimal peak absorption maximum because of overlap between the emission and absorption curves. The signal emission intensity is reduced and the sensitivity for detecting target molecules is decreased. The need for a large Stokes shift also limits the choices of fluorophores that can be used.
- Because the curves for absorption and emission are frequently very near to one another, accurate reading of the emission signal may be complicated. If the distance between the emission and absorption curves is small, it is difficult to separate the light from an emission spectrum from that of the absorption signal. Lasers with a narrow band at the absorption peak are frequently used with filters to cut out all light up to a certain critical point just below the emission spectral curve. By selecting an appropriate long pass filter, band pass filter, or combination of long pass and band pass filters, the emission signal can be observed in a narrow window, eliminating much of the interference from the excitatory light source. Interference from the excitatory light source is also avoided by aligning the detector and apparatus so that the emission signal can be read at a large incident angle to the excitation beam. Although filters eliminate most of the signal from the excitatory light source, they also cut out a significant portion of the evanescent (emitted) signal. Most band pass filters cut out as much as 40 to 50% of the emission signal. Long pass filters may cut an additional 10% of the emission signal.
- Fluorescent detection is used in a number of common test methods. DNA hybridization is commonly analyzed in this manner, using an appropriate fluorophore coupled to a set of known oligonucleotides that hybridize to capture oligonucleotides affixed to a slide. Sandwich immunoassays also employ this method of analysis, either using a tagged secondary antibody that binds to a primary antibody, or using a secondary biotinylated antibody and an avidin-fluorophore as the tag. Many variations on this method are well known.
- Various other types of light interference may occur in fluorescent detection. Light scatter occurs by reflection of the excitation beam, while light dispersion occurs by reflection and bending of the excitation beam. Scatter and dispersion may represent a large part of the light striking a detector. In general, when a substance (such as a protein, nucleic acid or other biomolecule) is affixed to the surface of a glass slide, it acts as a mirror to reflect and scatter light in a variety of directions. The amount of surface covered and the mass or density of the attached material may greatly affect the amount of scattered light. The chemical composition of proteins, oligonucleotides or polymers attached to the surface may also affect the scattered light (see
FIG. 25 ). In addition, the material attached to the surface material may itself fluoresce. The glass or other material used may also have surface irregularities that can affect the signals received by the detector. The energy absorbed across the surface may vary from one spot to another, making signal analysis very problematic. Such problems require the use of novel methods of fluorescent detection and/or data analysis. - Evanescent Emission and Scattered Light
- Evanescent signals are generally very weak and light scatter is intense, making accurate quantitative detection of analytes problematic. Light scatter is frequently assumed to be eliminated by filters. However, scattered light is almost always present and can be a significant part of the total signal reaching a detector. Filters used to remove light scatter also remove much of the target emission signal, thereby decreasing detector sensitivity. Filters may also transmit a small amount of scattered light. If the scattered light is relatively large compared to the evanescent emitted light, the detected signal will be a combination from several sources, only one of which represents target molecule binding.
- The components of light scattering are illustrated in
FIG. 25 : Two spots (e.g., different antibodies) are deposited on a surface. During a method to detect a target, one of the spots remains totally non-reactive. The other spot reacts with a target, such as a bacterial pathogen and/or other reagents. Target binding to the reactive antibody increases the mass attached to the spot and results in a larger surface area and a change in molecular structure at the spot. A mass effect has occurred. The light scatter from the reactive spot will be different from the light scatter before target molecule binding. A sensitive photon-counting detector could detect this difference in scatter. A variety of instruments, such as certain flow cytometers and turbidity meters take advantage of scatter to quantify the amount of material in a solution. Those instruments measure the angle of scatter for a beam of light impinging on a target material. The change in signal is the difference between the reference signal (Sref) and signal 2 (S2). InFIG. 25 the S2 signal is shown as having two components, a modified scatter signal plus a mass effect signal of the coupled pathogen. The signal from the reactive spot changes while the signal from the non-reactive spot signal is constant.
ΔS (non-reactive spot)=0
ΔS (reactive spot)=Modified (S p)+M 1 −S ref - If the mass effect is sufficient to cause a large scatter effect, the fluorophore used for target detection could be eliminated. For example in DNA hybridization experiments, the mass attached to a surface using standard oligonucleotide probes (about 24 nucleotides in length) may be increased by a factor of 2 or more upon binding of target nucleic acids. Such a large change in mass may be detectable by monitoring light scatter instead of evanescent waves. In the case of a sandwich immunoassay with a biotinylated secondary antibody, another mass effect occurs when the biotinylated antibody binds to the pathogen. A third mass effect occurs when avidin-conjugated fluorophore binds to biotin.
- The most sensitive signal may be obtained by subtracting the initial reference signal from the final captured signal, obtained after the fluorophore has been attached and excited. That signal represents the modified accumulated mass effects and the emission signal for the reactive spot.
ΔS (reactive spot)=Modified accumulated mass effects+Emission−S ref - This method of analysis may be used with a CMOS imager or any known digital imaging method that allows storage of pixel images for subsequent processing. The signal obtained from each spot will contain more useful information and will show a more intense change upon target binding if a proper subtraction method is used. The scatter effect may be turned to an advantage in detecting target binding. Moreover, it is unnecessary to have fluorophore emission and absorption curves well separated, since spurious signals are subtracted out of the image. The full intensity of an emission signal may be measured without reducing emitted light by with filters.
- A subtraction method also eliminates artifacts and defects that may derive, for example, from inhomogeneity (chips, flaws) in the slide surface. The non-reactive spots completely blank out and do not appear as a signal.
- Because CMOS imagers and pixel capturing devices in general exhibit a random, very low level noise there are limits as to what kinds of signals can be detected. At any given point in time, the baseline reference may exhibit a random number of spikes. A weak signal falling between two spikes would not normally be detected against this background noise.
- The signal-to-noise problem may be improved if numerous images are captured and added one upon the other. Because the random spikes inherent in a detector such as a CMOS imager are constantly shifting about, accumulating the frame images will tend to average out the random noise. However a weak signal from the emission of an excited fluorophore does not change its pixel location. Therefore, an accumulated signal caused by target binding will increase with time. This method is similar to taking a photoimage of a distant star or galaxy, by tracking the object as it moves across the sky. The object of interest appears brighter against the background with time because the signal has accumulated at the same spot on the detector, while the background light averages out.
- Method of Analysis
- In an exemplary embodiment of the invention, a glass slide or other matrix array is secured on a stage. A fluidic cube or other device is attached to the surface of the glass and used to deliver samples, second antibodies and other reagents. Before target molecule binding, an excitatory laser is focused on one end of the glass slide at an inclined angle about 30 to 40 degrees. The glass slide acts as a waveguide to conduct the excitatory light to spots, containing bound primary antibody, on the glass surface. A CMOS imager is used to capture the light signals. The CMOS chip is located beneath the glass slide and is aligned so that spots on the slide are directly above the imager and are sharply focused on the imager surface with optical lenses and apertures.
- A number of pictures are taken. Each picture represents a single frame. For example 10 frames are taken using a 50 millisecond exposure. The exposure is selected so that the amount of light captured in a single frame is within the sensitive range, for the camera. The 10 digital frames are then added to provide a reference set that is used for subtraction of unwanted (background) signals. The accumulated image is referred to as the calibration slide.
- The fluidic cube is used to expose primary antibody to a sample, bind any target molecules to the first antibody, and bind second antibody to the target. The process ends with binding of avidin-fluorophore to the biotinylated second antibody and a final set of washes. The same number of frames used to obtain the reference slide image are taken of the sample slide, using the same exposures. The cumulative set of frames is referred to as the sample slide image. The luminescent signal for each spot is determined by subtracting the reference slide image from the sample slide image. This process essentially eliminates background noise and matrix array artifacts, resulting in very sensitive detection of target molecules.
- In alternative embodiments of the invention, pictures may be obtained in either still frame or video mode. A typical video frame runs at 2000 ms and captures 100 frames each for the reference and sample analysis. This method removes artifacts and non-reactive spots, leaving only those signals that represent target molecule binding to the array.
- General Matters
- In the description above, for the purposes of explanation, numerous specific details are set forth in order to provide a thorough understanding of the present invention. It will be apparent, however, to one skilled in the art that the present invention may be practiced without some of these specific details. In other instances, well-known structures and devices are shown in block diagram form.
- The present invention may include various processes. The processes of the present invention may be performed by hardware components or may be embodied in machine-executable instructions, which may be used to cause a general-purpose or special-purpose processor or logic circuits programmed with the instructions to perform the processes. Alternatively, the processes may be performed by a combination of hardware and software.
- Portions of the present invention may be provided as a computer program product, which may include a machine-readable medium having stored thereon instructions, which may be used to program a computer (or other electronic devices) to perform a process according to the present invention. The machine-readable medium may include, but is not limited to, floppy diskettes, optical disks, CD-ROMs, and magneto-optical disks, ROMs, RAMs, EPROMs, EEPROMs, magnet or optical cards, flash memory, or other type of media/machine-readable medium suitable for storing electronic instructions. Moreover, the present invention may also be downloaded as a computer program product, wherein the program may be transferred from a remote computer to a requesting computer by way of data signals embodied in a carrier wave or other propagation medium via a communication link (e.g., a modem or network connection).
- Many of the methods are described in their most basic form, but processes can be added to or deleted from any of the methods and information can be added or subtracted from any of the described messages without departing from the basic scope of the present invention. It will be apparent to those skilled in the art that many further modifications and adaptations can be made. The particular embodiments are not provided to limit the invention but to illustrate it. The scope of the present invention is not to be determined by the specific examples provided above but only by the claims below.
- It should also be appreciated that reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature may be included in the practice of the invention. Similarly, it should be appreciated that in the foregoing description of exemplary embodiments of the invention, various features of the invention are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure and aiding in the understanding of one or more of the various inventive aspects. This method of disclosure, however, is not to be interpreted as reflecting an intention that the claimed invention requires more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive aspects lie in less than all features of a single foregoing disclosed embodiment. Thus, the claims are hereby expressly incorporated into this description, with each claim standing on its own as a separate embodiment of this invention.
- Colloidal nitrocellulose slides may be spotted with probes using any known methods for microarray production. Methods for spotting proteins, peptides, oligonucleotides and nucleic acids onto nitrocellulose surfaces are well known in the art. Antibodies and biotinylated bovine serum albumin were used to determine the colloidal nitrocellulose binding capacity. The estimated protein binding capacity for the initial matrix arrays was in the range of 100 to 200 μg/cm2.
- A CMOS imaging system that detected light emissions through the translucent nitrocellulose matrix arrays was used with a Cy5-streptavidin indicator dye. (See, e.g., U.S. patent application Ser. No. 09/974,089, filed Oct. 1, 2001.) At a loading volume of approximately 5 nanoliters per spot, biotinylated BSA was reproducibly detected at least down to 10 to 20 picograms of protein. Optimal CMOS images were obtained using a protein concentration range of about 20 to 100 μg/mL biotinylated BSA. The CMOS imaging data was confirmed using a 24 hour colloidal gold stain BioRad, Hercules, Calif.) of the spot arrayed translucent nitrocellulose slides.
- The ability of the colloidal nitrocellulose matrix to maintain antibody binding activity was confirmed by spotting a variety of antibodies on the translucent surface. A concentration range of 20 to 200 μg/mL was used. Nonspecific protein binding sites on the nitrocellulose membrane were blocked with 0.1% BSA in buffer solution. The antibodies were then exposed to solutions containing the appropriate target antigen. Binding was detected using biotinylated second antibodies and Cy5-streptavidin indicator.
- A 2D array spotted with 5 nanoliters per spot of primary goat anti-mouse antibody solution and was developed using a secondary mouse Listeria monoclonal antibody and a secondary biotinylated goat anti-mouse antibody. In this assay, the primary and secondary goat anti-mouse antibodies bound to different epitopes of the secondary mouse antibody. The two secondary antibodies were thus used to detect primary antibody bound to the array. Using a CMOS imaging system, the primary antibody could be detected down to a level of 100 picograms or less of antibody. The CMOS data was confirmed on the same slides using colloidal gold staining.
- Rous sarcoma virus (RSV) was titered using primary antibody probe binding and HRP-SA bioluminescent detection as disclosed above. Prespotted slides containing anti-RSV antibodies were prepared for RSV. RSV was serially diluted 10 fold with each dilution to finally reach a lower limit of detection where no further spots were detected. A lower limit of detection was estimated at is 0.000091 IU/mL for bioluminescent detection (1013 fold dilution from the initial stock titer).
- All of the COMPOSITIONS, METHODS and APPARATUS disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the COMPOSITIONS, METHODS and APPARATUS and in the steps or in the sequence of steps of the methods described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents that are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
TABLE 1 Pre-coated Blank Footpad Procedure Time (mins) Remove foil seal exposing first the footpad in the A reservoir. Carefully remove the footpad with an inverted eppendorf. Apply with an eppendorf a microspot index mark at the 12 o′ clock 1 position using an index marker. Apply from 1 to approximately 8 additional microspots on the footpad 2 in a pattern noting and recording accurately the position of each spot relative to the index. Allow approximately 30 minutes air drying in a clean protected area. 3 Prepare secondary biotinylated antibodies diluting with dilution buffers to an appropriate level (approximately 10-30 uG/mL). Do not use sodium azide or other antimicrobial growth inhibitors because they will interfere in the test. Dilution buffers are formulated with the appropriate inhibitors.1 Prepare the test sample that will be added to reservoir A. Prepare luminol-peroxide solutions mixing equal volumes of PriTest 1 provided substrate. Remove the foil covering reservoirs B through H. Add 100 uL luminol-peroxide substrate (step 8) to reservoir 8.Add 200 uL biotinylated antibody (step 6) to reservoir D. Place footpad face down into reservoir B (blocking solution) and allow 5 5 minutes incubation. Place test sample (step 7) in reservoir A. Place footpad face down into reservoir A, and allow 10 minutes 10 incubation. Remove footpad from A reservoir, immerse briefly in B to wash the 10 surface. Then move directly to reservoir C and briefly immerse and wash the surface, then place the footpad in D to incubate 10 minutes. Remove the footpad from D reservoir, wash in E briefly, and place it in 10 reservoir F to incubate 10 minutes. Remove the footpad from F reservoir, wash in G briefly, and place it in reservoir H. Immediately place the microplate on the TOAD stage and begin imaging. Imaging may take 15 minutes for very low level detection. 15
1ProClin 0.05%.
-
TABLE 2 Pre-Arrayed Footpad Procedure Time (mins) Remove foil seal exposing first the footpad in the A reservoir. Carefully remove the footpad with an inverted eppendorf from reservoir A and place it 5 face down in reservoir B (blocking solution) and allow 5 minutes incubation Prepare the test sample that will be added to reservoir A. Prepare luminol-peroxide solutions mixing equal volumes of PriTest provided 1 substrate. Remove the foil covering reservoirs C through H. Add 100 uL luminol-peroxide substrate (step 4) to reservoir 8.Place test sample (step 3) in reservoir A. Remove the footpad from reservoir B and place the footpad face down into reservoir 10 Allow 10 minutes incubation. Remove footpad from A reservoir, immerse briefly in B to wash the surface. Then 10 move directly to reservoir C and briefly immerse and wash the surface, then place the footpad in D to incubate 10 minutes. Remove the footpad from D reservoir, wash in E briefly, and place it in reservoir F to 10 incubate 10 minutes.Remove the footpad from F reservoir, wash in G briefly, and place it in reservoir H. Immediately place the microplate on the TOAD stage and begin imaging. Imaging may take 15 minutes for very low level detection. 15 -
TABLE 3 Component Configuration: Units per 96 Well Microplate Item Composition (per well/total) Well Footpad E.g. rayon, nylon, 1/12 A cellophane Spotting buffer PBS (phosphate buffered N/A saline) Dilution buffer 0.1% BSA, PBS N/A 0.05 % ProClin 950Index buffer PBS, 0.05% ProClin 950 N/ A 30 uG/mL B-BSA Blocking solution PBS, 0.1% BSA 100 uL/1200 uL B 0.05 % ProClin 950Wash solution PBS 100 uL/3600 uL C 0.1% BSA E 0.05% ProClin 950 G 0.03% Triton X100 HRP-SA PBS, 0.1% BSA 100 uL/1200 uL 0.05% ProClin 950 F 0.03% Triton X100 0.1 uG/mL HRP-SA Luminol-peroxide Mix 1:1 volumes prior to 100 uL/1200 uL H test procedure and fill H reservoir Antibody Cocktail PBS 0.1% BSA 0.05 % ProClin 950100 uL/1200 uL D 0.03% Triton X100 Biotinylated Antibodies -
TABLE 4 Pre-spotted Array Procedure Time (min) Prepare the test sample that will be used. The sample may be immobilized in dilution buffer. Prepare luminol-peroxide solutions mixing equal volumes of provided substrate. 1 Dilute the mixed reagents with a volume of dilution buffer equal to the total luminol + peroxide (example: 1 mL Luminol + 1 mL peroxide, then dilute with 2 mL dilution buffer to produce 4 mL total test reagent). Block the prepared slide by filling the incubation sleeve chamber with blocking 10 solution and allowing 10 minutes for complete blocking. Then remove and dispose of blocking solution. Place test sample into the incubation chamber and allow 10 minutes for probe 10 binding to occur. Then empty the reservoir contents and dispose of remaining sample. Wash × 1 the incubation chamber with wash solution by completely filling and 1 then emptying the reservoir chamber. Fill the reservoir chamber with the secondary biotinylated antibody, and incubate 10 10 minutes. Then remove and dispose of the fluid. Wash × 1 the incubation chamber with wash solution by completely filling and 1 then emptying the reservoir chamber. Fill the chamber with HRP-SA reagent and incubate 10 minutes. Then empty and 10 dispose the spent reagent. Wash twice (×2) the incubation chamber with wash solution by completely 2 filling and then emptying the reservoir chamber. Fill the reservoir chamber with Luminol-peroxide reagent. Peel away the outer protective surface on the incubation sleeve, exposing the optically clear window. Place the slide on the TOAD stage. Position the slide to accurately view the target 1 area. This may be confirmed using the Grid-template slide and centering the diamond as needed. Open the software Slider2, and set the exposure time at 10 minutes Set the Readout speed at 2.5 Mhz. 2 Click “Capture Image”. 1 After the image is obtained, make notes and save the file. The ID code on the slide 1 may be used as the file name. -
TABLE 5 Pre-coated Blank Slide Procedure Time (min) With gloves, place a slide on the spotting template with the logo face up. The target area for probe spotting is between the diamond points. Mark a slide with a label using a black marker pen. Apply with an eppendorf pipette tip, a microspot index mark at one end of the 1 target area spacing spots in a column. Note the position in a notebook, making a sketch of the slide. Apply from 1 to 8 additional columns of microspots on the slide in a pattern, 2 noting and recording accurately the position of each probe spot relative to the index in a notebook. Space columns at least 1 mm apart Allow approximately 30 minutes air drying in a clean protected area. 30 Prepare secondary biotinylated antibodies diluting with dilution buffers to an appropriate level (approximately 10-30 uG/mL). Do not use sodium azide or other antimicrobial growth inhibitors because they will interfere in the test. Dilution buffers are formulated with the appropriate microbial inhibitors.1 Affix the incubation sleeve to the slide, encompassing the spots deposited and 1 air-dried. Prepare the test sample that will be used. The sample may be immobilized in dilution buffer. Prepare luminol-peroxide solutions, mixing equal volumes of provided 1 substrate. Dilute the mixed reagents with a volume of dilution buffer equal to the total luminol + peroxide (example: 1 ml Luminol + 1 mL peroxide, dilute with 2 mL dilution buffer to produce 4 mL total test reagent). Block the prepared slide by filling the incubation sleeve chamber with blocking 10 solution and allowing 10 minutes for complete blocking. Then remove and dispose of in a waste container. Place test sample into the incubation chamber and allow 10 minutes for probe 10 binding. Then empty the reservoir contents and dispose of in a waste container. Wash × 1 the incubation chamber with wash solution by completely filling and 1 then emptying the reservoir chamber. Fill the reservoir chamber with the secondary biotinylated antibody, and 10 incubate 10 minutes. Then remove the fluid and dispose of in a waste container. Wash × 1 the incubation chamber with wash solution by completely filling and 1 then emptying the reservoir chamber. Fill the chamber with HRP-SA reagent and incubate 10 minutes. Then empty 10 and dispose of the spent reagent in a waste container. Wash twice (×2) the incubation chamber with wash solution by completely 2 filling and then emptying the reservoir chamber. Fill the reservoir chamber with Luminol-peroxide reagent. Peel away the outer 1 protective surface on the incubation sleeve exposing the optically clear window and then place the slide on the TOAD stage. Position the slide to accurately view the target area. This may be confirmed using the Grid-template slide centering the diamond as needed. Open the software Slider2, and set the exposure time at 10 minutes 2 Set the Readout speed at 2.5 Mhz. 1 Click “Capture Image” 1 After the image is obtained, make notes and save the file. The ID code on the slide may be used as the file name.
1ProClin 0.05%.
-
TABLE 6 Part # Description Components Supplier PriTest Part # Ref # Quantity Instrument: Toad ™ Illuminator FD-TI0001-0-001 Toad ™ Illuminator CCD Qimaging QIC-M-10- C 1 PCI firewire card Qimaging 1 Lens Sunex DSL914D2 1 Lens C-mount adapter Paul Harris FD 1 Firewire 6 pin Qimaging 1 Emerge Enclosure Emerge 1 Software interface Validio 1 Cooper Cooler- Heat Thermaltake A1349 1 Sink: GF4Ti Cooper Cooler Philmore DC Power Fry's Jack 2.1 mm × 5.5 mm Electronics 1 CA-979/500 mA AC Universal PWR adaptor Fry's UL Electronics 1 Shipping carton 1 Label 1 -
TABLE 7 Grid Focus Slide PriTest 1 Spotting Template PriTest FD-FS0006-0-001 1 Part # Description Components Supplier FD-ST0005-0-001 Ref # Quantity Disposables: Grabber ™ Nylon 75 mm × 25 mm × 1 n Emerge 1 Nitrocellulose Configuration 1 FD-GR0003-0-001 25 Configuration 2100 Incubation sleeves 500 uL adherent chambe Gasket Sp Chamber BIC 1 Configuration 1FD-IS0004-0-003 Chamber BIC 25 Configuration 2Chamber BIC 100 Blocking Solution (mL) BSA 0.1% w/v Sigma A3803? ProClin 950 0.05% w/vSupelco 46878-U Sigma PBS pack Sigma P3813 Configuration 1 SK-BS1001-0-001 100 Configuration 21000 Dilution Buffer (mL) BSA 0.1% w/v Sigma A3803 ProClin 950 0.05% w/v Supelco 46878-U Sigma PBS pack Sigma P3813 Configuration 1 SK-DB1002-0-001 500 Configuration 21000 Wash Solution (mL) BSA 0.1% w/v Sigma A3803 ProClin 950 0.05% w/v Supelco 46878-U Sigma PBS pack Sigma P3813 Configuration 1 SK-WS1003-0-001 100 Configuration 2500 Spotting Buffer (mL) Sigma PBS pack Sigma Configuration 1 SK-SB1004-0-001 25
Claims (20)
1-18. (canceled)
19. A method of data analysis comprising:
capturing a plurality of calibration images using an imager, the image comprising a plurality of pixels;
obtaining a plurality of pixel signals for each of the plurality of calibration images;
creating an average interpolation function to produce interpolated average signal values for the imager; and
creating an interpolation function for each pixel to produce interpolated signal values for the pixel.
20. The method of claim 19 , wherein each of the plurality of calibration images is at a different exposure level.
21. The method of claim 19 , wherein the exposure levels for the calibration images are spaced evenly over a range of exposure levels.
22. The method of claim 19 , wherein the average interpolation function and the interpolation function for each pixel are based on linear interpolation.
23. The method of claim 19 , further comprising:
capturing a test image at a test exposure level;
obtaining a plurality of pixel signals for the test image; and
producing a plurality of corrected pixel signal values for the test image.
24. The method of claim 23 , wherein producing the plurality of corrected signal values for the test image comprises multiplying each of the plurality of pixel signals by the average interpolation function for the imager divided by the interpolation function for the pixel.
25. The method of claim 23 , further comprising producing a plurality of leveled signal values for the plurality of corrected signal values.
26. The method of claim 25 , wherein producing the plurality of leveled signal values for the plurality of corrected signal values comprises:
producing a histogram of the plurality of corrected signal values;
determining a high threshold and a low threshold for the histogram; and
determining leveled signal values based on comparisons between the corrected test signals and the high threshold and low threshold.
27. The method of claim 26 , further comprising setting a leveled signal value for a pixel to zero if a corrected test signal value for the pixel is less than the low threshold.
28. A machine-readable medium having stored thereon data representing sequences of instructions that, when executed by a processor, cause the processor to perform operations comprising:
receiving a plurality of pixel signal values for each of a plurality of calibration images captured by an imager;
creating an average interpolation function to produce interpolated average signal values for the imager; and
creating an interpolation function for each pixel to produce interpolated signal values for the pixel.
29. The medium of claim 28 , further comprising instructions that, when executed by the processor, cause the processor to perform operations comprising:
producing leveled signal values for the plurality of corrected signal values.
30. The medium of claim 29 , wherein producing leveled signal values for the plurality of corrected signal values comprises:
producing a histogram of the corrected signal values;
determining a high threshold and a low threshold for the histogram; and
determining leveled signal values based on comparisons between the corrected test signals and the high threshold and low threshold.
31. The medium of claim 30 , further comprising instructions that, when executed by the processor, cause the processor to perform operations comprising:
setting a leveled signal value for a pixel to a depth value for the imager multiplied times a difference between the corrected test signal for the pixel and the low threshold and divided by a difference between the high threshold and the low threshold if the corrected signal value for the pixel is greater than or equal to the low threshold and less than or equal to the high threshold.
32. A total optical assay device comprising:
a light-tight casing with a lid;
a stage below the lid, the stage to hold slides or microtiter well plates;
a focusing lens below the stage;
an imaging device below the lens, the imaging device arranged to obtain optical images of slides or microtiter well plates on the stage;
a base to hold the imaging device in position; and
a cooling device.
33. The device of claim 32 , further comprising a machine readable medium according to claim 28 .
34. An optical assay device comprising:
a circular disk to fit into a well of a microtiter plate;
a probe-binding membrane attached to the bottom of the disk;
a stem attached to the top of the disk; and
a handle attached to the top of the stem.
35. The device of claim 34 , wherein the membrane is rayon, cellophane or translucent nitrocellulose.
36. The device of claim 34 , further comprising a multiplicity of spots bound to the lower surface of the membrane.
37. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/550,629 US20060211044A1 (en) | 2003-02-24 | 2004-02-17 | Translucent solid matrix assay device dor microarray analysis |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10373408 | 2003-02-24 | ||
US10/373,408 US7268925B1 (en) | 2003-02-24 | 2003-02-24 | Image sensor optimization |
US10373546 | 2003-02-24 | ||
US10/373,546 US6861251B2 (en) | 2003-02-24 | 2003-02-24 | Translucent solid matrix assay device for microarray analysis |
US54072004P | 2004-01-29 | 2004-01-29 | |
PCT/US2004/004675 WO2004076678A2 (en) | 2003-02-24 | 2004-02-17 | Translucent solid matrix assay device for microarray analysis |
US10/550,629 US20060211044A1 (en) | 2003-02-24 | 2004-02-17 | Translucent solid matrix assay device dor microarray analysis |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060211044A1 true US20060211044A1 (en) | 2006-09-21 |
Family
ID=32931282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/550,629 Abandoned US20060211044A1 (en) | 2003-02-24 | 2004-02-17 | Translucent solid matrix assay device dor microarray analysis |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060211044A1 (en) |
EP (1) | EP1599597B1 (en) |
AT (1) | ATE476494T1 (en) |
CA (1) | CA2519903C (en) |
DE (1) | DE602004028445D1 (en) |
WO (1) | WO2004076678A2 (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060292647A1 (en) * | 2004-12-03 | 2006-12-28 | Green Lawrence R | Reflex supplemental testing - A rapid, efficient and highly accurate method to identify subjects with an infection, disease or other condition |
WO2007095634A2 (en) * | 2006-02-17 | 2007-08-23 | Hanson Technologies, Inc. | Prion protein detection |
US20070276586A1 (en) * | 2006-05-25 | 2007-11-29 | Samsung Electronics Co., Ltd. | Method of setting a navigation terminal for a destination and an apparatus therefor |
US20080124738A1 (en) * | 2005-03-01 | 2008-05-29 | Pritest, Inc | Compositions and methods of testing for tuberculosis and mycobacterium infection |
WO2009018094A1 (en) * | 2007-07-27 | 2009-02-05 | Donnelly Corporation | Capacitive sensor and method for manufacturing same |
US20110110589A1 (en) * | 2009-11-06 | 2011-05-12 | Kabushiki Kaisha Toshiba | Image Contrast Enhancement |
US20120201437A1 (en) * | 2011-02-08 | 2012-08-09 | Quentiq | System and apparatus for the remote analysis of chemical compound microarrays |
US8592993B2 (en) | 2010-04-08 | 2013-11-26 | MCube Inc. | Method and structure of integrated micro electro-mechanical systems and electronic devices using edge bond pads |
US8652961B1 (en) | 2010-06-18 | 2014-02-18 | MCube Inc. | Methods and structure for adapting MEMS structures to form electrical interconnections for integrated circuits |
US8723986B1 (en) | 2010-11-04 | 2014-05-13 | MCube Inc. | Methods and apparatus for initiating image capture on a hand-held device |
US8794065B1 (en) | 2010-02-27 | 2014-08-05 | MCube Inc. | Integrated inertial sensing apparatus using MEMS and quartz configured on crystallographic planes |
US8797279B2 (en) | 2010-05-25 | 2014-08-05 | MCube Inc. | Analog touchscreen methods and apparatus |
US8823007B2 (en) | 2009-10-28 | 2014-09-02 | MCube Inc. | Integrated system on chip using multiple MEMS and CMOS devices |
US8869616B1 (en) | 2010-06-18 | 2014-10-28 | MCube Inc. | Method and structure of an inertial sensor using tilt conversion |
US8928696B1 (en) | 2010-05-25 | 2015-01-06 | MCube Inc. | Methods and apparatus for operating hysteresis on a hand held device |
US8928602B1 (en) | 2009-03-03 | 2015-01-06 | MCube Inc. | Methods and apparatus for object tracking on a hand-held device |
US8936959B1 (en) | 2010-02-27 | 2015-01-20 | MCube Inc. | Integrated rf MEMS, control systems and methods |
US8969101B1 (en) | 2011-08-17 | 2015-03-03 | MCube Inc. | Three axis magnetic sensor device and method using flex cables |
US8981560B2 (en) | 2009-06-23 | 2015-03-17 | MCube Inc. | Method and structure of sensors and MEMS devices using vertical mounting with interconnections |
US8993362B1 (en) | 2010-07-23 | 2015-03-31 | MCube Inc. | Oxide retainer method for MEMS devices |
US20150124072A1 (en) * | 2013-11-01 | 2015-05-07 | Datacolor, Inc. | System and method for color correction of a microscope image |
US9150406B2 (en) | 2010-01-04 | 2015-10-06 | MCube Inc. | Multi-axis integrated MEMS devices with CMOS circuits and method therefor |
US9321629B2 (en) | 2009-06-23 | 2016-04-26 | MCube Inc. | Method and structure for adding mass with stress isolation to MEMS structures |
US9365412B2 (en) | 2009-06-23 | 2016-06-14 | MCube Inc. | Integrated CMOS and MEMS devices with air dieletrics |
US9377487B2 (en) | 2010-08-19 | 2016-06-28 | MCube Inc. | Transducer structure and method for MEMS devices |
US9376312B2 (en) | 2010-08-19 | 2016-06-28 | MCube Inc. | Method for fabricating a transducer apparatus |
US20170154398A1 (en) * | 2015-11-30 | 2017-06-01 | Ncr Corporation | Watermarked enabled scanning |
US9709509B1 (en) * | 2009-11-13 | 2017-07-18 | MCube Inc. | System configured for integrated communication, MEMS, Processor, and applications using a foundry compatible semiconductor process |
US10316349B2 (en) * | 2007-10-12 | 2019-06-11 | Caris Science, Inc. | Use of aptamers in proteomics |
US10430955B2 (en) * | 2016-08-31 | 2019-10-01 | The Regents Of The University Of California | High content screening workflows for microscope imaging |
US20190386673A1 (en) * | 2018-06-13 | 2019-12-19 | Infineon Technologies Ag | Methods, Devices and Systems for Data Conversion |
US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
US20220170923A1 (en) * | 2020-12-01 | 2022-06-02 | National Cheng Kung University | Protein microarray, detection method thereof and evaluation method thereof |
US11635314B2 (en) | 2018-06-13 | 2023-04-25 | Infineon Technologies Ag | Methods, apparatuses and systems for data conversion |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009505106A (en) | 2005-08-19 | 2009-02-05 | ナノスフェアー インコーポレイテッド | Method for preparing a hybrid substrate comprising DNA and antibodies and use thereof |
CN101883865A (en) * | 2007-09-18 | 2010-11-10 | 普里莫里根生物科技有限责任公司 | Frameless multiplexed microarrays |
JP6820319B2 (en) * | 2015-08-26 | 2021-01-27 | アクセス メディカル システムズ,リミティド | Immunoassay with enhanced sensitivity |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4501495A (en) * | 1981-06-17 | 1985-02-26 | Smithkline Beckman Corporation | Slide carrier |
US5270163A (en) * | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
US5567588A (en) * | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
US5670637A (en) * | 1990-06-11 | 1997-09-23 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands |
US5831012A (en) * | 1994-01-14 | 1998-11-03 | Pharmacia & Upjohn Aktiebolag | Bacterial receptor structures |
US5886353A (en) * | 1995-04-21 | 1999-03-23 | Thermotrex Corporation | Imaging device |
US6069973A (en) * | 1998-06-30 | 2000-05-30 | Xerox Corporation | Method and apparatus for color correction in a multi-chip imaging array |
US20020015958A1 (en) * | 2000-05-04 | 2002-02-07 | Audeh Zuheir L. | Colloid compositions for solid phase biomolecular analytical, preparative and identification systems |
US20020050518A1 (en) * | 1997-12-08 | 2002-05-02 | Roustaei Alexander R. | Sensor array |
US6399295B1 (en) * | 1999-12-17 | 2002-06-04 | Kimberly-Clark Worldwide, Inc. | Use of wicking agent to eliminate wash steps for optical diffraction-based biosensors |
US20020110376A1 (en) * | 2001-02-08 | 2002-08-15 | Maclean Steven D. | Method and apparatus for calibrating a sensor for highlights and for processing highlights |
US6459509B1 (en) * | 1996-11-08 | 2002-10-01 | National Computer Systems, Inc. | Optical scanning device having a calibrated pixel output and a method for calibrating such a device |
US6462768B1 (en) * | 1995-07-19 | 2002-10-08 | The Victoria University Of Manchester | Image enhancement |
US20020179828A1 (en) * | 2001-05-30 | 2002-12-05 | Leica Microsystems Heidelberg Gmbh | Method and device for point-by-point scanning of a specimen |
US6542249B1 (en) * | 1999-07-20 | 2003-04-01 | The University Of Western Ontario | Three-dimensional measurement method and apparatus |
US6556932B1 (en) * | 2000-05-01 | 2003-04-29 | Xerox Corporation | System and method for reconstruction of spectral curves using measurements from a color sensor and a spectral measurement system model |
US20030228637A1 (en) * | 2001-04-10 | 2003-12-11 | The Trustees Of Columbia University In The City Of New York | Novel microarrays and methods of use thereof |
US20040102742A1 (en) * | 2002-11-27 | 2004-05-27 | Tuyl Michael Van | Wave guide with isolated coupling interface |
US6767733B1 (en) * | 2001-10-10 | 2004-07-27 | Pritest, Inc. | Portable biosensor apparatus with controlled flow |
US7268925B1 (en) * | 2003-02-24 | 2007-09-11 | Pritest, Inc. | Image sensor optimization |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0366241A3 (en) * | 1988-10-04 | 1990-05-23 | Fisher Scientific Company | Device with adsorbent surface and method |
WO2001057501A1 (en) * | 2000-02-03 | 2001-08-09 | Alpha Innotech Corporation | Improved microarray reader |
EP1379545A2 (en) * | 2001-04-19 | 2004-01-14 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Method for producing stable, regeneratable antibody arrays |
WO2002093144A1 (en) * | 2001-05-10 | 2002-11-21 | Regents Of The University Of Minnesota | Imaging of biological samples using electronic light detector |
-
2004
- 2004-02-17 WO PCT/US2004/004675 patent/WO2004076678A2/en active Application Filing
- 2004-02-17 US US10/550,629 patent/US20060211044A1/en not_active Abandoned
- 2004-02-17 CA CA2519903A patent/CA2519903C/en not_active Expired - Lifetime
- 2004-02-17 AT AT04711880T patent/ATE476494T1/en not_active IP Right Cessation
- 2004-02-17 EP EP04711880A patent/EP1599597B1/en not_active Revoked
- 2004-02-17 DE DE602004028445T patent/DE602004028445D1/en not_active Expired - Lifetime
Patent Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4501495A (en) * | 1981-06-17 | 1985-02-26 | Smithkline Beckman Corporation | Slide carrier |
US5270163A (en) * | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
US5567588A (en) * | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
US5670637A (en) * | 1990-06-11 | 1997-09-23 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands |
US5696249A (en) * | 1990-06-11 | 1997-12-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands |
US5843653A (en) * | 1990-06-11 | 1998-12-01 | Nexstar Pharmaceuticals, Inc. | Method for detecting a target molecule in a sample using a nucleic acid ligand |
US5831012A (en) * | 1994-01-14 | 1998-11-03 | Pharmacia & Upjohn Aktiebolag | Bacterial receptor structures |
US5886353A (en) * | 1995-04-21 | 1999-03-23 | Thermotrex Corporation | Imaging device |
US6462768B1 (en) * | 1995-07-19 | 2002-10-08 | The Victoria University Of Manchester | Image enhancement |
US6459509B1 (en) * | 1996-11-08 | 2002-10-01 | National Computer Systems, Inc. | Optical scanning device having a calibrated pixel output and a method for calibrating such a device |
US6552829B1 (en) * | 1996-11-08 | 2003-04-22 | Ncs Pearson, Inc. | Optical scanning device having a calibrated pixel output and method for calibrating such a device |
US20020050518A1 (en) * | 1997-12-08 | 2002-05-02 | Roustaei Alexander R. | Sensor array |
US6069973A (en) * | 1998-06-30 | 2000-05-30 | Xerox Corporation | Method and apparatus for color correction in a multi-chip imaging array |
US6542249B1 (en) * | 1999-07-20 | 2003-04-01 | The University Of Western Ontario | Three-dimensional measurement method and apparatus |
US6399295B1 (en) * | 1999-12-17 | 2002-06-04 | Kimberly-Clark Worldwide, Inc. | Use of wicking agent to eliminate wash steps for optical diffraction-based biosensors |
US6556932B1 (en) * | 2000-05-01 | 2003-04-29 | Xerox Corporation | System and method for reconstruction of spectral curves using measurements from a color sensor and a spectral measurement system model |
US20020015958A1 (en) * | 2000-05-04 | 2002-02-07 | Audeh Zuheir L. | Colloid compositions for solid phase biomolecular analytical, preparative and identification systems |
US20020110376A1 (en) * | 2001-02-08 | 2002-08-15 | Maclean Steven D. | Method and apparatus for calibrating a sensor for highlights and for processing highlights |
US20030228637A1 (en) * | 2001-04-10 | 2003-12-11 | The Trustees Of Columbia University In The City Of New York | Novel microarrays and methods of use thereof |
US20020179828A1 (en) * | 2001-05-30 | 2002-12-05 | Leica Microsystems Heidelberg Gmbh | Method and device for point-by-point scanning of a specimen |
US6767733B1 (en) * | 2001-10-10 | 2004-07-27 | Pritest, Inc. | Portable biosensor apparatus with controlled flow |
US20040102742A1 (en) * | 2002-11-27 | 2004-05-27 | Tuyl Michael Van | Wave guide with isolated coupling interface |
US7268925B1 (en) * | 2003-02-24 | 2007-09-11 | Pritest, Inc. | Image sensor optimization |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060292647A1 (en) * | 2004-12-03 | 2006-12-28 | Green Lawrence R | Reflex supplemental testing - A rapid, efficient and highly accurate method to identify subjects with an infection, disease or other condition |
US20080124738A1 (en) * | 2005-03-01 | 2008-05-29 | Pritest, Inc | Compositions and methods of testing for tuberculosis and mycobacterium infection |
WO2007095634A2 (en) * | 2006-02-17 | 2007-08-23 | Hanson Technologies, Inc. | Prion protein detection |
WO2007095634A3 (en) * | 2006-02-17 | 2008-04-03 | Hanson Technologies Inc | Prion protein detection |
US20070276586A1 (en) * | 2006-05-25 | 2007-11-29 | Samsung Electronics Co., Ltd. | Method of setting a navigation terminal for a destination and an apparatus therefor |
WO2009018094A1 (en) * | 2007-07-27 | 2009-02-05 | Donnelly Corporation | Capacitive sensor and method for manufacturing same |
US20090322705A1 (en) * | 2007-07-27 | 2009-12-31 | Donnelly Corporation | Capacitive sensor and method for manufacturing same |
US8610690B2 (en) | 2007-07-27 | 2013-12-17 | Tpk Touch Solutions Inc. | Capacitive sensor and method for manufacturing same |
US11624083B2 (en) | 2007-10-12 | 2023-04-11 | Caris Science, Inc. | Use of aptamers in proteomics |
US10995360B2 (en) | 2007-10-12 | 2021-05-04 | Caris Science, Inc. | Use of aptamers in proteomics |
US10316349B2 (en) * | 2007-10-12 | 2019-06-11 | Caris Science, Inc. | Use of aptamers in proteomics |
US8928602B1 (en) | 2009-03-03 | 2015-01-06 | MCube Inc. | Methods and apparatus for object tracking on a hand-held device |
US8981560B2 (en) | 2009-06-23 | 2015-03-17 | MCube Inc. | Method and structure of sensors and MEMS devices using vertical mounting with interconnections |
US9365412B2 (en) | 2009-06-23 | 2016-06-14 | MCube Inc. | Integrated CMOS and MEMS devices with air dieletrics |
US9321629B2 (en) | 2009-06-23 | 2016-04-26 | MCube Inc. | Method and structure for adding mass with stress isolation to MEMS structures |
US8823007B2 (en) | 2009-10-28 | 2014-09-02 | MCube Inc. | Integrated system on chip using multiple MEMS and CMOS devices |
US20110110589A1 (en) * | 2009-11-06 | 2011-05-12 | Kabushiki Kaisha Toshiba | Image Contrast Enhancement |
US9709509B1 (en) * | 2009-11-13 | 2017-07-18 | MCube Inc. | System configured for integrated communication, MEMS, Processor, and applications using a foundry compatible semiconductor process |
US9150406B2 (en) | 2010-01-04 | 2015-10-06 | MCube Inc. | Multi-axis integrated MEMS devices with CMOS circuits and method therefor |
US8936959B1 (en) | 2010-02-27 | 2015-01-20 | MCube Inc. | Integrated rf MEMS, control systems and methods |
US8794065B1 (en) | 2010-02-27 | 2014-08-05 | MCube Inc. | Integrated inertial sensing apparatus using MEMS and quartz configured on crystallographic planes |
US8592993B2 (en) | 2010-04-08 | 2013-11-26 | MCube Inc. | Method and structure of integrated micro electro-mechanical systems and electronic devices using edge bond pads |
US8797279B2 (en) | 2010-05-25 | 2014-08-05 | MCube Inc. | Analog touchscreen methods and apparatus |
US8928696B1 (en) | 2010-05-25 | 2015-01-06 | MCube Inc. | Methods and apparatus for operating hysteresis on a hand held device |
US8652961B1 (en) | 2010-06-18 | 2014-02-18 | MCube Inc. | Methods and structure for adapting MEMS structures to form electrical interconnections for integrated circuits |
US8869616B1 (en) | 2010-06-18 | 2014-10-28 | MCube Inc. | Method and structure of an inertial sensor using tilt conversion |
US8993362B1 (en) | 2010-07-23 | 2015-03-31 | MCube Inc. | Oxide retainer method for MEMS devices |
US9377487B2 (en) | 2010-08-19 | 2016-06-28 | MCube Inc. | Transducer structure and method for MEMS devices |
US9376312B2 (en) | 2010-08-19 | 2016-06-28 | MCube Inc. | Method for fabricating a transducer apparatus |
US8723986B1 (en) | 2010-11-04 | 2014-05-13 | MCube Inc. | Methods and apparatus for initiating image capture on a hand-held device |
US8873815B2 (en) * | 2011-02-08 | 2014-10-28 | Dacadoo Ag | System and apparatus for the remote analysis of chemical compound microarrays |
US20120201437A1 (en) * | 2011-02-08 | 2012-08-09 | Quentiq | System and apparatus for the remote analysis of chemical compound microarrays |
USRE47706E1 (en) * | 2011-02-08 | 2019-11-05 | Dacadoo Ag | System and apparatus for the remote analysis of chemical compound microarrays |
US8969101B1 (en) | 2011-08-17 | 2015-03-03 | MCube Inc. | Three axis magnetic sensor device and method using flex cables |
US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
US20150124072A1 (en) * | 2013-11-01 | 2015-05-07 | Datacolor, Inc. | System and method for color correction of a microscope image |
CN107248242A (en) * | 2015-11-30 | 2017-10-13 | Ncr公司 | Watermark enables scanning |
US10825123B2 (en) * | 2015-11-30 | 2020-11-03 | Ncr Corporation | Watermarked enabled scanning |
US20170154398A1 (en) * | 2015-11-30 | 2017-06-01 | Ncr Corporation | Watermarked enabled scanning |
US10430955B2 (en) * | 2016-08-31 | 2019-10-01 | The Regents Of The University Of California | High content screening workflows for microscope imaging |
US10771087B2 (en) * | 2018-06-13 | 2020-09-08 | Infineon Technologies Ag | Methods, devices and systems for data conversion |
US20190386673A1 (en) * | 2018-06-13 | 2019-12-19 | Infineon Technologies Ag | Methods, Devices and Systems for Data Conversion |
US11635314B2 (en) | 2018-06-13 | 2023-04-25 | Infineon Technologies Ag | Methods, apparatuses and systems for data conversion |
US20220170923A1 (en) * | 2020-12-01 | 2022-06-02 | National Cheng Kung University | Protein microarray, detection method thereof and evaluation method thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1599597A2 (en) | 2005-11-30 |
CA2519903A1 (en) | 2004-09-10 |
WO2004076678A3 (en) | 2006-03-02 |
CA2519903C (en) | 2011-11-01 |
EP1599597B1 (en) | 2010-08-04 |
DE602004028445D1 (en) | 2010-09-16 |
EP1599597A4 (en) | 2008-04-16 |
WO2004076678A2 (en) | 2004-09-10 |
ATE476494T1 (en) | 2010-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2519903C (en) | Translucent solid matrix assay device for microarray analysis | |
US20210311058A1 (en) | Methods and systems for extending dynamic range in assays for the detection of molecules or particles | |
US6861251B2 (en) | Translucent solid matrix assay device for microarray analysis | |
US9678068B2 (en) | Ultra-sensitive detection of molecules using dual detection methods | |
US9551663B2 (en) | Methods and systems for extending dynamic range in assays for the detection of molecules or particles | |
US11719641B2 (en) | Spatially resolved ligand-receptor binding assays | |
CA2458802C (en) | Rapid and sensitive detection of molecules | |
US20060170918A1 (en) | Detection Apparatus and Detection Method for Plasmon Resonance and Fluorescence | |
US20030157581A1 (en) | Use of an imaging photoelectric flat sensor for evaluating biochips and imaging method therefor | |
US20110306511A1 (en) | Methods for multiplex analyte detection and quantification | |
JP4527884B2 (en) | Chemical and biochemical assay methods and apparatus | |
JP2002526743A (en) | Analyte detection calculation method | |
CA2945040A1 (en) | Control marker for implementing analysis methods on spots | |
US7361515B2 (en) | Method and test kit for detecting analytes in a sample | |
US20040060987A1 (en) | Digital image analysis method for enhanced and optimized signals in fluorophore detection | |
JP2005291821A (en) | Light emission intensity analysis method and device | |
US20060063197A1 (en) | Quality control and normalization methods for protein microarrays | |
US20230123442A1 (en) | Biomolecular image sensor and method thereof for detecting biomolecule | |
WO2018168137A1 (en) | Biological substance analysis method, biological substance analysis device, biological substance analysis program, and biological substance analysis system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PRITEST, INC., WASHINGTON Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GREEN, LAWRENCE R.;REEL/FRAME:016861/0993 Effective date: 20050913 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |